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In this research, we developed a wide range of biological tools against two distinct 
targets from future diagnostic or therapeutic points of view. Firstly, we demonstrate 
that sporadic canine B cell lymphoma mimics the features of human equivalents 
which in turn will be advantageous for development of canine as well as human 
therapeutics. With a comparative oncological approach, here we developed a 
monoclonal antibody (NCD1.2) against canine CD20 which also binds to its human 
counterpart. Using flow cytometry and tissue microarray, we show that NCD1.2 
binds specifically to canine B cell lymphomas (CD20
+
) and not T-cell lymphoma 
(CD20
-
). We also cloned scFv scaffold by linking variable heavy and light chains 
from NCD1.2 hybridoma by a serine-glycine linker to see if it was active as a 
biological tool for future therapeutics. Intriguingly, we obtained two different kappa 
light chains from a single hybridoma cell (scFv3 and scFv7) after antibody phage 
display. These scFvs were cloned into mammalian vectors for expression in CHO 
cells and ADEPT - CpG2 vector for yeast expression to see if the activity of these 
scFvs was retained. Our data suggests that recombinant anti-CD20 scFv might be a 
useful tool for bioconjugate directed immunotherapies in comparative medicine.  
Secondly, in addition to mAbs we also developed peptide aptamers which are seldom 
described but have become attractive agents that typically target a specific 
biomolecule of interest. Parkinson’s disease (PD) is characterized by formation of 
lewy bodies (inclusion bodies) in the substantia nigra and the major content of lewy 
bodies is α-synuclein. To begin with we made recombinant α-synuclein and 
biophysically characterize this protein under different conditions on a native gel. We 
also performed Circular dichroism to look at its structure and demonstrate that α 
helicity could be achieved in presence of SDS. The aim of this project was to 
develop peptide aptamers, mAbs to α-synuclein, map the binding sites onto the 
peptides derived from the protein and also on recombinant protein. Further we 
demonstrated the development of biological tools and their potential ability against 
α-synuclein in α-synuclein expressing cell lines from future PD therapeutic 
perspective. Monoclonal antibodies were developed and mAb (3.1) was found to be 
immunopositive for α-synuclein in parts of kidney and brain. Moreover to estimate 
iii 
 
the oligomeric state of α-synuclein, we developed assays such as co-transfection of 
two different constructs i.e. cherry and GFP tagged α-synuclein and Proximity 
ligation assay to show its self - interaction. Peptide phage display screening (NEB 
Ph.D. 12 mer library) on recombinant WT α-synuclein was performed to identify 
aptamers and ultimately novel binding proteins. The peptides were selected based on 
iteration number and out of the selected panel of peptides; SHACWWDECTGS was 
found to effectively bind α-synuclein using ELISA. Scanning of peptide 
GDGNSVLKPGNW (highest iteration number) led to identification of interacting 
proteins with α-synuclein. Thus in conclusion, we show the validation of different 
antibody scaffolds and peptide aptamers which could be useful tools from future 
therapeutics point of view against two well characterized antigens in B cell 



















Chapter 1: Introduction 
1.1.  Biologics.. ...................................................................................................1 
1.1.1. Biologics and small molecules                                                            1 
1.1.2. Immunotherapy........ ...................................................................................3 
1.2.  Target selection for antibody therapy................ ...................................................4 
1.3.  Monoclonal antibodies..........................................................................................5 
1.3.1. Structure of antibodies......... .......................................................................9 
1.3.2. Selection criteria for monoclonal antibodies........... ..................................11 
1.4.  Recombinant antibodies............. .........................................................................12 
1.4.1. Developmental trends in antibody... .........................................................12 
1.4.2. Antibody fragments. .................................................................................13 
1.5.  Phage display................. .....................................................................................16 
1.5.1. Concept and types of phage display .........................................................16 
1.5.2. Different species for phage display. .........................................................19 
1.5.3. Expression of antibody fragments... .........................................................21 
1.6.  Bispecific antibodies...........................................................................................22 
1.6.1. Trifunctional hybrid antibodies....... .........................................................22 
1.6.2. Small bispecific constructs.. .....................................................................23 
1.7.  Antibody drug conjugates.......... .........................................................................24 
1.7.1. Antibody directed enzyme prodrug therapy (ADEPT......... .....................26 
1.8.  Mechanism of action of antibodies........ .............................................................27 
1.8.1. Antibody dependent cellular toxicity (ADCC)..... .................................27 
1.8.2. Complement dependent cytotoxicity (CDC)........... .................................27 
1.8.3. Phagocytosis .............................................................................................28 
1.9.  Other biologics..... ....................................................................................30 
v 
 
1.9.1. Tyrosine kinase inhibitors.... ....................................................................30 
1.9.2. Peptides........ ............................................................................................30 
1.9.1.1. Peptides as useful tools...........................................................30 
1.9.1.2. Current status of peptide aptamers..........................................31 
1.10. Future of biologics........ .....................................................................................32 
1.11. AIM....... .............................................................................................................33 
Chapter 2: Materials and Methods 
2.1.  General microbiological techniques........ .................................................34 
2.1.1. Preparation of competent cells for heat shock transformation method.......
 ..........................................................................................34 
2.1.2. Transformation of bacterial component cells...........................................35 
2.1.3. Purification of plasmid DNA........... ........................................................35 
2.1.4. Bacterial glycerol stocks...........................................................................36 
2.1.5. Expression and purification of recombinant protein................................36 
2.2.  Immunofluorescence.................. .........................................................................38 
2.3.  Molecular biology techniques.... .........................................................................39 
2.3.1. mRNA extraction and reverse transcription.............................................39 
2.3.2. Polymerase chain reaction.......................................................................39 
2.3.3. Restriction digestion of PCR product and destination vector DNA........41 
2.4.  Cell lines............ .................................................................................................41 
2.4.1. Maintenance of cell lines.........................................................................41 
2.4.2. Transfection of mammalian cells.............................................................42 
2.4.3. Harvesting of cells.......... .........................................................................42 
2.4.4. Lysis of cells............................................................................................43 
2.5.SDS gel preparation and Immunoblotting............................................................43 
2.5.1. 2X sample buffer preparation..... ............................................................43 
2.5.2. Coomassie staining..................................................................................46 
2.5.3. Western blot........ ....................................................................................46 
2.6.ELISA..................................................................................................................47 
2.6.1. Epitope mapping.....................................................................................47 
2.6.2. Binding of antibody to WT protein.........................................................47 
vi 
 
2.6.3. TMB substrate................  ........................................................................48 
2.7.  Monoclonal antibody isolation against canine CD20...... ........................49 
2.7.1. Immunization of BALB/c mice with canine CD20 peptide ....................... 
(NCDPANPSEKNSLSIQYCGS.............................................................49 
2.7.2. Octet binding assay......... ........................................................................49 
2.7.3. Transfection of GFP-CD20 into H1299 cells..... ...................................50 
2.7.4. FACS.......................................................................................................51 
2.7.5. Immunohistochemistry... ........................................................................52 
2.7.6. Characterization of anti-CD20 mAb on Raji cells by IF.........................52 
2.8.  Construction of mouse scFv antibody library....................................................53 
2.8.1. Extraction and isolation of total RNA from immunized mice................53 
2.8.2. Reverse transcription of total RNA to cDNA.........................................53 
2.8.3. PCR primers for the construction of murine scFv library.......................54 
2.8.4. Overlap extension primers......................................................................60 
2.8.5. Splicing of purified PCR products by overlap extension PCR...............61 
2.8.6.  Restriction digest of the purified overlap PCR product and vector 
DNA...................................................................................................................62 
2.8.7. Ligation of the digested overlap PCR product with vector DNA..........63 
2.8.8. Transformation of E.coli TG1 cells with pCOMB3xSS vector containing 
variable heavy and light chains and measurement of transformation 
efficiencies..............................................................................................64 
2.9.  Biopanning (following Barbas protocol)...........................................................64 
2.9.1. Panning round 1.....................................................................................66 
2.9.2. Panning – Round 2,3 and 4....................................................................66 
2.9.3. Polyclonal phage pool ELISA and colony pick PCR..... .......................69 
2.9.4. Monoclonal ELISA for detection of CD20 specific scFv......................70 
2.9.5. Antibody expression and purification................. ...................................71 
2.10. Phage bound scFv...... ...................................................................................72 
2.10.1. Cloning of scFv 3 and 7 into mammalian and bacterial expression system 
a. Mammalian and Bacterial expression of scFv 3 and scFv 7....... ............72 
b. Purification of His-tagged scFv and scFv-CPG2 bio conjugates       via    
metal affinity chromatography................................................................73 
vii 
 
2.10.2. Cloning of scFv 3 into Pichia for antibody expression.......................74 
2.11. Expression and purification of recombinant α-synuclein...............................75 
2.12. Native gel....... ................................................................................................75 
2.13. Circular Dichroism.........................................................................................77 
2.14. Development of antibodies and epitope mapping against α-synuclein......... 77 
2.15. Immunofluorescence and Immunohistochemistry..... ....................................78 
2.16. Assay development for self-interaction......... ................................................78 
2.16.1. α-synuclein constructs in pEGFP-(C) as well as pMCherry –(C).....78 
2.16.2. Co-localization of α-synuclein and interacting proteins in SHSY5Y   
and HCT116 (WT) cells.............. ............................................................79 
2.16.3. Proximity ligation assay (PLA)..................... ....................................79 
2.17. Peptide phage display ....................................................................................81 
2.17.1. Panning procedure..... ........................................................................81 
2.17.2. Phage amplification............... ............................................................82 
2.17.3. Phage tittering.......... ........................................................................83 
2.18. Next generation deep sequencing...... ............................................................83 
2.18.1. PCR for phage DNA amplification......................................................83 
2.18.2. DNA purification and quantification...................................................85 
2.18.3. Deep sequencing of phage pool ..........................................................86 
2.18.4. Peptide protein binding efficiency.......................................................86 
2.18.5. MEME analysis and co-transfection....................................................86 
2.18.6. Peptide pull down assay........... ...........................................................87 
Chapter 3: Development of monoclonal antibodies and Bioconjugate 
against canine CD20 receptor (a receptor, scFv model) 
3.1.  Introduction........................................................................................................89 
3.1.1. Cancer..................................................................................................... 89 
3.1.2. Concept of mutations, oncogenes and tumour suppressor gene............. .90 
3.1.3. Comparative oncology................ .............................................................90 
3.1.4. Mouse vs dogs as a relevant study model for humans................ .............91 
3.1.5. Lymphoma...............................................................................................92 
3.1.6. CD20 structure and its role in B cell lymphoma... ................................95 
viii 
 
3.1.7. Monoclonal antibodies against CD20 .....................................................99 
3.1.8. AIM .......................................................................................................102 
3.2.  Results............................ ...................................................................................103 
3.2.1. Production of mouse anti- canine CD20 from murine hybridomas.......103 
3.2.2. Designing peptides spanning the extracellular region of CD20............106 
3.2.3. Epitope mapping of the anti- CD20 mAb........... ...................................107 
3.2.4. Immunofluorescence....... .......................................................................108 
3.2.5. Octet binding assay......... .......................................................................109 
3.2.6. Fluorescence polarization assay.............. ...............................................111 
3.2.7. Reactivity of NCD1.2 to canine CD20 protein from clinical samples...112 
3.2.7.1.   Fluorescence activated cell sorting (FACS) ............................112 
3.2.7.2.   Immunohistochemistry......... ....................................................113 
3.2.8. Developing a scFv antibody phage library from hybridoma cell.NCD1.2.. 
....................................................................................................................115 
3.2.8.1.  Isolation  of RNA from the obtained murine spleen  containing B 
cells.............. ...............................................................................................115 
3.2.8.2. First round of PCR (Amplification of variable domain of heavy and 
light chains)............. ..........................................................115 
3.2.8.3.   Second round of PCR (overlap extension PCR).............. ...........117 
3.2.8.4.   Restriction digest, Ligation of purified PCR product and vector 
DNA (pCOMB3xSS)......... ..........................................................119 
3.2.8.5. Library size............ .......................................................................120 
3.2.9. Biopanning.......... .................................................................................122 
3.2.10. Bacterial and mammalian expression of scFv..... ...............................125 
3.2.11. Sequence analysis of scFv 3, 7... .......................................................128 
3.2.12. scFv-CpG2 Bioconjugate ...................................................................130 
3.2.13. Yeast expression and purification of scFv3-CpG2......... ...................133 






Chapter 4: Developing monoclonal antibodies and assays to 
biophysically characterized α-synuclein 
4.1.  Introduction................... ...................................................................................141 
4.1.1. Immunotherapy as tool for treatment of neurodegenerative diseases....141 
4.1.2. Current available treatment........  ...........................................................142 
4.1.3. Parkinson’s disease......... .......................................................................143 
4.1.4. Genes involved in PD..... .......................................................................144 
4.1.5. Synuclein family. ...................................................................................146 
4.1.6. α-synuclein.......... ...................................................................................148 
4.1.7. α -synuclein in Parkinson’s disease....... ...............................................149 
4.1.8. Controversial state of native α-synuclein ...............................................150 
4.1.9. AIM ........ ...............................................................................................151 
4.2.   Results... ...........................................................................................................152 
4.2.1. Expression and purification of WT α-synuclein  ...................................152 
4.2.2. Biophysical studies of α-synuclein......... ...............................................157 
4.2.3. Circular Dichroism.......... .......................................................................160 
4.2.4. Development of antibodies binding to WT α-synuclein .......................164 
4.2.5. Binding efficacy of monoclonal antibodies to α-synuclein........ ...........165 
4.2.6. Epitope mapping of the anti-α-synuclein antibodies.............................167 
4.2.7. Cell model to study α-synuclein oligomeric state........... .......................170 
4.2.8. Different Lysis methods, Fixing of immunoblot ...................................171 
4.2.9. Immunofluorescence....... .......................................................................173 
4.2.10. Immunohistochemistry.....................................................................175 
4.2.11. Co-localization of α-synuclein..........................................................175 
4.2.11.1. Development of distinct constructs of α-synuclein...............177 
4.2.11.2. Proximity Ligation Assay (PLA)..........................................180 
4.3. Discussion........... ...............................................................................................185 
Chapter 5: Peptide phage display screening against α-synuclein 
5.1.   Introduction....... ...............................................................................................191 
5.1.1. Phage display...... ...................................................................................191 
5.1.2. Need for peptides binding to α-synuclein........... ...................................192 
x 
 
5.1.3. AIM......... ...............................................................................................194 
5.2. Results..... ...........................................................................................................195 
5.2.1. Peptide phage display againstα-synuclein.......... ...................................195 
5.2.2. Identification of peptides binding to α-synuclein........... .......................198 
5.2.2.1. Abundance Method.... ...........................................................198 
5.2.2.1.1. Iteration number of each peptide..............................199 
5.2.2.1.2. Comparison of selected peptides      (Fast wash 
vs Slow wash)........................................................................................200 
5.2.2.1.3. MEME analysis and identification of interacting 
proteins.........................................................................................203 
5.2.2.1.4. Transfection    of   cloned   genes   identified  by 
phage display...............................................................208 
5.2.2.2. Percentage based method for identification of binding peptides
.............................................................................................................211 
5.3. Discussion..........................................................................................................218 
Chapter 6: Summary and future work 
6.1. CD20 as intriguing target in canine B cell Lymphoma.. ...................................221 
6.2. Biophysical studies and developing aptamers to α-synuclein.... .......................223 
6.3. Conclusion.......... ...............................................................................................224 
Chapter 7: APPENDICES 
Appendix I: scFv construction....................... ..........................................................225 
Appendix II: Recombinant dog IgG activity......................... ..................................228 
Appendix III: Transfection of protein constructs...... ..............................................230 
Appendix IV: Peptide phage display screening identified peptides............ .........................231 
 




Figures and tables 
Figures 
Figure 1.1: Production of monoclonal antibody.......  ...................................................6 
Figure 1.2: Structure of antibody molecule..  .............................................................10 
Figure 1.3: Antibody formats  .....................................................................................14 
Figure 1.4: Construction of antibody library  .............................................................18 
Figure 1.5: Antibody directed enzyme prodrug therapy (ADEPT) .. .........................26 
Figure 1.6: Different mechanisms of action of monoclonal antibodies ........ .............29 
Figure 2.1: Peptide pull down assay  .........................................................................88 
Figure 3.1: B cell lymphoma during B cell development...... .....................................94 
Figure 3.2: Structure of CD20........... .........................................................................96 
Figure 3.3: Detailed structure of human CD20 ......... .................................................98 
Figure 3.4: Clustalw analysis of CD20 ......... .............................................................99 
Figure 3.5: Isolation of a mouse CD20-specific monoclonal antibody that can 
recognize human and canine CD20 protein  ...........................................................105 
Figure 3.6: CD20 derived peptides and 3D structure of CD20 ........ .......................106 
Figure 3.7: Epitope mapping of NCD1.2 ...... ...........................................................108 
Figure 3.8: Immunostaining of NCD1.2 onto human CD20 expressing cells................
 .....................................................................................................................109 
Figure 3.9: Definition of relative affinity of the NCD1.2 mAb towards the epitope 
peptide ……………………………………………………………………..............110 
Figure 3.10: Fluorescence polarization assay ........... ...............................................111 
Figure 3.11: Expression of canine CD20 in clinical cell population. .......................113 
xii 
 
Figure 3.12: Expression of canine CD20 protein in formalin fixed paraffin embedded 
cancer tissue.……………………………………………………………….............114 
Figure 3.13: Amplification of variable heavy and light chains ........ .......................116 
Figure 3.14: Purified variable heavy and light chains .......... ...................................117 
Figure 3.15: Second round of PCR (Touch down PCR)....... ...................................118 
Figure 3.16: Restriction digestion ad ligation of scFv, pCOMB3xSS………..........120 
Figure 3.17: Restriction digestion of picked clones .................................................121 
Figure 3.18: scFv in pCOMB3xSS.... .......................................................................122 
Figure 3.19: Biopanning........ ...................................................................................124 
Figure 3.20: Phage expressing scFv ELISA.. ...........................................................125 
Figure 3.21: Mammalian expression of scFv ...........................................................126 
Figure 3.22: Bacterial expression of scFv.................................................................127 
Figure 3.23: Sequence analysis of scFv 3 and scFv 7 ...............................................129 
Figure 3.24: Bioactivity of recombinant scFv-3 and scFv-7 secreted from CHO cells 
and produced in bacteria as a CpG2- bioconjugate…………………………..........131 
Figure 3.25: scFv3- CpG2 expression, purification in Pichia pastoris…......……..134 
Figure 3.26: Regeneration of B cells…………………………………………........137 
Figure 4.1: Mechanism of neurodegeneration……………………………........…..145 
Figure 4.2: Sequence analysis of synuclein family…………………………….......147 
Figure 4.3: Expression of synucleins among different tissues………………..........148 
Figure 4.4: Detailed structure of α-synuclein………...………………………........149 
Figure 4.5: Structural changes in α-synuclein in PD…...…………………….........150 
Figure 4.6: Purification of recombinant α-synuclein. ...............................................152 
xiii 
 
Figure 4.7: α-synuclein on a native gel.......... ...........................................................154 
Figure 4.8: Recombinant purified α-synuclein in different conditions on a native 
gel..............................................................................................................................156 
Figure 4.9: Purified recombinant α-synuclein after buffer exchange .......................158 
Figure 4.10: Buffer exchange of recombinant α-synuclein... ...................................159 
Figure 4.11: Circular Dichroism spectra of recombinant α-synuclein........... ...........161 
Figure 4.12: Circular Dichroism of recombinant α-synuclein incubated with 
SDS……………………………………………….........………………..................163 
Figure 4.13: Dot blot of individual clones to test for IgG isotype..... .......................165 
Figure 4.14: ELISA onto WT α-synuclein..... ...........................................................166 
Figure 4.15: Activity of HRRP conjugated antibodies onto purified WT α-
synuclein………………………………………………………………….…..........167 
Figure 4.16: Epitope mapping of all the positive clones that bound to WT α-
synuclein………………………………………………………………….….….....169 
Figure 4.17: Binding efficiency of IgGs onto α-synuclein.... ...................................171 
Figure 4.18: Different types of lysis of SHSY5Y cells......... ...................................172 
Figure 4.19: Characterization of mAb 3.1, 4.1 onto SHSY5Y cells via 
immunofluorescence……………………………………….…...........174 
Figure 4.20: Immunohistochemistry on brain ad kidney tissues....... .......................176 
Figure 4.21: Transfection of α-synuclein constructs in SHSY5Y cells......... ...........178 
Figure 4.22: Transfection of α-synuclein constructs in HCT116+ cells........ ...........179 
Figure 4.23: Proximity ligation assay (PLA) on higher α-synuclein expressing cell 
line (SHSY5Y cells)…………………………………………………………..…...182 
xiv 
 
Figure 4.24: Proximity ligation assay (PLA) on lower α-synuclein expressing cell 
line (SHSY5Y cells)……………………………………..………………………...183 
Figure 4.25: Structural analysis of recombinant α-synuclein after CD spectral 
analysis………………………………………………..………………………....…188 
Figure 5.1: peptide phage display...... .......................................................................191 
Figure 5.2: Comparison of cumulative number of copies in phage library prior to use 
for biopanning…………………………………………………...…...........……….196 
Figure 5.3: Biopanning protocol for peptide library screening onto target of 
interest.......................................................................................................................197 
Figure 5.4: Percentage distribution of peptide GDGNSVLKPGNW .......................202 
Figure 5.5: MEME analysis of peptides with high iteration number........................204 
Figure 5.6: PCR amplification of identified genes.... ...............................................208 
Figure 5.7: Transfection of GAP, HADH and thrombopoietin in SHSY5Y cells....209 
Figure 5.8: GFP-HADH transfection in SHSY5Y cells........ ...................................210 
Figure 5.9: Peptide protein interaction ELISA.......... ...............................................214 
Figure 5.10: Peptide pull down assay .......................................................................217 
Figure 5.11: Secondary structure of peptide SHACWWDECTGS... .......................219 
Figure 6.1: Recombinant dog IgG binding efficacy.. ...............................................222 
Figure 7.1: ELISA (4 rounds biopanning...... ...........................................................225 
Figure 7.2: Vector construction (Mologics).. ...........................................................228 
Figure 7.3: Dog IgG ELISA.. ...................................................................................229 





Table 1.1: Difference between small molecules and biologics.....................................2 
Table 1.2: Approved monoclonal antibodies............. ...................................................7 
Table 2.1: Composition of buffers..... .........................................................................36 
Table 2.2: Cell lines... .................................................................................................41 
Table 2.3: SDS gel ingredients.......... .........................................................................44 
Table 2.4: Reverse transcription .........................................................................54 
Table 2.5: Parameters for different rounds of panning.......... .....................................65 
Table 2.6: Set of primer sequence...............................................................................84 
Table 3.1: Monoclonal antibodies against CD20 …………….……………..……..100 
Table 5.1: Iteration number of peptides......... ...........................................................200 
Table 5.2: Selected peptides iteration number in percentage ...................................201 
Table 5.3: Discovered motifs containing maximum sites...... ...................................205 
Table 5.4: Peptide occurrence in percentage against α-synuclein..... .......................211 
Table 5.5: Primers to clone identified genes.. ...........................................................215 











A                                            Alanine 
AADC                                     Aromatic amino acid decarboxylase 
AD    Alzheimer’s disease 
ADC Antibody drug conjugates 
ADCC Antibody dependent cellular cytotoxicity 
ADCP Antibody dependent cellular phagocytosis 
ADEPT Antibody directed enzyme prodrug therapy 
AML                                      Acute myelogenous leukemia 
Amp Ampicillin 
APC Antigen presenting cells  
ATP Adenosine tri phosphate 
BLAST Basic local alignment search tool 
bp Base pairs 
BSA                                        Bovine serum albumin 
bsDb Bispecific diabodies  
B-SLL B-cell small lymphocytic  
C Cysteine 
C1, c2, c3 and c5 
proteins    
Complement proteins 
CaCl2                                                 Calcium chloride 
CD Cluster of differentiation 
CD Circular Dichroism  
CDC Complement dependent cytotoxicity 
CDR Complementary determining region  
CEA                                                                               Carcinoembryonic antigen 
cfu colony forming units 
CH Constant heavy chain 




CH3COOK                             Potassium acetate 
CLL Chronic lymphocytic leukaemia 
cmAb Chimpanzee antibody 
CpG2 Carboxypeptidase 2 
CPL Circular polarized light 
DAPI 4’, 6-diamino-2-phenylindole 
DLBCL Diffuse Large B-cell lymphoma 
DMSO Dimethyl sulfoxide 
DNA Deoxy ribonucleic acid 
dNTP Deoxynucleotide tri phosphate 
DOX 
DTT                                                                          
Doxycycline 
Dithiothreitol 
ECL Enhanced chemiluminescence 
EDTA                                    Ethylenediaminetetraacetic acid  
EGFR Epidermal growth factor receptor 
ELISA Enzyme linked Immunosorbent Assay 
Fab                                                                          Fragment antigen binding region                                  
FACS Fluorescence activated cell sorting 
FBS Foetal bovine serum 
Fc                                     Fragment crystallizable region of antibody 
FcγR Fc gamma receptors 
FDA Food and drug administration 
FITC Fluorescein isothiocynate 
FL Follicular Lymphoma 
FLIM Fluorescence lifetime imaging microscopy 
FRET Fluorescence resonance energy transfer  
G                                             grams 
G Glycine 
GFP Green fluorescent protein 
(G4S)4                                     Glycine serine linker 
H Histidine 
H2SO4                                     sulphuric acid 
xviii 
 
HADH                                    Hydroxyl-coenyme A dehydrogenase 
HAMA Human anti- murine antibody 
HAT Hypoxanthine aminopterin thymidine 
HCAbs                                   Heavy chain antibodies 
HCL Hydrochloric acid 
HER Human epidermal growth factor 
HGPRT Hypoxanthine-Guanine Phosphoribosyl Transferase   
HPLC                                     High performance liquid chromatography 
HRP Horse radish peroxidase 
HPMA      N-(2-hydroxypropyl) methacrylamide 
I Isoleucine 
Ig Immunoglobulin 
IGFR                                      Insulin growth factor receptor 
IGF1 Insulin like growth factor 
IF Immunofluorescence 
IFITM1 Interferon induced transmembrane protein-1 
IHC Immunohistochemistry 
IMAC                                    Immobilized metal affinity chromatography 
IPTG Isopropyl β-D-1 thiogalactopyranoside 
K Lysine 
kb kilo bases 
KCl                                                                              potassium chloride
L Leucine 
L litre 
lacZ   gene coding for β-galactosidase 
LB                               Lysogeny broth 
LB lewy bodies 
M molar 
M Methionine 
mAb                                       monoclonal antibody 




MgCl2                                       Magnesium chloride 
MgSO4                                     Magnesium sulphate 
mRNA messenger RNA 
MRW                                    Mean residual weight 
MZL Marginal Zone Lymphoma 
N Asparagine 
NAC                                     non-amyloid component 
NaCl    Sodium chloride 
NaHCO3   Sodium bicarbonate 
NaOH Sodium hydroxide 
NCD1.2                                monoclonal antibody against canine CD20 
ng nanogram 
NGS Next generation sequencing 
ND 
NHL                                     
Neurological disorder 
Non-Hodgkin’s lymphoma 
NK Natural killer cells 
NMR Nuclear magnetic resonance 
OD                                        Optical density 
PARK7 Parkinson protein 7 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline with Tween-20 
PCR Polymerase chain reaction 
PD                                         Parkinson’s disease 
PDGFR platelet-derived growth factor receptor  
PEG Polyethylene glycol 
PFA paraformaldehyde 
Ph.D. 12 library                                                                           
 
Phage display 12 mer library 
 
PINK1   PTEN induced putative kinase-1 
PLA Proximity ligation assay 
PTCL Lymphoma and Peripheral T-cell Lymphoma  
xx 
 
PTK protein tyrosine kinases 
RbCl Rubidium chloride 
RNA Ribose nucleic acid 
Rpm                                      revolutions per minute 
RT   Reverse transcriptase 
SANH Succinimidyl 6-hydrazinonicotinate acetone 
hydrazone 
SDS                                        Sodium dodecyl sulphate 
scFv single chain fragment variable antibody 
SNARE Soluble N-ethylmaleimide sensitive   factor     
attachment  protein  receptor 
SNCA non A4 component of amyloid precursor (α-
synuclein) 
TaFv                                     Tandem scFv 
TBS Tris buffered saline 
VEGFR Vascular endothelial growth factor receptor 
VL                                       Variable light chain 
VH Variable heavy chain 
VHH single variable domain antibody 
TEMED                                                           Tetramethylethylenediamine 
TMA Tissue microarray 
TMB 3,3’,5,5’- tetramethylbenzadine 
TRAF6 TNF receptor associated factor  
WT wild type 
YNB Yeast nitrogen base 
μg                                         microgram 
μM   micromolar 
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CHAPTER 1: Introduction 
1.1. Biologics 
1.1.1. Biologics and small molecules 
Biologics include a wide variety of biologically derived tools that specifically target 
different types of cells including cancer cells and stimulate an immune response. The 
biologics differ from conventional drugs in the way that the former products are 
made in cells or living organisms, whereas conventional drugs are made in laboratory 
using several chemical reactions. The first biologic product ever to gain clinical 
significance and FDA approval was Humulin, a recombinant human insulin 
developed by Genentech [8]. Traditional therapeutic biologics include blood 
products, human and animal cells; however modern biologics that have been 
developed using biotechnology include products such as monoclonal antibodies, 
cytokines and growth factors.  
Biologics are expected to account for 75% of the total revenues generated from the 
top 10 selling drugs by the end of 2014, with 5 out of 10 predicted to be monoclonal 
antibodies and it is also believed that one third of newly developed therapeutic tools 
are a form of biologics [9]. They are often used in combination with different 
therapies and biologics are further subdivided into three types: (i) alternative proteins 
which are identical to body’s signalling proteins, that in turn can activate the immune 
system to fight various diseases, (ii) monoclonal antibodies including antibody 
fragments designed against a target of interest in a specific type of disease and (iii) 
tools that have an ability to cause changes in the cellular processes and in turn induce 
anti-tumor effects. Chemically, biologics form a secondary structure (secondary, 
tertiary or quaternary) which is in contrast to the small molecules [10]. Biologics are 
largely administered parenterally i.e. intravenously as oral delivery is limited by the 
barriers such as pH dependent degradation, solubility, low epithelial permeability 
and instability [5]. The characteristic differences between drugs (small molecules) 
and biologics are shown below in table 1.1. 
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Property Small molecules Biologics 
Manufacture made by chemical 
synthesis 
biotechnologically 
produced by host cell lines 
Size Small (<500Da) Large (>1000Da) 
Structure Defined structure Heterogeneous structure 
Physiochemical 
properties 
Well defined  complex properties 
 Entry into blood enter systemic circulation 
through blood capillaries 
larger molecules reach 
blood via lymphatic 
system 




From a biologics point of view, approval of Adalimumab (manufactured by AbbVie 
and Zydus Cadila) for the treatment of rheumatoid arthritis provides an insight into 
monoclonal antibodies as the fastest growing and most promising category of 
biologics. Adalimumab (also called Humira) binds to TNFα which normally binds to 
TNFα receptors and best evaluated for use in treatment of inflammatory joint 
disease. An issue that is always associated with biologics is the high cost of 
production as on average it costs $1.2 billion to bring a new biologic agent into the 
market [11]. This cost includes basic laboratory research, pre-clinical testing, clinical 
trials and production. For producing an effective pre-clinical model study for any 
biological tool, it is important to choose a relevant animal that is pharmacologically 
responsive to therapies. Other important factors for biologics to succeed in the clinic 
include its ability to bind to the target in animal model as well as in its human 
counterpart. Here we focus on the application of monoclonal antibodies and peptide 
aptamers as important biological tools to different targets in order to develop 
therapeutic tools. 
 
Table 1.1: Difference between small molecules and biologics: Based on 
several properties such as manufacture, size, structure, physiochemical 
properties, entry into blood and route of administration, both small molecules and 
biologics have been compared [5] 
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1.1.2. Immunotherapy 
Immunotherapy is a biologic treatment which is classified into active and passive 
types based on its mode of action. Introduction of immunotherapy has resulted in 
providing long term immunity to various diseases that operate by boosting the body’s 
natural defence mechanisms. Active immunotherapy has been useful in fighting and 
inducing immunity against self-limiting infections which requires the interaction of 
antigen presenting cells (APCs) and T cells. Immunotherapy has potential 
applications such as induction of long term immune response and has been 
implicated in treatment of various diseases such as anaphylaxis, asthma, cancer, etc. 
In comparison to conventional immunotherapy, modern immunotherapy is safer as it 
is capable of producing T cell responses with minimized risk of developing 
anaphylaxis [12]. Effective vaccines (type of active immunotherapy) have been 
developed against infectious agents such as typhoid, cholera, rabies, hepatitis B, 
mumps, tetanus and diphtheria toxins [13]. Types of vaccines developed include 
peptide, dendritic cells, whole tumor cell and viral vector vaccines. In fact preclinical 
studies indicate that combination of therapies might assist in enhancing initiating 
immune response causing destruction at the desired site. A major disadvantage with 
active immunotherapy is that it is much less effective against some diseases 
including cancer that have developed ways to escape immune response by different 
means. The best available example from effective active immunotherapy is cytotoxic 
T lymphocyte antigen-4 against which negative immunoregulatory mechanisms 
become potent in order to avoid destructive mechanisms that could further lead to 
disease [14]. 
Another type of immunotherapy is passive immunotherapy which involves all 
possible biological tools that target a specific antigen within a disease, for example 
monoclonal antibodies, drug conjugates, etc. Monoclonal antibodies by far have been 
the most attractive and effective tool with several modifications designed to increase 
their affinity, tissue penetrability and effective response following therapy. 
Antibodies have been used in conjugation with toxins, for example anti-CD25 
(LMB-2) or anti-CD22 specific antibody has successfully induced remissions in 
hairy cell leukemia patients [15]. Another approach to passive immunotherapy 
                                                     Chapter 1: Introduction                                                           4 
 
includes radioimmunoconjugates that delivers radioactivity to the tumor site to 
achieve high efficacy. Combined therapies such as monoclonal antibodies combined 
with cancer cell vaccine have managed to increase the uptake of cells and enhanced 
expression of co-stimulatory on dendritic cells triggering greater specific immune 
response compared with an agent alone [16]. 
1.2. Target selection for antibody therapy 
Selection of target is one of the major criteria to be considered towards development 
of monoclonal antibodies and two different approaches have been assigned to target 
selection. The first approach is based on the targets that have already been validated 
using biological tools or known to be clinically relevant based on available literature. 
The second approach is mainly focussed on targets newly identified via proteomic 
studies using tissue biopsies, fluid samples, etc. It is very important to identify the 
relative expression pattern of a chosen target in normal and affected cells, treatment 
should be planned in such a manner that it does not affect normal cells. Once a 
suitable target has been identified, immunotherapy becomes an ideal tool for 
specifically targeting the antigen without affecting normal cells. Passive 
immunization has gained its clinical relevance with more than 30 monoclonal 
antibodies approved against various diseases following success with in-vivo studies 
and minimal side effects. First generation antibodies such as Rituximab, trastuzumab 
and Cetuximab are directed against well validated targets i.e. CD20, HER2 and 
EGFR respectively [17].   
Following the success of first generation monoclonal antibodies, antibodies were 
either modified or targeted to a different epitope onto the same target eliciting a 
different mechanism of action. These modified antibodies are described as second or 
third generation antibodies. Second generation antibodies include modifications in 
the variable domains, increasing the affinity of the antibody and also various 
antibody fragments targeting antigen [18]. The examples of second generation class 
of antibodies is ofatumamab which is more human in nature and was developed 
following Rituximab as well as Adalimumab [17]. The third  generation of antibodies 
is more focused on triggering other mechanisms of action and these are engineered to 
improve half-life and Fc mediated activity [18]. An example of a third generation 
                                                     Chapter 1: Introduction                                                           5 
 
antibody is obinutuzumab targeting CD20 is found to be less immunogenic as 
compared to rituximab and is engineered to increase cytotoxic effects [19]. This 
immunogenicity is attributed to its different mechanism of action and also due to the 
fact that it is glyco-engineered to trigger increased cytotoxicity[20].  
1.3. Monoclonal antibody (Full length IgG) 
An antibody is a specialized immune glycoprotein secreted by B cells which is 
produced in response to the introduction of an antigen within the body and possesses 
the ability to neutralize the antigen. Such glycoproteins are divided into two: 
polyclonal and monoclonal antibodies, where polyclonal antibodies indicate the 
production of a pool of antibodies against different epitopes and possess a risk of 
antibodies cross reacting with other biomolecules containing similar epitopes. To 
circumvent this issue, concept of monoclonal antibodies has resulted in an antibody 
binding to a specific epitope of the target antigen. With the invention in 1970s by 
Kohler and Milstein, monoclonal antibodies have taken a strong hold in the area of 
clinical research where it is defined as magic bullet against tumour antigens as well 
as several other diseases [21].   
The standard protocol developed by Kohler and Milstein (figure 1.1) initiated with 
immunization of a suitable animal with target of interest. Once a suitable antibody 
titre is obtained, the immunized animal is sacrificed and splenocytes are recovered. 
The splenocytes were then fused with myeloma cells using polyethylene glycol 
(PEG), the fused hybridoma cells are selected in a medium that supports hybridoma 
survival. The cells are cultured in hypoxanthine aminopterin thymidine (HAT) 
medium where aminopterin plays a major role in blocking de novo synthesis or 
purines and pyrimidines required for DNA synthesis. This is when the cells use 
salvage pathway and the enzymes involved in this selection pathway are Thymidine 
kinase and Hypoxanthine-Guanine Phosphoribosyl Transferase (HGPRT). The 
myelomas lack HGPRT, thus unfused myeloma cells cannot proliferate in the 
medium and ultimately die, however the unfused splenocytes do possess HGPRT but 
only have a limited lifetime and thus die within two weeks. The hybridoma cells then 
grow indefinitely in the selection medium. Many hybridoma cells are obtained 
following this fusion protocol and each might have a different specificity towards the 
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immunized target. To identify the specifically binding candidate, hybridoma cell 
supernatants are tested via limiting dilution onto target of interest using Enzyme 
linked Immunosorbent Assay (ELISA). Following screening, a well containing a 
single positive cell is selected and cloned for stable expression of hybridoma so that 
it does not lose its potential ability to produce monoclonal antibody. 




The advent of hybridoma technology has enabled researchers to produce large 
quantities of monoclonal antibody by immortalizing the antibody producing B 
lymphocytes from the spleen of immunized mice. In 1986, the first ever monoclonal 
antibody (OKT3) targeting CD3 was approved by US Food and Drug administration 
(FDA) for use in treating patients with acute transplant rejection and is used as a drug 
in humans [22]. Since then, the field of antibody therapeutics has flourished and has 
gained immense clinical significance against different types of diseases. In the past 
25 years according to the antibody society more than 30 monoclonal antibodies have 
been approved and many have been under pre-clinical and clinical trials (table 1.2). 
Figure 1.1: Production of monoclonal antibody: Mice immunized with antigen 
of interest, following cycles of immunizations mice sacrificed and spleen/ B cells 
isolated. These B cells producing antibodies are fused with myeloma cells to 
obtain hybridoma population.  Individual hybridomas are tested onto ELISA plate 
coated with antigen by limiting dilution [6]. 
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A key criterion to be considered for development of antibody therapeutics is to 
identify a suitable target in the disease. The antibody can induce anti-tumor effects 
via a range of mechanisms such as mediating alteration in antigen, activating 
immune modulatory functions such as involvement of T cells and Fc receptors or 
lastly by drug conjugate targeting at the tumor site [23-25]. Recent advances in 
antibody engineering as well as molecular biology have resulted in the development 
of various manipulative forms of antibodies such as humanized, chimeric and fully 
human antibodies with an aim to overcome the issues such as human anti-mouse 
antibody response raised by mouse monoclonal antibodies [25]. Table 1.2 shows 









Antigen Target disease Sponser 
Muromomab Orthoclo
ne 






Abciximab Reopro Chimeric Fab GPIIb/IIIa 
receptor 
Prevention of cardiac 
ishemic complications 
Centocor 
Rituximab Rituxan Chimeric IgG CD20 Non-Hodgkin’s 
lymphoms, chronic 
lymphoms leukemia 




Daclizumab Zenapax humanized 
IgG1к  
IL-2Rα Prophylaxis of acute 




Basiliximab Simulect chimeric 
IgG1к 
IL-2Rα Prophylaxis of acute 
organ rejection in renal 
transplants 
Novartis 





























Alemtuzumab Campath humanized 
IgG1к 













Adalimumab Humira human IgG1к TNFα Rheumatoid arthritis 
and Crohn’s diseases 
Abbott 
Omalizumab Xolair humanized IgE Moderate to severe Genentech 
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Efalizumab Raptiva humanized 
IgG1к 
CD11a Moderate to severe 
plaque psoriasis 
Genentech 
Cetuximab Erbitux chimeric 
IgG1к 





Bevacizumab Avastin humanized 
IgG1к 
VEGF-A various solid tumors Genentech 








Ranibizumab Lucentis humanized 
Fab 





Panizumumab Vectibix human IgG2к EGFR Metastatic colorectal 
carcinoma 
Amgen 
Eculizumab Soliris humanized 
IgG2/4к 
C5 Paroxysmal nocturnal 
hemoglobinuria 
Alexion 
Certolizumab Cimzia Peglated 
humanized 
Fab 
TNFα Crohns disease and 
rheumatoid arthritis 
UCB, Inc 
Golimumab Simponi human IgG1к TNFα Rheumatoid arthritis, 





Canakinumab Ilaris human IgG1к IL-1β Cryopyrin-associated 
periodic syndromes 
Novartis 
Ustekinumab Stelara human IgG1к IL-12/IL-
23 
Plaque psoriasis Centocor 
Ortho 
Biotech 




Tocilizumab Actemra humanized 
IgG1к 
IL-6R Rheumatoid arthritis Roche/Chu
gai 
Denosumab Prolia human IgG2к RANK 
ligand 
Postmenopausal 
women with risk of 
psteoporosis 
Amgen 





treatment of malignant 













DNA Lung cancer MediPhar
m Biotech 
Nimotuzumab Theracim humanized 
IgG1 
EGFR Nasopharyngeal 
carcinomas and head 




Belimumab Benlysta human IgG1 BLyS Systemic lupus 
erythematosus 
GSK 














Pertuzumab Perjeta humanized 
IgG1 
HER2 Breast cancer Genentech 
Raxibacumab (Pending
) 
human IgG1 B anthrasis 
PA 










HER2 Breast cancer Hoffman 
La-Roche 













1.3.1. Structure of antibodies 
Monoclonal antibodies are large molecules and each molecule is comprised of two 
larger subunits known as heavy chains (50 kDa) and two smaller subunits i.e. light 
chains (23 kDa). The antibodies are classified into 5 different subtypes on the basis 
of their heavy chain constant regions IgM, IgG, IgA, IgE and IgD. IgG, IgD and IgE 
possess a common Y-shaped structure, with IgM being pentameric in nature. IgG is a 
monomeric immunoglobulin and has a molecular weight of 150 kDa and is the most 
widely studied immunoglobulin because of its higher occurrence in the human body. 
It is the most versatile immunoglobulin and forms the major part (75%) of the whole 
Ig content of serum in the body. Moreover, it is the only class that crosses the 
placenta and is further subdivided into 4 different classes: IgG1, IgG2, IgG3 and 
IgG4. The heavy and light chains are annealed together by a disulphide bonds and on 
the basis of similarity of amino acid sequence each chain is further classified into 
variable and constant domains. Another fragment of antibody not known to bind 
antigen is called the Fc (fragment crystallizable) portion of antibody. Within the Fab 
region (region excluding Fc), the regions with greatest variability are described as 
hypervariable regions or complementary determining regions (CDRs) and further 
Table 1.2: Approved monoclonal antibodies: Different types of monoclonal 
antibodies (including conjugates) approved against various targets. The table 
shows mAb targets, Ab formats, type of disease and manufacturing company [4].   
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classified into CDR1, CDR2 and CDR3 from the amino terminus of the antibody 
molecule. Intervening regions between three different CDRs contain amino acids that 
have less variability among them and are described as framework residues. The light 
chain of IgG is composed of two domains VL and CL, whereas heavy chain is 
composed of VL and CH1, CH2 and CH3. Also the light chains are of two different 
types, namely kappa (к) and lambda (λ) light chain, but only a single type of light 
chain is thought to occur within any single antibody molecule. According to 
experiments carried out by Porter it was demonstrated that the antigen binding site is 
embedded in the Fab portion of the antibody whereas Fc portion binds to various cell 
receptors. Fc region of antibody binds to receptors such as Fc receptors and immune 
cells and mediates effector functions to the antibody [26]. 
The Fc portion which is composed of hinge region and constant domains (CH2 and 
CH3) communicates with immune system for induction of effector functions such as 
antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular 
phagocytosis (ADCP) and complement dependent cytotoxicity (CDC). Among the 
four known IgG isotype, IgG4 possesses a unique property of monovalency and 
bispecificity which is due to the presence of CPSCP instead of CPPCP sequences 
(IgG1) in the hinge region [27]. This leads to interchain as well as intrachain 
disulphide bonds within each heavy chain which can further cause dissociation of 
heavy chain form each other. The structure of the whole antibody molecule along 
with its antigen binding sites is shown in figure 1.2. 
           






1.3.2. Selection criteria for monoclonal antibodies 
Based on the origin of the monoclonal antibody, it can be classified into 4 different 
categories: (i) murine antibodies, (ii) chimeric antibodies, (iii) humanized antibodies 
and (iv) human antibodies. Infact, the most difficult step in developing a monoclonal 
antibody is the target selection and biochemical pathways that might be associated 
with it. To start with, one has to preferentially choose a target that is expressed only 
on the tumor cell; however this is not possible in all the cases. Thus for developing 
antibody therapeutics, targets should be present in a limited number of cell types and 
highly expressed on tumor cells. One such example is mAb trastuzumab targeting 
HER-2 which is present in a limited number of cell types and overexpressed in at 
least 30% of breast cancers [28, 29].  
Mouse monoclonal antibodies were first among the antibody tools obtained from 
immunized mice and to show any activity in inducing anti-tumor effects. As the 
name suggests murine antibodies are totally murine in nature which contributes to 
their immunogenicity. However there are a few limitations to mouse monoclonal 
antibodies, (i) high immunogenicity of these foreign proteins in humans leading to 
development of human anti- murine antibody (HAMA) response which restricts 
repetitive dosing of antibody [30-32]. This immunogenicity is the result of human 
immune system recognising murine antibodies as foreign materials and thus in turn 
developing antibodies against such proteins, (ii) relatively shorter circulating half-life 
compared to human antibodies [33]. To circumvent these limitations, various 
attempts were made with the help of genetic engineering to overcome 
immunogenicity either by developing chimeric, humanized or human antibodies. 
 
Figure 1.2: Structure of an antibody molecule: Heavy and light chains both 
containing constant as well as variable domains connected by disulphide bonds. 
The antigen binding site resides in the variable domains of both chains. Variable 
domains contain complementary determining regions (CDRs) and framework 
regions that highly assist in antigen binding. Heavy chain constant domain is 
divided into three parts i.e. CH1, CH2 and CH3 where both CH2 and CH3 form 
Fc portion of the antibody responsible for its effector functions. 
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1.4. Recombinant antibodies 
1.4.1. Developmental trends in antibody 
To overcome very well defined issues associated with mouse monoclonal antibodies, 
recombinant antibodies have been developed. Recombinant antibodies have been 
classified into two different types: Type 1 comprises of full length antibodies with 
changes in variable domains i.e. chimeric and humanized antibodies, whereas type 2 
includes all antibody fragments that have been engineered from the mAb. 
Recombinant DNA technology has been applied to construct chimeric antibodies that 
comprise the variable region of the mouse antibody annealed to the constant region 
of the human antibody thus retaining the binding efficiency of the original 
monoclonal antibody and reducing introduction of foreign material within the body 
[34]. Moreover, improved ADCC and other types of anti-tumor effects have been 
reported with chimeric antibodies [34]. Since the whole variable region is still of 
mouse origin, there is still considerable risk of immunogenicity in some patients, 
known as human anti-chimeric antibody (HACA) responses.  
Soon after the introduction of chimeric antibodies, the concept of ‘reshaping 
antibodies’, now called humanized antibodies evolved with an aim of improved anti-
tumor effects and less immunogenicity. The development of a humanized antibody 
involves substitution of mouse CDRs that contain the antigen binding site and Fc 
portion by human germline amino acids [35]. Thus around 90-95% sequences are of 
human origin and 5-10% of sequences are murine in nature [36]. One main issue 
with chimerization or humanization is the binding affinity of the final antibody could 
be reduced if the certain murine sequences that play a role in antigen binding are not 
transferred to the final modified antibody molecule. To overcome such issues raised 
by murine, humanized or chimeric antibody, several attempts have been made to 
develop fully human antibodies which would in principle have minimal 
immunogenicity in humans. Currently available techniques to develop human 
antibodies include phage display of libraries, transgenic mice, human-human 
hybridoma, B cell immortalization, Hybrid hybridoma and cloning which are 
explained briefly below:  
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Phage display is a very well-known candidate for developing human antibodies that 
involves displaying of human antibody onto engineered bacteriophage [37]. Each 
phage displays a different antibody on its surface and such phage displaying 
antibodies are then selected for binding to antigen. The benefit of phage display is 
the diversity of the antibodies obtained from the huge size of the libraries. This in 
turn can lead to a number of antibodies from the same library targeting different 
epitopes on the same protein. A major advantage that phage displaying antibodies 
hold over other available candidates is the ease of obtaining antibodies and also it 
avoids the need for immunization of animals. There have been two types of vectors 
involved in order to favour display of antibodies onto phage i.e. phage vector and 
phagemid vector. Phagemid vectors  advantages over phage vectors such as better 
transformation efficiency and can also be modified for direct secretion into the 
periplasmic space without subcloning [38]. Similarly, displaying antibody fragments 
onto yeast provides an advantage of post-translational modifications to the antibodies 
which does not occur in prokaryotes, however these modifications might differ when 
antibodies are administered in humans [39]. However the antibodies obtained 
initially might elicit low affinity towards the target; some optimizations such as 
affinity maturation might be needed in order to increase the affinity of the antibody. 
Adalimumab was the first monoclonal antibody derived from phage display that was 
approved by FDA for treatment of rheumatoid arthritis [40]. The use of transgenic 
mice is another way of developing human antibodies by genetically engineering the 
mice with humanized humoral immune system and the remaining components 
remain murine in nature. Thus, the antibodies can be obtained by standard hybridoma 
technology and such obtained proteins are highly human in nature. 
1.4.2. Antibody fragments 
In the recent past, ‘Engineered antibodies’ have made a significant impact on the 
biotechnological market with their ability to genetically manipulate antibody 
fragments [41].  The trouble with full length antibodies is sometimes their longer 
serum half-life which can lead to inappropriate activation of Fc receptor expressing 
cells, ultimately causing undesirable cytokine release and toxic effects [42]. 
Moreover even if the binding efficiency of the IgG is significantly higher in vitro, its 
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binding ability in-vivo always remains a question to be answered.  It has been 
demonstrated that the half-life of such fragments can be increased from a few hours 
to weeks through PEGylation i.e. conjugation to PEG (polyethylene glycol) [43]. The 
selection of antibody fragments (scFv or Fab) is carried out by phage display, 
however with growing antibody engineering techniques scFv and Fabs have been 
reformatted into a recombinant IgG which is often required for functional assays. For 
improving the antibody fragments pharmacokinetics, two studies using scFv diabody 
and Fab have indicated glycosylation to be highly effective in increasing the half-life 
by at least two fold along with increased tumor uptake [44, 45]. These antibody 
fragments have also been modified by either linking Fc to only variable domains of 
heavy and light chains or by dimerizing scFv or Fab. Various formats of antibodies 
show different expression and solubility levels depending upon their folding nature, 
different formats of antibody have been shown below in figure 1.3.  





Figure 1.3: Antibody formats: Top panel shows full length IgG molecule, 
scFv (annealed heavy and light chain variable domains) linked to Fc region 
and lastly Fab region containing variable and constant domains from heavy 
and light chains with no Fc portion of antibody. Lower panel shows minibody 
containing only variable domains attached to CH3 domain of Fc portion, scFv 
containing only variable heavy and light chain domains connected by a flexible 
linker, Fab containing both variable and constant domains of heavy and light 
chain with no Fc region and diabodies formed by linkage of two scFvs. 
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Importantly, IgG form of antibody can be expressed in E.coli but is inefficient in 
binding to the target due to minimized glycosylation and therefore it becomes 
necessary to clone the V regions from the antibody into expression constructs 
containing remaining parts of IgG [46]. The first attempt in expressing recombinant 
antibodies did not succeed due to improper folding and aggregation of polypeptides 
in the bacterial cytoplasm [41, 47]. The breakthrough for competent E.coli 
expression of antibody fragments was brought about by introducing phagemid 
vectors which offers soluble antibody secretion directly into the cytoplasm by means 
of oxidising environment [48, 49]. The oxidising environment facilitates correct 
folding of disulphide bonds in cytoplasm by exchanging cysteine residues and 
importantly can vary depending upon antibody class [50]. Following the success of 
scFv expression, phage display technology has been widely used to express other 
fragments such as Fab [51], di-sulphide stabilized fragments [52] and diabodies [53] 
onto phage. In comparison to the parental antibody, antibody fragments are much 
shorter in length and retain the antigen binding sites of the antibody. These antibody 
fragments have several advantages over full length mAb such as better penetration, 
more rapid blood clearance and lower immunogenicity. Different types of antibody 
fragments are described below. 
 
Fragment antigen binding (Fab) 
Fragment antigen binding (Fab) is a monovalent antibody fragment with a molecular 
weight of 50 kDa containing only a single antigen binding site. It is composed of a 
single variable domain and one constant domain of each of heavy and light chain. 
Papain cleavage is used to create two Fab fragments and a Fc fragment, whereas 
enzyme pepsin cleaves below the hinge region and yields F(ab)2 and partial Fc region 
fragments. These agents are the oldest and most successful among antibody fragment 
therapeutics and account for 49% of all antibody fragments to have entered clinical 
trials [54]. Jostock et al reported the first fully recombinant IgG constructed from 
Fab construct developed using phage display against Tie-1, a receptor tyrosine kinase 
involved in angiogenesis [55]. They nearly account for 50% of all identified antibody 
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fragments that enter clinical trials and are more stable for storage as compared to full 
length IgG [56].  
 
Single chain fragment variable (scFv) 
Single chain fragment variable (scFv) antibody is made up of a variable domain of 
heavy chain (VH) connected by a flexible peptide linker to the variable domain of 
light chain (VL) which is about 35 nm in length and both orientations of scFv i.e. 
VH-L-VL and VL-L-VH have been made. It is important that the peptide linker does 
not interrupt the proper folding of the scFv when expressed in bacteria. The most 
extensively used linker to anneal the variable heavy and light chains is composed of 
Glycine and serine residues which provides flexibility and enhances   solubilisation 
[57]. One of the most popular methods for annealing is PCR which was first 
described by Horton et al [58].  The annealed product can be ligated into a phage or 
phagemid vector, followed by transformation in order to construct the antibody 
library [59]. Antibody engineering has enabled researchers to develop scFv linked to 
another scFv resulting in diabodies which might increase the serum half-life and also 
its binding affinity. Also with sophisticated molecular biology and rational modelling 
techniques available now, several modified formats such as complementary scFv and 
bispecific tandem scFv have been constructed [60]. Interestingly, shortening of the 
length of the linker by three residues could promote formation of trimers or tetramers 
depending on the length of linker and also the orientation of the variable heavy and 
light chain domains [61-63]. Use of scFv as a potential tool for cancer therapy has 
gained significant clinical importance in the recent past by facilitating different 
effector functions [64].  
  
1.5. Phage display 
1.5.1. Concept and types of phage display   
The concept of linkage of foreign DNA fragments with gene III coat protein of a 
non-lytic filamentous phage was first revealed by Smith in 1985 [65]. Five years 
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later, McCafferty et al [66] demonstrated for the first time that scFv could be 
displayed on the surface of the virion as a functional protein retaining its antigen 
binding capacity. pCOMB3xSS is the most common phagemid vector used for 
antibody expression [67], all the structure proteins needed for phage packaging are 
provided by M13KO7 that acts as a helper phage. Several formats of antibody 
fragments have been displayed onto phage such as scFv, Fabs and diabody fragments 
[66, 68, 69]. A Phage displaying antibody library can be easily constructed with huge 
library size as shown in figure 1.4. Depending upon the origin of the antibody, three 
types of antibody libraries have been described i.e. immune libraries, naïve libraries 
and synthetic libraries.  
(i) Immune libraries: Variable domain repertoires can be created from B cells 
obtained from mice immunized with the target of interest. As compared to a 
library made from hybridoma cells, library made from spleen might give better 
diversity but also contain non-specific antibodies. The construction of such 
libraries has been carried out in various species such as chicken [70, 71], humans 
[72, 73], mouse [68, 74, 75], rabbit and camels [76]. The biggest advantage of 
immune libraries is the variable genes that encode antibodies are biased towards 
a specific target. However this can also be considered as a potential drawback as 
for each target, a new phage library has to be constructed each time from B cells 
following immunization of mice which can take upto three months. 
(ii) Naïve libraries (libraries from non-immunized donors): Such unbiased libraries 
provide an advantage as they contain antibodies to a range of targets including 
self, non-immunogenic, toxic antigens and are constructed from B cells of 
unimmunized human donors. The affinity of an antibody towards a specific 
target varies proportionally with size of the library [77]. The reliable source of 
variable domains amplification is either IgM mRNA or total mRNA, as building 
libraries from IgG mRNA do not perform well due to unrelated immune 
response [78]. 
(iii) Synthetic libraries: In this case, antibody is built artificially by in-vitro assembly 
(PCR) of variable gene segments and D/J segments with highly optimized 
human frameworks [79]. Most structural and sequence diversity is found in 
CDR3 region of the heavy chain, with the other five CDRs possessing limited 
                                                     Chapter 1: Introduction                                                           18 
 
variation [80]. High affinity antibodies can be generated against most antigens 
by introducing diversity in particular positions within four of all six CDRs. 
Independent of the origin of the antibody, optimizations might be needed to 
increase the affinity of the antibody which can be achieved by affinity 
maturation. This essentially involves introduction of diversity in the V regions 
which might be achieved by error prone PCR [81], chain shuffling [69], DNA 







Figure 1.4: Construction of antibody library: Following hybridoma technology 
mRNA was isolated from antibody producing cells; prepared cDNA from RNA 
was used to amplify variable domains of heavy and light chains via PCR. These 
variable regions were annealed using a glycine serine linker by second round of 
PCR, subsequently purified products digested along with vector DNA and finally 
ligated into phagemid vector to represent phage displaying scFv 
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The activity of the scFv has been modified by fusing scFv with radioisotopes for 
cancer imaging [84-86], enzymes in Antibody directed enzyme prodrug therapy 
(ADEPT) [87], toxins for targeted tumor cell targeting [88] and biosensors for real 
time detection of target molecules. scFv antibody fragments are known to diffuse 6 
times faster than IgG due to  their small size [89]. These tools have been developed 
against hapten [90], receptors [91], tumor antigens [92, 93],  carbohydrates [94] and 
proteins [95] with high potential for diagnostic or therapeutic applications.  
1.5.2. Different species for phage display 
Chimpanzee: Chimpanzees have been employed as another species for production 
of monoclonal antibodies to human targets. The variable regions have been cloned 
from immunized chimpanzees and a panel of antibodies has been identified in a 
study carried out against antigen DENV- 4 [96]. One of the positive clones from the 
panel was cloned with human sequences to construct humanized IgG1for expression 
in CHO cells [96]. Chimpanzees are highly genetically similar to humans [97], for 
this reason it is very likely that the effector functions imparted by Fc portion of 
chimpanzee antibody (cmAbs) could be highly functional in case of humans. 
However on few occasions it has been shown that cmAb might not bind to its human 
counterpart or other related species [98].   
Mouse: Antibody fragments have been constructed from hybridoma as well as 
splenic cells obtained from immunized mice on various occasions. Following the 
advent of hybridoma technology, mouse models have become an ideal candidate for 
production of antibody fragments from different sources such as spleen and 
hybridoma cells. In fact from a combinatorial immunotherapy point of view, mice 
immunized with phage displaying scFv instead of soluble scFv could result in the 
production of anti-idiotypic antibodies which could provide insights into immune 
response [64]. 
Camelids: Although significant efforts have led to construction of scFv and Fabs in 
various species, it was not until 1993 when Hamers- Casterman discovered an unique 
type of antibody in species called Camlids [99]. In sera of camelids, classical 
antibody isotype as well as heavy chain antibodies (HCAbs) have been identified and 
                                                     Chapter 1: Introduction                                                           20 
 
each of them contributes to the immune response of these animals. Studies with 
camelid antibodies have indicated the occurrence of three different isotypes: IgG1, 
IgG2 and IgG3, out of which IgG1resembles a conventional monoclonal antibody 
whereas IgG2 and IgG3 do not associate with the light chains [99]. The antigen 
binding site resides in a single domain defined as VHH or nanobody and is the 
smallest effective molecule with respect to the binding efficiency. The main 
difference between VH and VHH is based on amino acid length, CDR1 and CDR3 
are much longer in the case of VHH as compared to VH [100]. Also VH contains 
more hydrophobic amino acids, whereas VHH contain more hydrophilic bonds 
providing an evidence for absence of VL association [101]. Studies have indicated 
the possibility of retrieving useful binders using a naive camelid library [100]. 
Rabbits: Since some epitopes are not immunogenic in mice, another species might 
provide an advantage of being immunogenic and eliciting an immune response. 
Polyclonal rabbit antibodies have already been implicated in diagnostic applications 
and since then rabbits have been an interesting choice for production of antibodies. 
Rabbit mAbs have been utilized for decades now and have become an outstanding 
source for production of antibodies with high binding affinity and specificity [102]. 
Rabbit antibody fragments (scFv or Fab) have been displayed on phage usually via 
PCR similar to antibody fragments expressed in other species. Antibody fragments 
from this species have shown therapeutic potential in chronic lymphocytic leukemia 
cells [103]. From the immunized rabbits, antibody fragments were displayed onto 
phage and Rader et al for the first time reported humanization of such fragments 
[104].  Interestingly unlike human and mice, rabbits possess two different types of 
kappa light chains (K1 and K2) in which the dominating light chain is K1 [105].  
Sharks: In cartilaginous fishes such as sharks, a new member of immunoglobulin 
has been reported from a nurse shark species Ginglymostoma cirratum [106]. This 
member similar to camelid antibodies does not possess any light chain and contains 
one variable as well as five constant domains in serum. Moreover these single 
domain (IgNAR) antibody fragments from immunized sharks have been well 
characterized via phage display [107]. It has been demonstrated by Dooley et al that 
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IgNAR antibody isolated against HEL are highly stable, highly specific and binds to 
HEL in nanomolar range [107].    
Chicken: The variable domains of the chicken antibodies are similar to those in 
humans, however the constant heavy region has an extra domain i.e. CH4.The 
production and extraction of antibodies from egg yolk (IgY) exhibits high stability to 
pH as well as temperature changes [108]. For construction of chicken antibody 
library, only single 5’ primer is required in contrast to mammalian variable gene 
amplification primers [109]. These study models could be preferred over mice 
models in future as they are known to exhibit more vigorous immune response. 
Jennifer et al constructed three different types (scFv, diabody and Fab) libraries from 
bone marrow against BSA [110]. Chicken antibody might offer several advantages 
such as large quantity of antibody production and has led to decreased background in 
immunological assays due to phylogenetic differences between avian and 
mammalian species.   
Canine: Following the discovery and similarity of canine genome with humans, it 
was realized that use of dogs as a companion model could be an important step from 
veterinary care point of view. Recently canine specific antibody against CD52 
(Aratana therapeutics) has been approved for treatment of T cell lymphoma in dogs. 
Antibody fragment libraries from such species have been constructed either from 
immunized dog or from spleen of domestic dogs. With the need for more useful 
animal models in human disease drug development, canine models offer a close 
linkage to its human counterpart. For the first time Andrea et al described the 
designing of degenerative primers for amplification of variable heavy and light 
chains to construct scFv [111].  
1.5.3. Expression of antibody fragments 
As mentioned above, like other antibody fragments scFv is cloned using PCR 
assembly and finally ligated into the most frequently used phagemid vector 
pCOMB3XSS followed by electroporation to present the antibody library with each 
phage representing a scFv. The size of the antibody library is calculated based on the 
titres and can vary depending upon factors such as efficiency of transformation, 
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concentration of DNA, etc  The specific clones are obtained and selected using a 
selection procedure carried out on an immunotube described as ‘biopanning’. The 
selection procedure is carried out against the target used for immunization in case of 
immunized libraries, however in case of naïve libraries it is carried out against target 
of interests. There are two kinds of bonds in disulphide bonds in an antibody 
molecule i.e. inter domain bonds which are not present in the scFv and intra domain 
bonds which are present in immunoglobulin fold and also in scFv. These intra 
domain bonds are very crucial in maintaining the stability of the antibody [112]. For 
expression of scFv, prokaryotic expression (E.coli) has proved to be the most cost 
effective and indeed best for solubilizing into periplasmic space as compared to yeast 
[113], plants [91] and insect cells [114] expression. There have been different 
strategies used for expression of scFv in E.coli with or without signal peptide, in 
absence of signal peptide the polypeptides are well expressed in bacterial cytoplasm 
along with formation of insoluble aggregates called inclusion bodies [48, 115]. To 
circumvent this inclusion body issue, expression using signal peptide directs 
secretion of scFv into periplasmic space. Also, lac Z is the most common promoter 
used to control expression and expression is induced by isopropyl β-D-1 
thiogalactopyranoside (IPTG). 
1.6. Bispecific antibodies 
Bispecific antibodies represent another second generation antibody tool which is 
engineered to bind to two antigens and are capable of inducing immune response. 
Production of bispecific antibodies was engineered by either chemically cross linking 
or fusion of hybridoma cell lines containing different antigen binding sites. Currently 
available platforms employed for development of bispecific antibodies have been 
described below: 
1.6.1. Trifunctional hybrid antibodies 
Trifunctional hybrid antibodies (Triomab) is a mixture of portions of two antibodies 
that has one site binding to the tumor whereas the other site binding to the CD3 
expressed on T cell which assists in T cell mediated response. The examples of 
antibodies developed using this technology are catumaxomab (anti-EpCAM – anti-
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CD3), ertumaxomab (anti-HER2–anti-CD3) and FBTA05 (anti-CD20-anti-CD3) 
[116]. Another recent evolved technology is using scFv to develop either tandem 
scFv (TaFv) or bispecific diabodies (bsDb).  
 
1.6.2. Small bispecific constructs 
Tandem scFv (TaFv) can be constructed by covalently bonding of two different scFv 
with a flexible peptide linker in a tandem orientation. Bispecific T cell engagers 
(BiTE) is a type of TaFv that causes cell lysis via formation  of synapses between 
target and effector cells resulting in release of cytotoxic effector molecules [117]. 
One BiTE that has advanced in the clinical studies is Blinatumomab derived from 
murine scFvs targeting human CD19 and CD3. Multiple trials are ongoing to 
determine treatment schedule, clinical efficacy and side effects in NHL and leukemia 
patients. Other TaFv constructs have been developed targeting different antigens 
following humanization to avoid HAMA responses and are being evaluated in 
clinical trials [118]. 
Bispecific diabodies (bsDb) are formed by non –covalent association of two scFvs, 
comprising of variable heavy and light chains from a different parental antibody 
connected by a linker. Both attached chains are oriented in opposite directions but 
the stability of the antibody might still be a limiting factor as there is a possible 
chance of disintegration, dimerization and aggregate formation [116].  Based on the 
length of linker bsDb can be multimerized and increasing the disulphide bonds 
between the chains might increase stability of the antibody. 
Moreover, Fc domain of antibody molecule enhances the serum half – life and hence 
it is important to consider that the above mentioned antibody fragments may result in 
quick clearance without showing significant effects. To extend half-life most 
common techniques that have been employed include PEGylation and N-
glycosylation [119]. Such bispecific small antibody tools as compared to IgG (150 
kDa) have better tissue penetrance ability and tend to have prolonged target retention 
with homogenous distribution within tumors [42]. Bispecific antibodies thus provide 
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a ray of hope with advanced antibody engineering to target antigens and engage 
effector functions. 
1.7. Antibody drug conjugates 
The whole idea of drug conjugation is selectively ablating cancer cells by covalently 
linking monoclonal antibody binding specifically to an antigen with a highly potent 
cytotoxic agent. The aim behind developing such antibody drug conjugates (ADC) 
constructs is the enhancement of the mAb activity which can be achieved by 
selective delivery of highly potent cytotoxic drugs to tumor cells [120]. Several 
issues were addressed with first generation drug conjugates such as selection of 
antigen, type of toxin as well as format of the antibody used. Refinement in antibody 
fragments generation, well studied cytotoxic agents in combination with deeper 
understanding of targets have led to the emergence of second generation ADCs. The 
first tumoricidal agents to be linked to monoclonal antibodies were plant derived 
protein toxins i.e. gelonin, ricin and pokeweed antiviral protein, and bacterial toxins 
such as Diphtheria toxin [121-123]. The second generation conjugates involved 
linkage of antibody fragments which are much smaller in size and DNA sequence 
coding the toxin to facilitate effective tumor targeting. 
Another strategy involved covalent linkage of antibody with radionuclide with a goal 
to deliver sufficiently high dose of radiation to eradicate the tumor while not 
affecting the normal tissue. The most critical factor in this design is the dose of 
radionuclide delivered as radiation can easily damage cells that lie in close proximity 
to tumor cells [124]. Such tools have been developed for treatment for Non-
Hodgkin’s lymphoma with an FDA approval for two such candidates: 
131
I-
tositumomab (Bexxar) and 
90
Y- Ibritumomab tiuxetin (Zevalin) [125]. Following 
these two inventions and significant progress in conjugation studies, in 2000 
gemtuzumab ozogamicin became the first ADC to be FDA approved for treatment of 
acute myelogenous leukemia (AML). However this drug was withdrawn from the 
market in 2010 as it failed to meet the efficacy targets that were required for approval 
by FDA. Another two Ab drug conjugate have been approved by FDA, namely 
trastuzumab emtansine (2013) [126] and brentuximab vedotin (2011) [127] for breast 
cancer and Hodgkin’s lymphoma respectively.   
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For developing effective ADCs, it is important to determine the water solubility and 
prolonged stability of the compounds in aqueous formulations and in plasma [124]. 
Even behaviour of linker is an important factor in developing conjugates as they 
must be stable in circulation as their cleavage causes release of drug to the target 
tissue and should ideally increase the solubility [128, 129].    
 
1.7.1. Antibody directed enzyme prodrug therapy (ADEPT) 
Antibody directed enzyme conjugated prodrug therapy (ADEPT) is a relatively novel 
therapeutic approach that uses an enzymatic approach to convert a non-toxic prodrug 
into an active cytotoxic drug. ADEPT involves a two-step mechanism in order to 
carry out effective tumor targeting [130]. The first step involves administration of 
antibody conjugated with enzyme to the tumor site and allowed to accumulate at the 
tumor site along with clearance from blood and normal tissues. In the second step, a 
non-toxic prodrug is administered which is converted into a cytotoxic drug by the 
enzyme that is present in the antibody conjugate [131]. It is very important to 
characterize the antibody very well by measuring its binding potential to the target 
before linking it to any enzyme and it was realized that using antibody fragments 
would be beneficial because of their penetrability advantage over IgGs. On previous 
occasions, ADEPT has mainly used enzymes of non-human origin to activate the 
prodrug at the tumor site as the bacterial enzymes have activities orthogonal to the 
human proteome [132]. The conjugation of antibody to enzyme always raised a 
question whether enzyme would mask the binding site of antibody and similarly if 
antibody would mask enzymatic site needed for prodrug activation.  
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The first compound that was approved as prodrug was acetanilide, which was 
brought into the medical practice by Cahn and Hepp in 1867 as an antipyretic agent 
[133]. The term prodrug was introduced in 1958 by Adien Albert, described as 
biologically inert derivative of drug molecules that undergo enzymatic conversion 
into a pharmacologically active parent drug [134]. In ADEPT, leak back is an issue 
to be addressed as the delivered drug could leak back into the blood and other 
susceptible tissues due to longer half-life [135]. However, one study has shown to 
decrease or diminish the enzyme from the blood by delivering an antibody to the 
enzyme antibody conjugate in CEA positive colon cancer Xenograft model [136]. 
 
Figure 1.5: Antibody directed enzyme prodrug therapy: Antibody conjugated 
to an enzyme is first delivered to a tumor site, following accumulation at the 
tumor site and clearance from blood prodrug is administered in the body. The 
prodrug then becomes cytotoxic at the tumor site where antibody enzyme 
conjugate resides. Finally this cytotoxic drug then induces cell death.  
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1.8. Mechanism of action of antibodies 
Antibodies operate through various mechanisms in directing cytotoxic effects at the 
tumor site [137]. Monoclonal antibodies in combination with immune cells target 
tumor cells via mechanisms such as antibody dependent cellular cytotoxicity 
(ADCC), complement directed cytotoxicity (CDC) or using prodrug application as in 
the case of ADEPT system. Amongst the effector functions reported i.e. ADCC, 
ADCP and CDC; the first two mediate their effect via interaction of antibody with Fc 
gamma receptors, whereas CDC is mediated through a series of blood proteins that 
constitute complement cascade proteins. FcγR receptors are classified into three 
different types: FcγRI (CD64), FcRγII (CD32) and FcRγIII (CD16), class II and III 
are subdivided into type A and B. several mechanisms of action by which antibodies 
can induce anti-tumor effects are shown in figure 1.6. 
1.8.1. Antibody dependent cellular cytotoxicity (ADCC) 
Antibody dependent cellular cytotoxicity is said to occur when antibodies bind to 
antigen and employ Fc portion of the antibody which interacts with Fc receptors on 
the immune effector cells such as neutrophils, macrophages and natural killer cells 
[138]. The importance of Fc receptors in inducing ADCC was studied by Clynes and 
Ravetch by examining the effect of clinically effective monoclonal antibodies against 
human tumor xenografts in FcγRIII knockout mice. It was noted that anti-tumor 
activity was diminished in case of FcγRIII knockout mice and retained or enhanced 
when inhibitory Fcγ - receptor isoform was deleted [139].  Full length IgG1 provides 
effector functions, however if the presence of effector functions is   detrimental then 
switching to IgG4 might be more desirable. ADCC largely depends on activation 
state of NK cells [140] as well as affinity of IgG for FcγR [141].  
1.8.2. Complement dependent cytotoxicity (CDC) 
Another common mechanism by which antibodies induce anti-tumor effects is 
phagocytosis via a series of proteins defined as complement cascade proteins. 
Complement dependent cytotoxicity is mediated by binding of complement cascade 
protein c1q to Fc portion of the IgG bound to the target site. C1 also cleaves C2 into 
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C2a and C2b which in turn forms C3 convertase that enzymatically cleaves C3 into 
C3a and C3b.  Like C3b, C5b is also accumulated on the cell surface and subsequent 
complement protein formation C6 to C9 leads to the formation of membrane attack 
complex (MAC). This MAC leads to the formation of pores within the target cell 
leading to its lysis and is thus defined as complement mediated cytotoxicity. There 
have been several mechanisms controlling the activation of complement proteins and 
their ultimate effect [142]. Although IgM is the most effective isotype in activating 
complement cascade cycle, it does not hold clinical importance in most cases as it 
cannot escape from vascular structures and is also hard to purify [4]. 
1.8.3. Phagocytosis 
Phagocytosis can be initiated by a variety of mechanisms but the common 
mechanism studied is Fc receptor mediated phagocytosis.  The therapeutic antibody 
depends highly on macrophages and associated FcγR for their efficient activity on 
target cells [143, 144]. This typically depends on opsonized target cells and effector 
cells cultured together for few hours, however effector cell lines for deeper 
understanding of phagocytosis is not available. Flow cytometry is the most common 
method used as it is a rapid, accurate and a reliable quantitative method available 















Figure 1.6: Three different mechanisms of action of monoclonal 
antibodies: Complement dependent cytotoxicity (CDC) mode of action using 
a series of complement proteins via formation of membrane attack complex. 
Antibody dependent cellular cytotoxicity (ADCC) activated via enrolment of 
FcγR region on antigen presenting cells (APCs) with release of perforins and 
granzymes causing lysis of tumor cells. Lastly phagocytosis targeting affected 
cells after antibody binding via engagement of immune cells 
                                                     Chapter 1: Introduction                                                           30 
 
1.9. Other biologics 
1.9.1. Tyrosine kinase inhibitors 
Protein tyrosine kinases are an important member of signalling pathway proteins that 
are involved in protein-protein interactions. They are mainly divided into two types: 
transmembrane receptor kinases that are characterized by membranous locations and 
non- receptor kinases that are located in the cytoplasm. Examples of protein tyrosine 
kinases (PTKs) include members of epidermal growth factor receptor (EGFR), 
vascular endothelial growth factor (VEGFR), platelet-derived growth factor receptor 
PDGFR and insulin growth factor receptor (IGFR) [145].  A number of tyrosine 
kinase inhibitors have been developed for treatment of cancer and have depicted the 
importance of tyrosine kinases as prime targets for treatment therapy. TKIs have an 
ability to bind to the ATP binding site inhibiting the protein catalytic activity which 
has been done in reversible as well as irreversible ways. Potential inhibitors of EGFR 
and HER2 have been the most successful clinical evaluated candidate in lung, head 
and neck, ovarian, colorectal and breast cancer [146].  More than 14 tyrosine kinase 
inhibitors have been approved for different types of cancers and can be administered 
orally with inexpensive production cost. The overall clinical outcome using such 
small tools has resulted in side effects and non-specific targeting on a few occasions 
with very short half – life [147].  
1.9.2. Peptides 
1.9.2.1. Peptides as useful tools 
In recent years, another type of biologics i.e. peptide aptamers are emerging as a tool 
for targeting different markers in several diseases. Peptide aptamers are 
approximately 10-25 amino acids in length conformationally constrained derived 
from combinatorial libraries and are known to inhibit the activity of target with high 
affinity [148, 149]. Peptides are short amino acid sequences that can be produced 
biosynthetically, either chemically such as peptide synthesis or recombinant 
microbial production. In comparison to monoclonal antibodies, aptamers are 
relatively much small (10 - 20 kDa) with reduced immunogenicity [150]. These 
small molecules when conformationally constrained hold several advantages over 
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disordered peptides such as exposure of buried hydrophobic amino acids under 
aqueous conditions within the cells, often exhibit higher binding affinities as 
compared to unstructured peptides.  Such peptide aptamers act by binding to the cell 
surface proteins and inhibit one or more signal transduction pathway [151].  
1.9.2.2. Current status of peptide aptamers 
Various roles of peptide aptamers as a therapeutic agent have been demonstrated 
such as binding to the DNA binding domain of Stat3, inducing apoptosis in tumor 
cells and phage display derived peptide binding neuroblastoma tumor cells [152, 
153]. Peptides have two major advantages over large molecules (monoclonal 
antibodies and larger protein molecules) such as good delivery to the tumor site due 
to small size and they do not induce dose limiting toxicity to liver and bone marrow 
[154]. More than 60 approved peptide drugs are available in the market generating 
total revenue $13 billion with the number of peptide drugs entering the market has 
been increasing [151]. Peptides have been used in different ways such as peptides 
directly, vaccines, hormones and peptides linked to cytotoxic drugs with higher 
specificity towards the target.  
Natural peptides can be designed using crystallography to study the receptor ligand 
binding and the specific interface that is known to be critical in protein interaction. 
This could also be a very useful tool when a certain specific mutation in a gene is 
known to cause a disease. An example of such useful tools is peptide binding to 
TRAF6 derived from sequence of its natural binders [151]. An advantage of natural 
peptides is because its sequence is already known; screening using a library is not 
needed as such peptides can be straight away manipulated to visualize the binding 
efficiency into the target protein. 
Peptide aptamers could be really useful if the structure of protein or its interface with 
interacting proteins is unknown as peptides can be selected from synthetic peptide 
libraries of randomized peptide sequences. The high complexity of peptide libraries 
(i.e. presence of millions of peptide sequences) provides a high probability of 
identifying peptides binding to different domains within the protein. Moreover 
diverse peptide libraries can have peptides that can bind to domains that might play a 
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role in decreasing the effects of protein involved in aberrant mechanisms or can also 
bind specifically to the domain involved in dimerization or oligomerization. The 
most common way of selection of peptide aptamers from the diverse libraries is via 
in vitro phage display technique and many peptides have been identified using such 
approach against extracellular targets, for example IGF-1, EGF, MCP1, etc [155, 
156]. 
Significant progress has been made with peptides as therapeutic option for various 
diseases and chemical modifications of peptides have been performed to increase the 
binding efficacy. Since the peptides are really small in length, it is necessary to 
determine the binding efficacy following change in precise amino acid as amino acid 
at different positions might increase or decrease binding affinity. From therapeutics 
point of view, peptides have been used as hormones, radionuclide carrier, peptide 
vaccines and as cytotoxic drugs carrier. Due to great advancement in synthesis of 
peptides, it will be soon possible to make peptides as a cost effective small molecule 
tool.  
1.10. The future of biologics 
With the tremendous amount of success in treatment approaches to many diseases, 
biologics is one field where pharmaceutical industry has been investing heavily. 
With over 30 monoclonal antibodies approved by FDA, these biologics have indeed 
become the main focus for many researchers as an important tool to fight against 
various diseases. Due to advancement in molecular biology techniques, hybrid 
structures that combine biologics with well-defined entities have taken such tools to 
a different level to treat diseases. As mentioned in section 1.1 monoclonal antibodies 
form the backbone of biologics therapy for several diseases, however the cost of 
production is a major issue associated with such tools.. The third generation 
antibodies (especially antibody fragments) have still not managed to achieve high 
efficacy when compared to second generation antibodies. However with the success 
of full length conventional antibodies in recent years, it will be very intriguing to see 
how antibodies including fragments, Fc modified antibodies, peptide aptamers and 
drug conjugates will have an impact on the market. With ease of availability of 
peptide libraries as well as production of antibody libraries, it is an important step 
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forward to increase the affinity of tools by subjecting them to various modifications 
such as Fc engineering, mutagenesis, etc [157].  
 
1.11. AIM 
The aim of our research was to develop different types of biologics against two well 
characterized distinct targets. Firstly, we intended to develop full length monoclonal 
antibody (mAb) as well as single chain fragment variable antibody (scFv) against 
canine CD20 receptor in B cell lymphoma. Moreover we also planned to make 
different conjugates with scFv to increase the binding affinity of the antibody. 
Secondly, we developed biologics such as mAb and peptide aptamers to a protein 
called α-synuclein that is aberrantly expressed in Parkinson’s disease (PD). Also here 
we aimed to develop new assays that will be useful in future to study a protein’s 
native state. The individual aims of the project are described in more detail in 
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CHAPTER 2: Materials and Methods 
2.1 General microbiological techniques 
All the microbiological techniques were carried out using sterile glass, plastic 
apparatus and under strict aseptic conditions. Different techniques used in the lab 
have been described below: 
2.1.1 Preparation of competent cells for heat shock transformation 
method 
E.coli bacteria from a glycerol stocks were inoculated into 3 mls of Lysogeny Broth 
(LB) medium (1% (w/v) tryptone, 0.5 % (w/v) yeast extract, 1% (w/v) NaCl; 
sterilized by autoclaving) and incubated overnight in an incubator shaking at 37
0
C, 
220 rprm. 500 µl of overnight culture was added to 100 ml fresh LB and further 
incubated until an OD600nm of 0.4 was reached. All the steps from here on were 
carried out at 4
0
C in the cold room. The culture was then cooled down on ice and 
centrifuged at 2,200 g for 15 minutes at 4
0
C. The pellet was gently resuspended in  
32 mL of ice-cold buffer I (table 2.1) and incubated for 10 mins on ice. The cells 
were again centrifuged as before and the cell pellet was resuspended in 4 mL of ice 
cold buffer II (table 2.1), incubated on ice for 10 mins and quickly aliquoted into pre-
chilled sterile microcentrifuge tubes. The aliquots were snap frozen in liquid nitrogen 
and stored at -80
0
C.  The transformation efficiency of the prepared cells was checked 
via transformation of a competent cell aliquot with plasmid DNA. 
Buffer I: 
100 mM RbCl 
40 mM MgCl2.6H2O 
60 mM CH3COOK 
100 mM CaCl2.2H2O 
15% Glycerol 
Adjust the pH to 5.8 with CH3COOH and 
sterilize by filtration (0.22 µm) 
Buffer II: 
10 mM MOPS 
10 mM RbCl 
75 mM CaCl2. H2O 
15% (v/v) Glycerol 
Adjust the pH to 6.5 with NaOH and sterilize 
by filtration (0.22 µM)  
 
Table 2.1: Composition of buffers: Composition of buffer1 and 2 for creating 
competent cells for heat shock transformation method 
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2.1.2 Transformation of bacterial competent cells 
Between 50 to 200 ng of plasmid DNA or 5 µl of ligation product was added to a    
50 µl cell aliquot of E.coli DH5α cells for plasmid propagation and BL21/DE3 for 
plasmid transcription and translation. The cell aliquots containing DNA were 
incubated on ice for 30 mins, placed in a water bath at 42
0
C for 45 sec and back on 
ice for 2 mins. Under sterile conditions, 500 µl of fresh LB medium was added to the 
cell aliquot and incubated shaking at 37
0
C for 60 mins. LB agar 10 cm dishes were 
prepared (LB containing 1.5% (w/v) agar) with 100 µg/ml Ampicillin (#A9618, 
Sigma) or 25 µg/ml Kanamycin (#11815032, Invitrogen), depending on the 
appropriate antibiotic resistance encoded by plasmid. All the unused plates were 
stored at 4
0
C upside down, sealed in parafilm and pre-warmed in 37
0
C incubator 
before use. In a sterilized area, 50-200 µl of the culture was plated out onto the pre 
warmed LB plate using the glass spreader. Plates were incubated overnight upside 
down in 37
0
C incubator.  
2.1.3 Purification of plasmid DNA 
Under sterile conditions, a single colony was picked from the transformed plate using 
a sterile tip. The colony was dropped into a 5 ml LB medium (100 µg/ml Ampicillin 
or 25 µg/ml) in a 15 ml falcon tube (for small scale purification). The tube was 
incubated overnight at 37
0
C, 220 rpm and the following day the tube was centrifuged 
at 4000 rpm for 10 mins at 4
0
C. Following centrifugation, the tip and supernatant 
was discarded carefully. QIAprep Spin Miniprep Kit (#27106, Qiagen) instructions 
were followed to extract and purify plasmid DNA which was then further eluted in 
30-50 µl of elusion buffer. The concentration of the DNA was measured on a 
Nanodrop and stored at -20
0
C. 
For a larger scale purification of plasmid DNA, colony was dropped in a similar way 
but the volume of LB containing appropriate antibiotic was increased to 150-200 mL 
and grown overnight at 37
0
C. HiSpeed Plasmid Kit (#12663, Qiagen) was used for 
extraction and purification of plasmid DNA, and finally DNA was eluted in 1 ml of 
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2.1.4 Bacterial glycerol stocks 
From the overnight culture of a picked colony, 750 µl was aliquoted in a sterile 
microcentrifuge tube and 250 µl of sterile 70% (v/v) glycerol was added to the tube 
and mixed gently. The glycerol stocks were immediately snap frozen and stored at    
-80
0
C. For setting up starter cultures, a sterile tip was used to take a stab from the 
glycerol stock and streaked onto the LB agar plate containing appropriate antibiotic 
in a sterile manner. The plate was then incubated overnight at 37
0
C and a colony was 
picked up and grown to make a starter culture. 
2.1.5 Expression and purification of recombinant protein (α-
synuclein) 
Expression: 
E.coli BL21 (DE3) cells were transformed with 2 µl DNA coding for α-synuclein in 
pT7-7 vector (from C. Robert) via heat shock transformation technique. Single 
colony was grown overnight at 37
0
C in 5 ml LB (100 µg/ml Amp.) and this 
overnight culture was used to inoculate 3-4 litres of LB media (100 µg/ml Amp). 
This inoculated culture was grown at 37
0
C until an OD600nm of 0.4 was reached        
(~ 2 hours). Once an OD600nm of 0.4 was reached, the cells were induced using 1 mM 
IPTG with an incubation period of 5 hours at 30
0
C. 1 ml of sample was taken from 
the culture before induction and another 1 ml after 5 hours of induction to check for 
protein expression on the SDS gel. The cells were then pelleted down by centrifuging 
at 5,000 g for 15 minutes at 4
0
C, the pellets were snap frozen and stored at -80
0
C 
until used.  
Purification:  
1. The cell pellets were resuspended in lysis buffer:  
20 mM Tris-HCL, pH 7.5 (measure at RT, Δ pH=0.028/
0
C);  
1 mM EDTA; Protease inhibitor mixture (Roche, cat# 
11873580001);  
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1 tablet/25 ml lysis buffer; 
1 mM DTT 
Make upto 100 ml with water 
2. Each of 1 litre pellets was resuspended in 30ml lysis buffer and lysozyme  
(50 mg) was added to the lysate. The resuspended mixture was incubated on 
ice for 30 minutes for lysis to occur and was subjected to freeze thaw 
protocol to enhance lysis.  
3. Subsequently, the cells were sonicated 3 x 15 seconds with an interval of     
10 seconds. The lysate was centrifuged at 16,000 g for 15 minutes at 4
0
C and 
the supernatant was transferred to a new tube.  
4. This obtained lysate was centrifuged at 18,000 g for 30 minutes to remove 
any possible debris. This clarified lysate supernatant was collected and the 
pH was adjusted to 3.5 to precipitate any E.coli contaminating proteins.  
5. The mixture was stirred for 30 mins at RT, followed by centrifugation at full 
speed for 1 hour at 4
0
C.  
6. Meanwhile, 500 ml of buffer A and buffer B were prepared and incubated on 
ice. 
            Buffer A (low salt): Tris- HCL pH 7.5 + 25 mM NaCl 
            Buffer B (high salt): Tris- HCL pH 7.5 + 1 M NaCl 
The pH of each of the buffer was measured once the solutions were cooled to 
4
0
C. Purification was performed using a 5 ml His trap column which was 
washed by low salt buffer (Buffer A) with a flow rate of 1 ml/min.  
7. The supernatant was collected and pH was adjusted to 7.5.  This supernatant 
was filtered and stored on ice. 
8.  Following washes of column with buffer A, the tubing was placed in a flask 
containing the filtered lysate at a flow rate of 1 ml/min. 
9. The filtered lysate was collected and snap frozen in order to analyse onto the 
gel. 
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10. Once the lysate was passed through the column, high salt buffer was passed 
through the column using gradient apparatus to elute the protein.  
Gradient tube preparation: 60 test tubes were placed in the round gradient 
tubing apparatus and each containing 1.5 ml eppendorf labelled from 1 to 60 
in order to elute the protein. Buffer A was poured in the inner round flask 
whereas the outer chamber was filled with buffer B. the knob was then placed 
upside down in such a way that buffer B can enter buffer A chamber. The 
flow rate was set up at 1 ml/min. 




To determine the efficiency of purification, 10 µl of each of the fraction from the 
purification step was taken and mixed with 2 X sample buffer to be analysed onto 
12% SDS gel.  
2.2. Immunofluorescence 
For Immunofluorescence, the cells were seeded at the same density onto the required 
number of chambers. The following day transfection was performed in a similar way 
as mentioned above and subsequently chambers containing cells were washed thrice 
with PBS. The cells were then fixed onto the chambers via 4% (v/v) 
Paraformaldehyde in PBS and incubated for 15 minutes at RT. The cells were then 
permeabilised with 500 µl of 1% (v/v) Triton X 100 in PBS and incubated for         
10 minutes at RT. Following incubation, the chambers were washed thrice with PBS, 
blocked with 500 µl of 3% (w/v) BSA in PBS and incubated at RT for 30 minutes. 
The blocking agent was discarded and primary antibody diluted 1:1000 in antibody 
diluent was added to the chambers. This antibody incubation was carried out for       
1 hour at RT or overnight in humidity chamber at 4
0
C.  Then the chambers were 
washed thrice with PBS and secondary antibody (Rabbit anti-mouse 488 nm) diluted 
1:1000 in antibody diluent was added to the chambers with an incubation period of 1 
hour in humidity chamber at RT. The chambers were again washed thrice with PBS 
and were prepared for mounting. For mounting, 3 µl of DAPI fluorescent stain was 
made up in 10 drops of mounting medium (DAKO) and placed onto the slides before 
placing the chambers on it. The chambers were then placed with cells facing the 
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slides and stored in the dark until dried. Once the slides containing the chambers had 
dried, slides were ready for imaging. 
2.3. Molecular biology techniques 
All primers were designed and ordered from Sigma Genosys, whereas all enzymes 
and buffers were ordered from New England Biolabs unless stated otherwise. 
The plasmids used and their sources were: 
pGEX6p1 (28-9546-48, GE Healthcare) 
pcDNA 3.1+ ( V790-20, Invitrogen) 
pEGFP (N and C terminal vector) (Addgene) 
pMCherry (N and C terminal vector) (Addgene) 
pCOMB3Xss (Erin Worrall) 
DNA quantification 
The concentration of DNA was measured using Nanodrop spectrophotometer 
(absorbance at 260 nm). 
2.3.1 mRNA extraction and reverse transcription 
mRNA was extracted from harvested SHSY5Y cells using RNeasy Mini kit (#74104, 
Qiagen) handbook. The concentration of RNA was also quantified using Nanodrop. 
One µg of mRNA was reverse transcribed using the Omniscript reverse transcription 
kit (#205110, Qiagen). Following manufacturer’s protocol the concentration of 
cDNA was measured as mentioned above. 
2.3.2 Polymerase chain reaction 
A suitable template as cDNA or plasmid DNA is used to amplify the desired gene by 
PCR. The primers were designed in such a way that forward primer contains a 
restriction site which cuts at the 5’end of the gene and a reverse primer which has a 
                                          Chapter 2: Materials and Methods                                                   40 
 
site attached at the 3’ end of the primer. A list of primers with their restriction sites 
have been mentioned in each chapter separately.  
While designing the primers, it was ensured that the gene was in frame with the      
N-terminal of the vector sequence. Few base pairs were added to the 5’end of the 
primers before the restriction sites in order to allow efficient binding of the 
restriction sites to the primer and allow significant digestion of the insert. Also, 
primer length was manipulated to get a suitable melting temperature and presence of 
GC at the primer extremities was favoured. PCR reactions were carried out on ice in 
nuclease free tubes with 2 X high Fidelity Phusion Master mix (#M2075 NEB), 
100ng of plasmid DNA, 0.5 µM of each primer, nuclease free H2O made up to 50 µl.  
Thermal cycling conditions were: 
95
0
C for 2 min 
95
0
C for 20 sec 
58
0
C for 40 sec     repeated 30 times 
72
0
C for 3 min 
72
0




5-10 µl of PCR reaction was run on a 1.5% (w/v) agarose gel to check if the desired 
band for the amplification of the gene was obtained. Multiple PCR reactions were 
run on 1.5% (w/v) agarose gel until maximum separation of the desired and non-
specific bands was achieved. The desired band was cut using a sterile scalpel and this 
excised gel was purified by using Gel extraction kit (#28704, Qiagen) manufacturer’s 
protocol. The DNA was eluted in 30-50 µl of elusion buffer (Buffer EB) and the 
concentration of the DNA was determined using Nanodrop (OD600nm). 
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2.3.3 Restriction digestion of the purified PCR product and 
destination Vector DNA  
For these above purified PCR products, double digestion was performed using two 
different enzymes and compatible buffers recommended by supplier. The destination 
vector along with the insert was digested using these two enzymes and incubated for 
1-2 hours depending upon the amount of the vector and insert. To ensure efficient 
digestion has taken place, controls were set up such as single digestion using enzyme 
1 and enzyme 2 individually as well as no enzymes. 
2.4. Cell lines 
2.4.1 Maintenance of cell lines 
Cell lines were maintained in the appropriate medium supplemented with 10% (v/v) 
foetal bovine serum (FBS; Autogen Bioclear). Cells were incubated at 37
0
C in a 
humidified 5% CO2 incubator or 10% CO2 for specific cell lines (table 2.2).  
Cell line Cell line type Culture medium Origin 












Adherent human colon 
carcinoma 




H1299 Adherent lung carcinoma RPMI 1640 












Table 2.2: Cell lines: Various cell lines used within the experiments along with 
their origin, supplemented growth medium. 
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Cells were maintained in 10 cm tissue culture dishes and were sub-cultured 2-3 times 
a week once the confluency rate reached ~90%. The appropriate media needed for 
the cell line was warmed upto 37
0
C in the water bath along with trypsin. Medium 
was removed and cells were washed with 7-8 ml of sterile PBS. The PBS was poured 
off and cells were trypsinised using 2 ml of trypsin –EDTA 0.5% (#25300, Gibco, 
Invitrogen) with an incubation period of 5 minutes at 37
0
C. Following 5 minutes of 
trypsinisation, 8 ml of pre-warmed fresh media was added and 2 ml was transferred 
to a new 10 cm dish containing 8 ml of fresh relevant media. The dishes were then 
incubated at 37
0
C overnight.  
2.4.2. Transfection of mammalian cells 
Cells were seeded in such a way that they reached a confluency of 50-70% in order 
to transfect. Cell lines used in transfection: SHSY5Y (Dox repressible), SHSY5Y 
(low α-synuclein), HCT116+ and H1299 cells. Transfection was carried out under 
laminar air flow in tissue culture room. For transfection, sterile eppendorfs as well as 
filter sterile tips were used after spraying with 70% ethanol. For preparing 
transfection reaction mix, 100 µl of respective serum free media (based on the cell 
line) was taken in a sterile eppendorf. To this media, appropriate amount of DNA 
was added (0.5, 1 and 5 µg) along with 5 µl of transfection reagent. The reactions 
were then incubated for 15 minutes. Subsequently, the transfection reactions were 
added to the cells that were seeded before 12-14 hours previously. The plates were 
incubated for 18- 24 hours in a 37
0
C with 5% CO2. 
2.4.3 Harvesting of cells  
The cells were washed once within the 10cm plate with PBS and 1ml of PBS was 
added in order to harvest the cells. The cells were harvested by using a plastic 
scraper and harvested cells were then transferred into a fresh sterile eppendorf. The 
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2.4.4. Lysis of cells  
Lysis buffer (10%Triton) 
 Triton 10% 
 KCl -1 M 
 B- glycero phosphate (10 mM) 
 Potease Inhibitor tablet 
 EDTA (100 mM) 
 EGTA (100 mM) 
 Na2VO3 (100 mM) 
The cells were incubated on ice for 30 minutes for lysis and centrifuged at         
10000 rpm and the supernatant were transferred to a sterile eppendorf. The protein 
concentration within the lysate was determined by Bradford assay (Bio-Rad) after 
reading the plate at wavelength of 595 nm. The samples were then prepared using 2X 
sample buffer containing 1 M DTT and normalized with water. The prepared 
samples were heated at 85
0
C for 5 minutes and loaded onto an appropriate 
percentage SDS gel.   
2.5. SDS gel preparation and Immunoblotting: 
2.5.1. 2X Sample buffer preparation: 
2 ml Tris (1 M, pH 6.8) 
4.6 ml glycerol (50%) 
1.6 ml SDS (10%) 
0.4 ml bromophenol blue (0.5%) 
0.4 ml β- mercaptoethanol 
The samples after normalizing were made up to a certain amount with 2X sample 
buffer. Based on the size of protein, the lysate/ protein were run on an appropriate 
percentage of SDS polyacrylamide gel. The samples were loaded onto the gel along 
                                          Chapter 2: Materials and Methods                                                   44 
 
with a pre-stained ladder and the gel was run in 1X running buffer at 150 V for 1 
hour at RT. Solutions needed for Tris glycine SDS - polyacrylamide gel 
electrophoresis- three different size of combs: 0.75 mm, 1.0 mm and 1.5 mm (10, 15 
wells), the appropriate percentage of SDS gel was made based on the molecular 





       Component volumes  (ml) per gel mold volume of 










   
 2.6          5.3         7.9         10.6          13.2          15.9           21.2           26.5 
 1.0          2.0         3.0           4.0            5.0            6.0             8.0           10.0 
 1.3          2.5         3.8           5.0            6.3            7.5           10.0           12.5 
 0.05        0.1         0.15         0.2           0.25           0.3             0.4             0.5 
 0.05        0.1         0.15         0.2           0.25           0.3             0.4             0.5 
     









   
 2.3         4.6         6.9            9.3           11.5          13.9           18.5           23.2 
 1.3         2.7         4.0            5.3             6.7            8.0           10.7           13.3 
 1.3         2.5         3.8            5.0             6.3            7.5           10.0           12.5 
 0.05       0.1         0.15          0.2            0.25           0.3             0.4             0.5 
 0.05       0.1         0.15          0.2            0.25           0.3             0.4             0.5 
  









   
 1.9         4.0         5.9             7.9            9.9           11.9           15.9          19.8 
 1.7         3.3         5.0             6.7            8.3           10.0           13.3          16.7 
 1.3         2.5         3.8             5.0            6.3             7.5           10.0          12.5 
 0.05       0.1         0.15           0.2           0.25            0.3             0.4            0.5 
 0.05       0.1         0.15           0.2           0.25            0.3             0.4            0.5 
  




   
 











1.6            3.3          4.9             6.6            8.2            9.9           13.2        16.5  
2.0            4.0          6.0             8.0          10.0          12.0           16.0        20.0 
1.3            2.5          3.8             5.0            6.3            7.5           10.0        12.5 
0.05          0.1          0.15           0.2            0.25          0.3             0.4          0.5 
0.05          0.1          0.15           0.2            0.25          0.3             0.4          0.5 
 









   
1.1           2.3          3.4             4.6             5.7            6.9             9.2         11.5  
2.5           5.0          7.5           10.0           12.5          15.0          20.0         25.0 
1.3           2.5          3.8             5.0             6.3            7.5          10.0         12.5 
0.05         0.1          0.15           0.2             0.25          0.3            0.4           0.5 
0.05         0.1          0.15           0.2             0.25          0.3            0.4           0.5 
 





       Component volumes  (ml) per gel mold volume of 
 











     
 0.68      1.4          2.1         2.7        3.4           4.1           5.5            6.8 
 0.17      0.33        0.5         0.67      0.83         1.0           1.3            1.7 
 0.13      0.25        0.38       0.5        0.63         0.75         1.0            1.25 
 0.01      0.02        0.03       0.04      0.05         0.06         0.08          0.1 
 0.01      0.02        0.03       0.04      0.05         0.06         0.08          0.1 
 





Table 2.3: SDS gel ingredients: different percentage of gel based on thickness 
to run higher and lower molecular weight proteins. Both resolving as well as 
stacking gels have been mentioned in the table with respective volume of each 
component 
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2.5.2 Coomassie staining 
Following SDS-PAGE, visualization of proteins was performed by Coomassie 
staining. The gels were immersed in 20-25 ml of Coomassie stain and kept shaking 
for 1hour at RT followed by destaining until distinct bands become visible. The gel 
was then dried using a gel dryer. The staining solution comprised of 50% (v/v) 
methanol, 10% (v/v) glacial acetic acid and 0.2% (w/v) Coomassie brilliant blue R-
250. The destaining solution was made up using 7.5% (v/v) methanol, 10% (v/v) 
glacial acetic acid.   
2.5.3 Western blot 
Once the gel was run, it was transferred onto nitrocellulose membrane in such a way: 
Black side of cassette – sponge - blotting paper – gel - membrane – blotting paper –
sponge. 10 X transfer buffer was diluted down to 1 X with an addition of 200 ml of 
methanol to enhance transfer of small proteins. The western blot was performed at 
100 V for   1 hour with an ice block. Subsequently, the membrane was ink stained 
and blocked with 5% (w/v) skimmed milk in PBS-T (0.1%) for 1 hour. Following on, 
primary antibody was diluted in 5% milk (in PBS-T) and added to the blocked 
membrane and incubated for 1 hour at RT or overnight at 4
0
C. The blot was then 
washed thrice with PBS - T (0.1% (v/v)) and HRP conjugated appropriate secondary 
antibody was diluted in blocking buffer and added to the blot and again incubated for 
hour. The blots were then washed thrice again with PBS-T 0.1% (v/v) and the results 
were analysed by overlaying the blots with ECL (1+2) for 2 minutes. 
 ECL I ECL II 
100 mM Tris HCL pH 8.5 100 mM Tris HCL pH 8.5 
2.5 mM Luminol 0.02% (v/v) H2O2 
0.4 mM p- Coumaric acid - 
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2.6. ELISA 
2.6.1. Streptavidin coated overnight plate for measuring antibody 
binding to the biotinylated peptides (epitope mapping) 
96 well ELISA plate (Nunc) was coated with streptavidin (200 ng/well) and 
incubated overnight at 4
0
C. The following day the plate was washed thrice with PBS 
- Tween 20 (0.1% v/v) and the overlapping peptides were diluted down to             
100 ng/well in 3% (w/v) BSA. The peptides were added in four different dilutions to 
each respective well and incubated at RT for 1 hour. Subsequently, the plate was 
washed thrice with 0.1% (v/v) PBS-T and was blocked for 1 hour at RT with 3% 
(w/v) BSA in PBS.  Meanwhile several dilutions for antibody were prepared in 3% 
(w/v) BSA and following blocking these antibody dilutions were added to each 
respective well of the plate and incubated for 1 hour at room temperature. Following 
this, the wells were washed once again 3 X PBS-T and HRP conjugated anti-rabbit 
anti-mouse/ swine anti-rabbit was added at a dilution of 1:1000 prepared in 3% (w/v) 
BSA with an incubation period of 1 hour. During the incubation period, the TMB (3, 
3’, 5, 5’- tetramethylbenzadine) substrate was prepared. 
 
100 µl of TMB substrate was added to each well and the plate was incubated with 
shaking gently at RT for 15 minutes. The reaction in the wells was stopped once 
colour change was observed from colourless to blue. Following incubation, 50 µl 
stopping solution was added to each well (blue to yellow) and the plate was read at 
an absorbance of 450 nm. In all the experiments we made use of negative controls 
and blank.     
 
2.6.2. Binding of antibody to WT protein 
96 well plate (Nunc) was coated with protein of interest diluted at 200 ng/ well in 
NaHCO3 buffer and incubated overnight at 4
0
C. Following day the plate was washed 
thrice using 3 X PBS-T and blocked with 3% (w/v) BSA in PBS for 1 hour. During 
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this blocking stage antibody dilutions in 3% BSA (w/v) were prepared and this step 
was preceded by addition of primary antibody to each well for an incubation period 
of 1 hour. The plates were then washed thrice with 0.1% (v/v) PBS-T and HRP 
conjugated secondary antibody (Rabbit anti-mouse/ swine anti- rabbit @ 1:1000) was 
added to all the wells and incubated for another hour. After the incubation was done, 
the wells were again washed 3 x PBST and developed using TMB as a substrate. 
Once the blue colour was developed within the wells, the reaction was stopped using 
dilute H2SO4. 
 
2.6.3. TMB substrate 
Citrate/acetate buffer: 1 ml 0.1M sodium acetate + 40 µl 0.1 M citric acid 
Diluted H2O2: 15 µl 30% H2O2 + 10 µl H2O  
TMB: 100 µl diluted TMB 
Make upto 10 ml with H2O 
Stopping solution: Dilute H2SO4- 5 ml H2SO4 + 195 ml H2O 
50 μl of substrate was added to each ELISA well and incubated for 15-30 minutes. 
This is followed by addition of stopping solution each well just before reading the 
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2.7. Monoclonal antibody isolation against canine CD20  
2.7.1. Immunization of BALB/c mice with canine CD20 peptide 
(NCDPANPSEKNSLSIQYCGS) 
BALB/c mice aged 6-8 weeks was initially immunized with a final concentration of 
100 μg/ml CD20, mixed in a 1:1 ratio with Freund’s complete adjuvant. A volume of 
200μl was injected into the peritoneal cavity of the BALB/c mice for immunization. 
Subsequent injections were performed with 25 μg/ ml CD20 peptide mixed in a ratio 
1:1 with Freund’s incomplete adjuvant. A tail bleed was taken from the mice 7 days 
after injection and the antibody titre against CD20 was determined. Once a high titre 
was reached, the mice was given a final boost into the peritoneal cavity and then 









2.7.2. Octet binding antibody-peptide binding assay.  
The binding assay was carried out using streptavidin-coated biosensors on an Octet 
RED biolayer interferometry system (FortéBio Inc.) that measures binding to the 
sensor tip as a wavelength shift (in nm) in real time. All the steps of the assay 
process were performed at 30 °C with the plate shaking speed set at 1000 rpm. 96-
well microtitre plates (Greiner Bio) were made up using 200 µl volumes. Analytes 
were diluted with PBS (pH 7.4) containing 0.02 % Tween 20, 0.005 % sodium azide 
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and 100 µg/mL bovine serum albumin (Kinetics Buffer – Forte Bio). Biotinylated 
CD20 peptide was loaded onto to 8 sensors from a 2 µg/mL solution containing        
2 mM dithiothreitol (Sigma-Aldrich) until a wavelength shift of 0.5 nm had been 
achieved. The association data were collected for 10 minutes from solutions of 
monoclonal CD20 antibody where the concentration was varied between 32 nM and 
0.5 nM by half serial dilution. The dissociation step was carried out over a 40 minute 
time period in Kinetics Buffer. The assay data were processed using Data Analysis 
(version 6.3 – Forte Bio) to obtain kinetic values. Briefly, a buffer blank was used as 
a reference cell subtraction and the data series was evaluated using a global fit 
algorithm for 1:1 binding interaction.  
Fluorescent polarization assay was performed using anti-canine monoclonal antibody 
onto FITC tagged human CD20 peptide, with the human-mouse chimeric 
monoclonal antibody Rituximab as the control antibody. Purified monoclonal 
antibody NCD1.2 and Rituximab diluted in PBS were titrated against 30 nM 
fluorescein-labelled peptide corresponding to human CD20 
(NCEPANPSEKNSPSTQYCYS) in assay buffer (PBS, 0.05% Tween-20). To 
subtract the nonspecific binding, we used purified mouse immunoglobulins with the 
same concentration as analysed antibodies. All reactions were carried out in a total 
volume of 60 µl per well of a 96-well black Nunc Plate (Sigma-Aldrich). The plate 
was incubated for 1 hr at room temperature with shaking. Fluorescence polarization 
was measured at 21 °C using FilterMax™ F5 Multimode Microplate Reader 
(Molecular Devices) with excitation and emission wavelengths of 485 nm and      
535 nm, respectively.  
 
2.7.3. Transfection of GFP-CD20 into H1299 cells 
Primers introducing BamHI and XhoI sites at the ends of reported sequence 
(Genbank accession number NP_068769.2) of human CD20 were designed for its 
amplification. Forward primer introduced the Kozak consensus sequence in front of 
the initiation codon. The PCR product was digested and cloned into the mammalian 
expression vector pCDNA 3.1 (Clontech) digested using the same enzymes. 
Specificity of primers was confirmed by BLAST programme. GFP- CD20 expression 
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was driven by EF1 promoter, a strong promoter in mammalian cells, also the plasmid 
contained Ampicillin (Sigma Aldrich) resistance gene as a selectable marker. Once 
the gene was cloned, the specificity and efficiency of cloning was determined via re-
digestion and DNA sequencing. H1299 cells were grown as monolayers in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS). 0.25, 0.5 and 1 µg of DNA 
(GFP - CD20) was transfected in H1299 cells, along with GFP as a negative control 
using Attractene in order to measure the binding efficiency of the mouse anti-canine 
monoclonal antibody to its human CD20 counterpart. The activity was determined 
via Western blot as well as Immunofluorescence. Chemical fractionation into 
compartments was carried out using a fraction kit (Calbiochem) that separates into 
cytosolic, membrane/organelle, nuclear and insoluble proteomes. Cell lysis and 
membrane fractionation were performed in collaboration with Lisa Pang (David 
Argyle’s lab) to analyse the expression of CD20. 
2.7.4. Fluorescence activated cell sorting (FACS)  
Flow cytometry (FCM) expression of CD20 was evaluated on fine needle aspirate 
biopsies in RPMI 1640 medium (Invitrogen) obtained from dogs with different 
lymphoma subtypes with help of Stefano Comazzi (Department of Veterinary 
Science, Via Celoria, Milano, Italy). On each sample immunophenotyping was 
performed according to the previously published protocols in order to define 
immunophenotype and to identify the lymphoma subtype. Evaluation of expression 
of membranous CD20 was performed using the following procedure: To avoid any 
non-specific binding, cells (adjusted at 5x 105 cells per tube) were incubated in 
RPMI 1640 medium containing 5% fetal bovine serum (FBS) and 0.2% sodium 
azide, followed by resuspension in PBS. One µl of mouse anti- canine CD20 Ab was 
added and incubated for 20 mins at 4 
0
C. After two washes in RPMI/ FCS/ sodium 
azide, 2 µl of goat anti-mouse Ig (FITC, Becton Dickinson) was added and incubated 
in the dark for 20 mins at 4 
0
C. To evaluate non-specific binding of secondary 
antibody, one of the vials was used with lack of primary antibody. Isotype control 
was not used due to the lack of isotype matched available antibody. Following the 
incubation, cells were washed and cells were acquired using FacScalibur equipment 
(Becton Dickinson). The acquisition parameters were kept constant for the duration 
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of the study and the machine was routinely calibrated using calibration beads 
(CaliBRITE, Becton Dickinson, San Jose, CA, USA) to ensure comparable readings 
between different days. A minimum of 10,000 events were gated to exclude dead 
cells, and analysis was performed with Cell Quest software (Becton Dickinson, San 
Jose, CA, USA). Thus, the efficiency of anti-canine CD20 antibody was determined 
on different types of B and T cell lymphomas that are meant to be positive and 
negative for CD20, respectively using FACS.  
2.7.5. Immunohistochemistry  
Biopsies were obtained from dogs with different types of B and T cell lymphomas, 
including Diffuse Large B-cell lymphoma (DLBCL), Marginal Zone Lymphoma 
(MZL), Follicular Lymphoma (FL), B-cell small lymphocytic (B-SLL), and 
Lymphoma and Peripheral T-cell Lymphoma (PTCL). All lymphoma samples were 
taken as part of normal diagnostic procedures from dogs with newly diagnosed, 
previously untreated lymphoma. For tissue microarray (TMA), hematoxylin and 
eosin-stained sections from each paraffin-embedded, formalin fixed block were used 
to define diagnostic areas and cores were obtained from each case and inserted in a 
grid pattern into a recipient paraffin block using a tissue arrayer. Sections were then 
cut and stained with antibodies to CD20 as well as CD79. Following 
deparaffinization, heat induced antigen retrieval techniques were used for each 
antibody. Sections were analysed for presence of positive immunolabelling to the 
mouse anti-canine CD20 antibody.  
 
2.7.6. Characterization of anti-CD20 mAb on Raji cells by 
Immunofluorescence  
Immunofluorescence was performed on CD20 expressing human Raji cells using 
mouse anti-CD20 mAb. This experiment was performed in order to measure the 
activity of anti-CD20 mAb onto human CD20 expressing cells. A488 was used as a 
detection fluorescent tag attached to the secondary antibody. Rituximab coupled to 
A488 and secondary antibody coupled to A488 were used as positive and negative 
control respectively.  
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2.8. Construction of mouse scFv antibody library 
2.8.1. Extraction and isolation of total RNA from immunized mice 
Prior to the extraction procedure, some preparatory steps are followed. Oakridge 
tubes are cleaned with Virkon® to remove any contamination. They are then washed 
with RNAse free water (Sigma), sprayed with RnaseZap® (Sigma) and left overnight 
to make sure no contaminating Rnases are present. The homogenizer is thoroughly 
washed with ‘Rnase free’ water, autoclaved and then baked in a 60 
0
C oven 
overnight. A laminar flow hood is de-contaminated by cleaning with 70% ethanol 
prepared in Rnase free water and also all the materials used for the extraction 
procedure are decontaminated. The mice was sacrificed by cervical dislocation, 
spleen was removed and placed in Rnase free tube. The spleen was then 
homogenized in 10 ml Trizol reagent using a sterile homogenizer and the tubes were 
centrifuged in an Eppendorf 5810r centrifuge at 1575 g for 10 minutes at 4 
0
C. The 
supernatant was removed into 50 ml Oakridge tubes containing 2 ml of chloroform. 
This was mixed well by shaking and incubated at RT for 15 minutes. This incubated 
sample was then centrifuged at 17500 g for 20 minutes at 4 
0
C. Following 
centrifugation, three layers become visible. The upper aqueous layer is carefully 
removed ensuring that none of the organic layer is transferred from the interphase. 
This aqueous layer is added to a large Oakridge tube with 5 ml of isopropanol for 
precipitation. This is mixed and left at RT for 10 minutes. It is then centrifuged at 
17500 g for 20 minutes at 4
0
C. The supernatant is carefully removed and discarded 
ensuring that the pellet is not disrupted. The RNA pellet is washed by adding 10 ml 
of 75% ethanol. This is centrifuged again at 17500 g for 10 minutes at 4
o
C and the 
supernatant is again discarded. The pellet is air dried in laminar flow cabinet and 
gently resuspended in 250 μl of molecular grade water (Sigma). The RNA is then 
subsequently quantified on Nanodrop and cDNA synthesis is performed. 
2.8.2. Reverse transcription of total RNA to cDNA 
Omniscript Reverse transcription kit (Qiagen) was used in order to make cDNA from 
RNA 




         Final concentration 
Master mix 
  
10X Buffer RT 
 
  
         2 µl 
 
 
         1 x 
 
dNTP mix (5 mM each dNTP) 
 
         2 µl 
 
         0.5 mM each dNTP 
 
Oligo –dT primer (10 µM) 
       
         2 µl 
 
        1 µM 
 
RNAse inhibitor (10 units/ µl) 
 
         1 µl 
 





         1 µl 
 
        4 units    (per 20 µl) 
 
RNAse free water  
 
       variable 
Template RNA  
Template RNA, added at step 5 
 
       variable 
 
Upto 2 µg (per 20 µl reaction) 
 
Total volume                                          20 µl 
 
 
2.8.3. PCR primers for the construction of a murine scFv library 
(pCOMB3xSS vector) 
A set of total 17 forward primers (5’) and 3 reverse primers (3’) was used for the 
amplification of variable kappa light chain, two primers for amplification of lambda 
light chain (3’, 5’). For amplification of heavy chain a total of 19 forward primers 
(5’) were used with 3 reverse primers (3’). The sequence of all the primers used has 
been mentioned below: 
 
 
Table 2.4: Reverse transcription: Qiagen protocol for reverse transcription 
(RNA to cDNA) 
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VK 5’ Sense primers 
MSCVK-1 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TCC AGC TGA CTC AGC C 3’ 
MSCVK-2 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C 3’ 
MSCVK-3 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT C 3’ 
MSCVK-4 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C 3’ 
MSCVK-5 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 3’ 
MSCVK-6 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT C 3’ 
MSCVK-7 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT C 3’ 
MSCVK-8 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA C 3’ 
MSCVK-9 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT C 3’ 
MSCVK-10 
5’ GGGCCC AGG CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT C 3’ 
MSCVK-11 
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5’ GGG CCC AGG CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C 3’ 
MSCVK-12 
5’ GGG CCC AGG CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C 3’ 
MSCVK-13 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK C 3’ 
MSCVK-14 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG A 3’ 
MSCVK-15 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW T 3’ 
MSCVK-16 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC C 3’ 
MSCVK-17 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C 3’ 
VK 3’ Reverse primer 
MSCJK12-BL 
5’ GGA AGA TCT AGA GGA ACC CCC ACC ACC GCC CGA GCC ACC GCC 
ACC AGA GGA TIT KAT TTC CAG YTT GGT CCC 3’ 
MSCJK4-BL 
5’ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TTT TAT TTC CAA CTT TGT CCC 3’ 
MSCVJK5-BL 
5’ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TTT CAG CTC CAG CTT GGT CCC 3’ 
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Vλ 5’ sense primer 
MSCVL-1 
5’ GGG CCC AGG CGG CCG AGC TCG ATG CTG TTG TGA CTC AGG AAT C 
3’ 
Vλ 3’ reverse primer 
MSCJL-BL 
5’ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA GCC TAG GAC AGT CAG TTT GG 3’ 
VH 5’ Sense primers 
MSCVH1 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG CTT CAG GAG 
TC 3’ 
MSCVH2 
 5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG CTB CAG CAG 
TC 3’ 
MSCVH3 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG CTG AAG SAS TC 
3’ 
 MSCVH4 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR CTG CAA CAR TC 
3’ 
MSCVH5 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG CTB CAG CAR TC 
3’ 
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MSCVH6 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR CTG CAG CAG TC 
3’ 
MSCVH7 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC GTG AAG CAG 
TC 3’ 
MSCVH8 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS STG GTG GAA TC 
3’ 
MSCVH9 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG YTG GTG GAG 
TC 3’ 
MSCVH10 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG SKG GTG GAG 
TC 3’ 
MSCVH11 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM CTG GTG GAG 
TC 3’ 
MSCVH12 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG CTG ATG GAR 
TC 3’ 
MSCVH13 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR CTT GTT GAG TC 
3’ 
MSCVH14 
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5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT CTC GAG TC 
3’ 
MSCVH15 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR STT GAG GAG TC 
3’ 
MSCVH16 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT CTR AAA GWG 
TST G 3’ 
MSCVH17 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA CTV CAG CAR 
CC 3’ 
MSCVH18 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAC TTG GAA GTG TC 
3’ 
MSCVH19 
5’ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG GTC ATC GAG 
TC 3’ 
VH 3’ Reverse primers 
MSCGlab-B 
5’ CCT GGC CGG CCT GGC CAC TAG TGAA CAG ATG GGG STG TYG TTT 
TGG C 3’ 
MSCG3-B 
5’ CCT GGC CGG CCT GGC CAC TAG TGA CAG ATG GGG CTG TTG TTG T 
3’ 
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MSCM-B 
5’ CCT GGC CGG CCT GGC CAC TAG TGA CAT TTG GGA AGG ACT GAC 
TCT C 3’ 
2.8.4. Overlap Extension primers 
For splicing heavy and light chains i.e. making scFv, another round of PCR was 
performed using 100 ng of each purified variable heavy and light chain. The primers 
used in this PCR contain the site for digestion with SfiI as well as linker sequence to 
anneal the two chains. The sequence of each of the primer has been mentioned 
below: 
RSC-F (sense) 
5’ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 
3’ 
RSC-B (reverse) 
5’ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG 3’ 
 
Amplification of antibody variable domain genes using pCOMB series primers 
The standard PCR reaction components and conditions were as follows: 
Component                                                  Concentration in 50 μl reaction 
cDNA                                                                             0.5 μg 
2x Phusion master mix                                                            25 μl                                                                       
(Phusion polymerase, dNTPs and Phusion buffer)                                                                                                                                     
Forward primer                                                                60 pM 
Reverse primer                                                                60 pM 
This mixture is made up to 50 μl with Mg H2O. 
                                          Chapter 2: Materials and Methods                                                   61 
 
PCR amplification of the variable domains from murine cDNA was performed in a 
Biometra TGradient PCR machine and under the following conditions: 
 Step 1:                      94
o
C for 5 minutes 
Step 2:                      30 cycles of;                                       94
o
C for 15 seconds 
                                                                                         56
o
C for 30 seconds 
                                                                                         72
o
C for 90 seconds 
Step 3:                                                                               72
o
C for 10 minutes 
 
After the amplification of the variable regions, five microliters of each PCR product 
was analysed on a 2% (w/v) agarose gel. The reaction was scaled up (10 X) in order 
to obtain more of PCR product and then PCR products were pooled together and 
ethanol precipitated to extract DNA using 3 M sodium acetate. The PCR products 
were purified on a 1.5% (w/v) agarose gel, DNA was quantified using Nanodrop at 
an absorbance of 260nm. 
 
2.8.5. Splicing of purified PCR products by overlap extension PCR 
In SOE - PCR, appropriate purified variable heavy and light chains (VH and VL) are 
mixed in equal ratios in order to generate the overlap product. Both the purified 
variable fragments are joined together via a glycine serine linker (G4 S) 4, producing 
a fragment of approximately 750 bp. A total of 10 µg of total product was made via 
PCR and gel extraction in order to proceed to the next step.  
 
SOE PCR components for amplification of mixed variable heavy and light chains; 
 Component                       Concentration in 50 μl reaction 
Phusion Mastermix (2X)                               25 μl  
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VH                                                               100 ng 
VL                                                               100 ng 
Forward primer                                            60 pM 
Reverse primer                                            60 pM 
The mixture was made up to 50 μl with Mg H2O. 
The PCR amplification was again performed in a Biometra TGradient PCR machine 
under following conditions: 
            Step 1      94
o
C for 5 minutes 
 Step 2 
 20 cycles of;       94
o
C for 15 seconds 
       56
 o
C for 15 seconds 
       72
 o
C for 2 minutes 
 Step 3      72
 o
C for 10 minutes                  
 
2.8.6. Restriction digest of the purified overlap PCR product and 
vector DNA 
Restriction digest of the purified overlap PCR product: 
 Component concentration per reaction                                     1 X 
 Purified overlap PCR product                                                 10 ng 
 SfiI (36 U per μg of DNA)                                                     360 U 
 NEB Buffer 2 (10 X)                                                             1 X 
 BSA (100 X)                                                                        1 X 
 Molecular grade was added to a final volume of 500 μl. 
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Restriction digest of the purified vector DNA: 
 Component Concentration per reaction                                     1 X 
 Vector DNA (pCOMB3xSS)                                                  20 μg 
 SfiI (6 U per μg of DNA)                                                      120 U 
 NEB Buffer 2 (10 X)                                                              1 X 
 BSA (100 X)                                                                         1 X 
 Molecular grade water was added to a total volume of 200 μl. 
The digestion reactions were incubated for 5 hours at 50
0
C. PCR products were 
pooled together and ethanol precipitated. The digested PCR fragment and 
pCOMB3xSS vector along with stuffer fragment were purified on a 1% (w/v) 
agarose gel and 0.6% (w/v) agarose gel, respectively. DNA was quantified by 
measuring the absorbance at 260 nm on Nanodrop. 
 
2.8.7. Ligation of the digested overlap PCR product with vector 
DNA 
The gel purified SfiI restricted scFv insert fragment was cloned into digested 
pCOMB3xSS facilitated by T4 DNA ligase. 
 Component Concentration per reaction                                 20 X 
 pCOMB3xSS (digested and purified)                                   1.4 μg 
 Overlap PCR product (digested and purified)                       700 ng 
 T4 DNA ligase buffer                                                           1 X 
 T4 DNA ligase                                                                   10 μl 
 Molecular grade water was added to a total volume of 400 μl. 
Ligation reaction was incubated at 16
0
C overnight. The ligation reaction was then 
purified the following day by mini purification kit (Invitrogen) and DNA pellet was 
resuspended in 10 μl of molecular grade water and transformed into E.coli TG1 
electrocompetent cells by electroporation. 
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2.8.8. Transformation of E.coli TG1 cells with pCOMB3xSS vector 
containing variable heavy and light chains and measurement of 
transformation efficiencies 
The eluted 10 μl purified ligation reaction (5 x 2 μl) was transformed into TG1 cells. 
30 μl of cells were added to each reaction in electrocuvettes and stored on ice for      
1 minute. This was followed by electroporation at 2.5 kV, immediately flushed with 
250 μl of SOC media. These electroporated samples were then incubated for 1 hour 
at 37
0




 (library titre) were 
prepared for both i.e. vector containing insert as well as vector DNA only. Also rest 
of the transformed culture was plated out on a large assay plate containing LB     
(100 μg/ml Ampicillin) with 2% glucose. 100 μl of each dilution was poured onto the 
respective LB plates containing 100 μg/ml carbenicillin and all the plates were 
incubated overnight at 37
0
C. 
The total transformants were the number of colonies from the titered plates, 
multiplied by total culture volume (1.3 ml) and divided by plating volume (0.1 ml). 
The whole library was scrapped off using LB media containing 2% glucose and 
glycerol. Also, OD of the library was measured and the optimum amount of library 
to be used for biopanning experiment was calculated.  Library stocks were flash 




2.9. Biopanning (following Barbas protocol) 
All biopanning experiments were carried out in a clean area to avoid any 
contamination in the prep lab. Liquid waste including blocking solutions were 
decanted into glassware containing either Virkon or bleach. The liquid waste will be 
handled in method outlined in the SOP for handling aflatoxin and phycotoxin 
material. 
Personal protective equipment has to worn when working with toxic materials, and 
also during decontamination, disposal and spillage procedures. Gloves to be worn at 
all times and all the waste materials should be discarded into a waste container. 
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Glassware, centrifuge chambers, etc to be used were soaked in Virkon overnight, 
rinsed and following day rinsed with tap water.  Centrifuge chambers were then 
autoclaved. The parameters set in different rounds of panning are mentioned in table 
2.5. 




The transformed library was transferred to 1000 ml LB containing 100 µg/ml 
ampicillin and the cells were grown at 37
0
C to an OD600nm of 0.6. One ml of              
1 x 10
11
 pfu/ ml helper phage was added and culture was incubated stationary at 37
0
C 
for 30 minutes. The culture was then propagated at 200 rpm and 37
0
C for 2 hours.  
Subsequently kanamycin (50 µg/ml) (Invitrogen) was added and the cultures were 
incubated overnight at 200 rpm at 30
0
C. Also, overnight cultures (5 ml) of E.coli 
TG1 cells were prepared for sub-culturing following day to prepare phage titres.    
500 µl of streptavidin was coated onto the immunotube; the tube was covered in 




 LB media 
 100 mg/ml Ampicillin 
 4 autoclaved 250 ml centrifuge chambers 
Table 2.5: Parameters for different rounds of panning: Culture volume, 
peptide concentration and number of washes in each of the four rounds of 
biopanning. 
                                          Chapter 2: Materials and Methods                                                   66 
 
 PEG/ NaCl 
 GSA Rotor (40C) 
 3% BSA in PBS 
 
2.9.1. Panning round I: 
Several dilutions (1:1000, 1:2000, 1:4000 and 1:8000) of the overnight TG1 cells 
were sub-cultured in 20 ml LB and grown to an OD600nm of 0.6 (Use fresh 
electrocompetent cells for each overnight i.e. aliquot cells to prevent phage 
contamination).  
Phage preparation 
- The overnight phage library was placed in 4 x 250 ml centrifuge bottles    
(250 ml per centrifuge bottle). Centrifuge at 9000rpm in a GSA rotor (brake 
off) for 20 minutes. 
- The phage supernatant was transferred to fresh 250 ml  centrifuge bottles 
containing 8 g of PEG (4% w/v) and 6 g of NaCl (3% w/v). These centrifuge 
bottles were placed in a shaker at 200 rpm for 20 minutes until PEG and NaCl 
were fully dissolved. This precipitated mixture was placed on ice for            
30 minutes. 
- Centrifuge at 9000 rpm in a black rotor (brake off) for 15 mins at 40C. 
Discard supernatant and dry inverted on tissue for 10 minutes. 
- Resuspend the pellet thoroughly using 2 ml 3% (w/v) BSA and transfer to a 
microcentrifuge tube. Centrifuge again at full speed for 5 minutes at 4
0
C. 




2.9.2. Panning –Round 2, 3 and 4 
Several dilutions (1:1000, 1:2000, 1:4000 and 1:8000) of the overnight TG1 cells 
were sub-cultured in 20 ml LB and grown to an OD600nm of 0.6 (Use fresh 
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electrocompetent cells for each O/N i.e. aliquot cells to prevent phage 
contamination).  
Phage preparation 
- The overnight phage library was placed in 2 x 50 ml centrifuge bottles (50 ml 
per chamber). Centrifuge at 9000 rpm in a GSA rotor (brake off) for            
20 minutes. 
- The phage supernatant was transferred to fresh 50ml chambers containing 2 g 
of PEG (4% w/v) and 1.5 g of NaCl (3% w/v). These chambers were placed 
in a shaker at 200 rpm for 20minutes until PEG and NaCl were fully 
dissolved. This precipitated mixture was placed on ice for 30 minutes. 
- Spin at 9000 rpm in a black rotor (brake off) for 15 mins at 40C. Discard 
supernatant and dry inverted on tissue for 10 minutes. 
- Resuspend the pellet thoroughly using 2 ml 3% (w/v) BSA and transfer to a 
microcentrifuge tube. Spin again at full speed for 5 minutes at 4
0
C. Transfer 





- An immunotube was coated overnight with streptavidin 
- Following day, the tube was washed 3 x PBS-T and CD20 peptide was added 
to the immunotube and incubated shaking for 1 hour at RT. 
- The immunotube was then blocked with 3% (w/v) BSA for 1 hour at RT. 
- The immunotube was washed once with PBS-T – fill up the immunotube and 
tap off the excess. 
- 1ml of input phage (precipitated phage) was added onto the immunotube and 
incubated for 2 hours at RT rotating. 
- The phage was then discarded into bleach waste bucket. The immunotube 
was then washed with required amount of times depending on the round of 
panning and washing was discarded into bleach bucket. 
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- For elusion of binding phages, 1 ml of 10 mg/ml trypsin (in PBS) was added 
and placed on a rotator for 15 minutes. This was pipetted up and down to 
obtain all the binding phage. 
- This eluted phage (800 µl) was then infected into E.coli TG1 cells (5 mls) 
that have been grown to an OD600nm of 0.6 and incubated static at 37
0
C for    
15 minutes. 
- This TG1 infected phage culture was added to 6 mls of pre warmed LB 
medium in a 50 ml falcon tube. This 12 ml culture was incubated at 37
0
C for 
1 hour with shaking at 220 rpm. 
- After 1 hour, 800 µl of commercial M13KO7 helper phage (NEB N0315S) 
was added. This was transferred to a new glass conical flask (250 ml) that 
contains 88 ml of pre-warmed media containing 100 µl ampicillin and kept 
shaking for 2 hours at 37
0
C. 
- Following 2 hours incubation, 200 µl of kanamycin (50 μg/ml) was added 




- Output titres (eluted phage): A series of dilutions (10-1 to 10-8) was prepared 
using 2 µl of eluted phage in 223 µl E.coli TG1 cells (OD600nm ~0.6). The 
eppendorfs were then incubated static at 37
0





) were plated out after incubation onto LB (Amp) plates.  
- Input titres (phage before adding to the immunotube for selection) and 





prepared in 223 µl E.coli TG1 cells in sterile eppendorfs.   
- Following overnight incubation at 300C, the culture was centrifuged at    
3,200 g in an Eppendorf 5810r centrifuge for 15 minutes at 4
0
C. The 
supernatant was PEG precipitated as mentioned in the above section. 
- As mentioned in above section, overnight fresh TG1 cultures were set up and 
immunotube coated overnight with streptavidin for next rounds and similar 
mentioned protocol was followed. 
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2.9.3. Polyclonal phage pool ELISA and colony pick PCR 
A Nunc Maxisorb
TM 
plate was coated with 100 µl of 1 µg/ml streptavidin and 
incubated overnight at 4
0
C. Following day, the plate was washed with 3 x PBS-T 
(0.1% (w/v)) and 100 µl of biotinylated CD20 peptide (1 µg/ml) was added and the 
plate was incubated for 1 hour at RT. The excess conjugate was discarded and the 
plate was subsequently blocked with 200 µl of 3% (w/v) BSA in PBS for 1 hour. The 
blocked plate was washed again 3 x PBS-T (0.1% (w/v)) and the stored phage pool 
from all the rounds was added to different wells of the plate and incubated for 1 hour 
at RT.  
The excess phage was discarded in the bleach bucket, plate was washed again 3 x 
PBS-T (0.1% (w/v)) and 100 µl of HRP conjugated anti-M13 secondary antibody 
(1:1000) in PBS containing 3% (w/v) BSA. The plate was incubated for 1 hour, 
washed 3 x PBS-T (0.1% (w/v)) and 100µl of TMB substrate (Sigma) was added to 
each well. After incubating the plate for 30 mins, the reaction was stopped using 
dilute H2SO4 (10% (v/v)) and the absorbance was read at 450 nm on a Tecan 
Safire2
TM
 plate reader. 




 round of panning 
to ensure the vector was harbouring the scFv fragment. A sterile tip was used to pick 
up a colony and placed in the below mentioned reaction mixture. The PCR reaction 
was run in a Biometra TGRADIENT PCR machine, the amplified scFv fragment from 
the colonies were analysed on gel electrophoresis on a 1% (w/v) agarose gel. 
Component                                             Concentration in 50 µl reaction 
Phusion Master mix                                                 2 X 
cDNA                                                                     colony 
Forward primer                                                      60 pM 
Reverse primer                                                       60 pM 
The reaction was made upto 50 µl with dH2O. 
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Below mentioned conditions were used in order to run PCR reaction on TGRADIENT 
PCR machine: 
 
Step 1:                                                                            94
o
C for 5 minutes 
Step 2:                      30 cycles of;                                    94
o
C for 15 seconds 
                                                                                      56
o
C for 30 seconds 
                                                                                      72
o
C for 90 seconds 
Step 3:                                                                            72
o
C for 10 minutes 
 
2.9.4. Monoclonal ELISA for detection of CD20 specific scFv 
Individual colonies (192) from round 3, 4 were picked up and grown in single wells 
containing 100 µl of LB (100 µg/ml amp). These were labelled as stock plates and 
were grown overnight shaking at 220 rpm at 37
0
C. Following day, the stock plates 
were then sub cultured (30 µl) into 2 ml 96 well plate (Greiner Bio One) containing 
500 µl of LB (100 µg/ml amp) containing 1 x 505 (0.5% (v/v) glycerol, 0.05% (v/v) 
glucose final concentration), 1 mM MgSO4 100 µg/ml ampicillin. The plate was 
incubated with shaking at 220 rpm at 37
0
C for 3 hours until an OD600nm of 0.6 is 
reached and 70% (v/v) was added to the overnight stock plates to a final 
concentration of 15% (v/v) and the transferred to a -80
0
C freezer  for long term 
storage. Expression was induced by addition of 1 mM IPTG and finally incubated at 
30
0
C overnight with shaking at 220 rpm. Also, alongside two Nunc Maxisorb
TM 
plates were coated with streptavidin (200 ng/ well) and left overnight at 37
0
C. 
Following day, the plate was washed 3 x PBS-T (0.1% (v/v)) and 1 µg/ml of CD20 
peptide was added to all the wells with an incubation period of 1 hour.  The plates 
were then washed 3x PBS-T (0.1% (v/v)) and blocked with 3% (w/v) BSA in PBS. 
Meanwhile, the overnight plates containing expressed clones were removed from the 
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incubator and subjected to freeze thaw protocol for the production of scFv enriched 
lysate. The plates were first placed at -80
0
C until fully frozen and then thawed at 
37
0
C (freeze-thaw protocol repeated 3 times). The plates were then centrifuged at 
3,220 g for 15 minutes in an Eppendorf 5810r centrifuge, to obtain the scFv enriched 
lysate. The lysate supernatant (100 µl) was added to the corresponding well in the 
respective ELISA plate, mixed gently and incubated for 1 hour at RT. The plates 
were then washed 3 x PBS-T (0.1% (v/v)) and 100 µl of HRP labelled protein A 
antibody at a dilution of 1:1000 in 3% (w/v) BSA. The plates were incubated for 1 
hour and washed again three times. TMB was again added as a substrate onto all the 
wells of the ELISA plate, the reaction was stopped again after 30 minutes incubation 
period by using 10% (v/v) H2SO4 and the absorbance was read at 450nm on a Tecan 
Safire2
TM
 plate reader. 
 
2.9.5. Antibody expression and purification 
10 ml LB media containing 1% (w/v) glucose and 100 µg/ml ampicillin was 
inoculated with 100 µl of transformed scFv stocks and grown overnight at 37
0 
C, 
while shaking at 220 rpm. The overnight cultures were then used to seed 500 ml LB 
media containing 1 x 505 supplement and 100 µg/ml ampicillin and grown until an 
OD600nm of 0.6 was reached. The cultures were then induced by the addition of 1mM 
IPTG and incubated overnight at 30
0 
C, while shaking at 220 rpm. The following day 
the cultures were centrifuged at 3,220 g for 30 minutes at 4
0
C and the supernatant 
was discarded. The cell pellet was resuspended in 10 ml lysis buffer (50 mM 
Na2H2PO4, 300 mM NaCl, 10 mM imidazole, pH 8). This was sonicated on ice three 
times for 45 seconds (5 seconds interval) at amplitude of 40, using a microtip Vibra 
Cell
TM
 sonicator. The cell debris was then removed by centrifuging at 15,000 g for 
10 minutes at 4
0
C in an Eppendorf 5810r centrifuge.  
The lysate supernatant was filtered through a 0.2 µm filter to remove any residual 
cell debris, prior to subsequent purification. 2 ml of Ni-NTA slurry (Qiagen) was 
added to a 20 ml column and equilibrated with lysis buffer (50 mM Na2H2PO4,     
300 mM NaCl, 10 mM imidazole, pH 8). The filtered lysate was added to the 
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equilibrated column and the flowthrough was collected. The column was then 
washed with 20 ml of 50 mM Na2H2PO4, 300 mM NaCl, pH 8. 20 mls of 50 mM 
Na2H2PO4, 300 mM NaCl, 10 mM imidazole, pH 8 was added to the column to 
remove any loosely bound proteins. Elusion of bound scFv was performed by adding 
5 ml of 50 mM Na2H2PO4, 300 mM NaCl, 250 mM imidazole, pH 8 to the column. 
Antibody containing fractions were buffer exchanged against filtered PBS using a    
5 kDa cut off Vivaspin
TM
 column (AGB, VS0611). The buffer exchanged scFv was 




2.10. Phage bound scFv 
10 random colonies were picked up from round 3, 4 and grown in 15 ml LB         
(100 µg/ml amp) and grown to an OD600nm of 0.6 in a 50 ml falcon tube in a 37
0
C 
incubator, shaking at 220 rpm. The helper phage was then added to the individual 
tube and incubated static for 30 minutes, followed by shaking at shaking at 220 rpm 
at 37
0
C. This was followed by addition of kanamycin (50 µg/ml) and incubated 
overnight at 30
0
C. Also, a Nunc Maxisorb
TM 
plate was incubated overnight with 
streptavidin (200 ng/well).   
The following day, the falcon tubes were centrifuged and PEG precipitated in a 
similar manner as mentioned above. The phage pellet was then resuspended in 200 µl 
of PBS and was added to the respective ELISA well. ELISA was performed in 
several titrations and similarly to the above mentioned protocol (Section 2.6). 
2.10.1. Cloning of scFv3 and 7 into mammalian and bacterial 
expression system 
a. Mammalian and Bacterial expression of scFv-3 and scFv-7 
scFv-3 and scFv-7 were cloned into bacterial and mammalian expression vectors, 
pTRCHisB and pCDNA3.1 (Clontech), respectively. The mammalian expression was 
carried out by transfection of CHO-k1 cells with the indicated scFv expression vector 
(Jianguo Shi, Ted Hupp lab) using Attractene Reagent. A day before transfection, 
CHO cells were split in 3 wells of a 6-well plate at density of 1 x 104, 5 x 104, and 1 
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x 105, respectively. Next day, for each well cells, 0.2 µg of construct was mixed with 
60 µl medium (without serum) first, then 1.5 µl of Attractene Reagent (Qiagen) was 
added in the above solution mixed. The solutions were incubated at RT for 15 min to 
allow the complex formation, and then the transfection complexes were added drop-
wise onto the cells in 2 ml of fresh media. The cells from each well were split into 
100 mm tissue culture dishes the following day in 10 ml selective medium to allow 
individual colonies formation. Finally, the individual colonies were transferred into 
24-well plate (one colony per well, 96 colonies were picked up for each antibody). 
After 4 rounds selection by ELISA, the best colonies (higher yield and low cell 
density) were cultured at a large scale in selective media [DMEM supplemented with 
10 % low IgG FBS (Life Technologies Ltd, USA), 1% Penicillin/Streptomycin , 2% 
L-glutamine, 250 μg/ml Mycophenolic acid (Sigma Aldrich, UK), 12.5 μg/ml 
Xanthine (Sigma Aldrich, UK), 200 ng/ml  Geneticin (Invitrogen Ltd, UK). The 
bacterial expression of was carried out in BL21 after induction of expression using 
IPTG. The resuspended pellets were thawed in ice and resuspended in 10 ml lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). Lysozyme was 
directly added at a final concentration of 1 mg/ml and the solution was stirred on ice 
for 30 minutes. Cells were sonicated on ice for 7 x 12 seconds with a 15 seconds 
interval between each cycle and the crude lysate was centrifuged for 30 minutes at 
10,000 g at 4˚C to remove cellular debris. The supernatant was transferred to a clean 
tube for subsequent purification. 
b. Purification of His-tagged scFv and scFv-CPG2 bio conjugates via metal 
affinity chromatography 
The E. coli lysate was added to the NTA magnetic agarose beads (QIAGEN) in a 
6ml column and equilibrated with 15 ml equilibration column buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and incubated overnight 
rotating at 4˚C. The following day, the column was allowed to empty by gravity flow 
and the flow-through was collected in a 15 ml Falcon tube. The column was then 
washed with 100 ml washing buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH 8.0) to remove any non-specifically bound proteins. After washing,    
4 ml elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) 
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was added to the column and incubated at 4˚C for 1 hour. Following this incubation 
step, the sample was collected at room temperature. The efficiency of the purification 
process was evaluated using SDS-PAGE and Western Blot. The eluted antibody was 
buffer exchanged into PBS via the dialysis technique (technique used for removal of 
small, unwanted compounds by selective diffusion through a semi permeable 
membrane). The concentration of the resultant antibody was determined using a 
Nanodrop 1000 spectrophotometer and then the solution was stored at -20˚C. For 
Cloning of scFv 3, 7 into CPG2, a bacterial expression system contained a derivative 
of CPG2 that has previously been used as a bioconjugate to scFv targeting CEA41 
and was provided by Mologics (Bedford, UK). The fusion protein was highly 
insoluble using the scFv lysis buffer (above) but soluble protein could be recovered 
in lysis buffer containing 100 mM Tris (pH 8.0), 500 mm NaCl, 10% Glycerol,         
1 mM PMSF, 1 mg/ml lysozyme, 1 mm DTT, 2 mm MgCl2, and benzonase. Protein 
was eluted in imidazole buffer from the nickel affinity column in stabilization buffer 
containing 50 mM Tris pH 8, 500 mM NaCl, 10% glycerol, 1 M betain, 0,5% Triton 
x-100, and 250 mM imidazole). 
 
2.10.2. Cloning of scFv 3 into Pichia for antibody expression  
The cloning and expression of scFv into Pichia was carried out with help of post - 
doctoral scientists in the Hupp laboratory (Jianguo Shi and Euan Murray). 
Materials required: 
 Buffered Glycerol complex Medium (BMGY) 
 Buffered Methanol complex Medium (BMMY) 
 1% yeast extract 
 2% peptone 
 100 mM potassium phosphate, pH 6.0 
 1.34 % YNB 
 4 x 10-5 % biotin 
 1% glycerol or 0.5% methanol 
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Dissolve 10 g of yeast extract, 20 g peptone in 700 ml water and autoclave for        
20 minutes on liquid cycle. Let it cool down to room temperature and add following 
ingredients:  
 100 ml 1 M potassium phosphate buffer, pH 6.0 
 100 ml 10 X YNB 
 2 ml 500X B, 100 ml 10X GY 
For BMMY, add methanol (10X M) instead of glycerol. 
The growth temperature for yeast is in the range of 28-30
0
C for cultures, plates and 
slant. The storage life of BMMY/BMGY buffer is atleast 2 months at 4
0
C. After 
cloning of scFv into yeast expression vector, 25 ml BMGY medium was inoculated 
using a single colony and grown at 28-30
0
C in a shaking incubator until an OD600nm 
of 2-6 is reached (approximately 24 hours). Cells were harvested by centrifuging at 
1500-3000 g for 5 minutes at room temperature and pellet was resuspended in 
BMMY medium to induce expression. This flask was then covered with 2 layers of 
sterile tissues and incubated again in a shaking incubator. Methanol (100%) was 
added to a final concentration of 0.5% to maintain induction. 1ml of induction 
sample was taken out daily at different time points, centrifuged and pellets were 
stored to be run on a SDS gel to analyse the expression level. The expression and 
purification of yeast CpG2 scFv construct is explained in detail in section 3.2.13. 
2.11. Expression and purification of recombinant α-synuclein 
The protocol followed for expression and purification of α-synuclein is already 
mentioned in section 2.1.5. 
2.12. Native gel 
α-synuclein was run on a native gel after purification to determine its precise 
molecular weight. The native gel preparation is very similar to SDS gel preparation, 
except no SDS, DTT and avoids heating the samples. The running buffer (10x) and 
loading buffer (4x) were prepared in the following way: 
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 10X running buffer:           30.28 g Tris 
                                       144.13 g Glycine 
                                       Check pH ~ 8.3 
4X loading buffer:            50% glycerol 
                                       0.6 M Tris pH 6.8 
                                       <=0.4%w/v bromophenol blue 
Working sample buffer (1 ml): 400 μl 4X stock + 600 μl H2O   
The running buffer (10 X and 1 X) were both stored in a 4
0 
C cold room overnight. 
The gel prepared was 10%, 10 wells and stored in running buffer overnight in cold 
room. The samples were normalized and diluted in 4 X sample buffer and not heated. 
The amount of protein ran on the gel is usually double the amount we run on SDS 
gel. The following day the gel was pre-run at 4
0
 C for 1 hour and the running buffer 
was then discarded. Subsequently, fresh 1 X running buffer was added to the gel 
apparatus, samples were loaded onto the gel along with an unstained ladder and the 
gel was run at 50 V for 2 hours until loading dye reaches the end of stacking gel. 
Once it passes that, the gel was run at 100 V for 4 hours in the cold room. Following 
this step, gels were used for Coomassie staining or Immunoblotting in same ways as 
SDS gels. The purified protein was incubated at three different temperatures and 
loaded onto 12% native gel. The gel was run at 4
0
C and RT to investigate the nature 
of the protein at different conditions. Following optimization of gel running 
conditions, different amounts of SDS was titrated onto the same amount of purified 
α-synuclein. We also performed a time course (0 to 6 hours) of 0.1% (w/v) SDS 
addition to α-synuclein was carried out at RT. Also activity of several detergents 
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2.13. Circular Dichroism 
Circular Dichroism spectroscopy measures the differential absorbance of left and 
right handed circularly polarized light when it passes through a sample containing 
any chiral molecules. The CD signals arise when absorption of radiation occurs and 
thus the spectral bands correspond to structural pattern of the molecule. CD has been 
used for studying structural changes by predicting the conformation of protein.   
Circular Dichroism = ΔA = A (λ) LCPL – A (λ) RCPL,  
where λ is the wavelength, LCPL: left circular polarized light and RCPL: right 
circular polarized light    
CD is performed by placing diluted sample in a small cuvette in JASCO CD 
spectropolarimeter. As described in 4.2.3., CD was performed on three different 
types of sample preparation of α-synuclein. Sample preparation was carefully carried 
out for α-synuclein with and without SDS in the cuvette with respective dilution. The 
selected total visible wavelength range was between 185 to 285nm for visualisation 
of signal to noise ratio. Several algorithms are available online for performing 
deconvulation but each requires considerable technical effort to execute the program 
from source file. The main issue with different database is the method of input and 
the file format from the CD machine which might not be compatible with each 
database. DICHROWEB is a very user friendly interface which accepts various file 
formats and can easily interpret CD data using reference data and available 
algorithms. DICHROWEB supports five different algorithms for analysing CD data: 
SELCON 3, CONTIN, CDSSTR, VARSLC and K2d. The obtained data was 
interpreted using DICHROWEB software and the secondary structure was 
determined  
2.14. Development of antibodies and epitope mapping against α-
synuclein 
Monoclonal antibodies were developed against α-synuclein in a similar manner to 
the one described in section 2.7.1. The epitope of all mAbs was demonstrated by 
epitope mapping (ELISA) onto a panel of peptides as shown in section 4.2.5. 
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Subsequently, we tested the potential ability of all positive IgGs onto α-synuclein in 
α-synuclein expressing neuroblastoma cell line. Also described in section 4.2.8 is 
immunoblotting after different types of lysis described below probed with anti-α-
synuclein antibody (BD Biosciences). We performed lysis of SHSY5Y cells in 4 
different ways (+/- paraformaldehyde): 
(i) 10% Triton buffer (described in section 2.4.4.) 
(ii) RIPA buffer : 50mM Tris – HCL, pH 7.5, 1% (v/v) NP-40, 0.5% Na-
deoxycholate, 0.1% SDS, 150 mM NaCl, 2mM EDTA and 50 mM NaF 
(iii) Hypotonic buffer : 20 mM Hepes 7.4, 2 mM EGTA and 2 mM MgCl2  
(iv) 8 M Urea buffer : 8M Urea, 300 mM NaCl, 0.5% NP40, 50 mM 
Na2HPO4, 50 mM Tris pH 8, 1 mM PMSF, 1 ng/ml Aprotinin. Make up 
total volume with Millipore H2O.  
Paraformaldehyde in PBS was used at 0.4% on the immunoblot for 30 minutes 
following immunoblot transfer before blocking. 
 
2.15. Immunofluorescence and Immunohistochemistry 
Immunofluorescence was performed on SHSY5Y cells in 25 mm coverslips with 
antibody 3.1 at a dilution of 1:500 and commercial antibody as positive control at a 
dilution of 1:1000. The protocol followed for IF was similar to the one described in 
section 2.2. Moreover, we performed immunohistochemistry on brain and kidney 
tissue samples (Henle’s loop, brain gray matter, skin and mast cells, etc) in 
collaboration with Rudolf Nenutil, Brno, Czech Republic. The protocol followed for 
IHC was similar to the protocol described in section 2.7.5 
2.16. Assay development 
2.16.1. α-synuclein constructs in pEGFP-(C) as well as pMCherry –
(C) 
RNA was extracted from SHSY5Y cells, followed by reverse transcription in order 
to make cDNA. This cDNA was used for the amplification of α-synuclein with 
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BamHI and XhoI sites flanking the DNA sequence of the gene. The sequence of the 
designed primers is mentioned below:  
Forward (XhoI):    5’ GC CTC GAG ATG GAT GTA TTC ATG A 3’ 
Reverse (BamHI): 5’ GC GGA TCC GGC TTC AGG TTC GTA G 3’ 
The purified DNA obtained after PCR amplification as well as vector DNA was 
double digested with BamHI and XhoI. These products were once again gel extracted 
and ligated into each other with a ratio of 5:1 (Insert: Vector). The ligation product 
was then transformed into DH5α cells, a single colony was grown overnight from the 
plate and miniprep purified. This DNA was sequenced, maxiprep purified and 
concentration of DNA was determined using Nanodrop. 
2.16.2. Co-localization of α-synuclein and interacting proteins in 
SHSY5Y and HCT116 (WT) cells 
GFP and Cherry tagged α-synuclein constructs were co-transfected in SHSY5Y as 
well as HCT cells. Different amount of DNA was transfected into cells using 
attractene to see a significant expression in these cells lines. For initial experiments, 
0.25; 0.5 and 1 µg of GFP, cherry tagged α-synuclein was transfected in 6 well plates 
and an optimum level of DNA was determined that showed a significant amount 
which was analysed by Immunoblotting.  
2.16.3. Proximity ligation assay (PLA) 
As means of developing new assay to demonstrate co-localization of α-synuclein, we 
performed PLA onto SHSY5Y cells. SHSY5Y cells were grown on a 19 mm cover 
slip for 18-24 hours before proceeding with PLA. Following day coverslips were 
made ready for PLA to be carried in 2 days.  
PLA using Duolink  
DAY 1  
- Wash cover slips 3x Sterile Ice cold PBS 
- Fix in 4% PFA for 15 minutes at RT 
- Wash cover slips 3x Sterile Ice cold PBS 
- Permeabilise with 0.25% Triton X-100 in PBS for 10 minutes 
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- Wash cover slips 3x Sterile Ice cold PBS 
- Block coverslips using 3% BSA in PBS for 30 minutes 
- Remove blocking buffer and add primary (diluted 1:250 in 3% BSA in PBS), 
incubate overnight at 4
o
 C/ 2hours at RT in humidified chamber 
Minimum sufficient amount of each prepared solution should atleast be 40 μl and all 
solutions were prepared fresh. 
  DAY 2 
- Make PLA probe mixture and incubate 20 minutes 
a. Ab diluent  32 µl 
b. PLA plus 4 µl 
c. PLA minus 4 µl 
- Wash cover slips 3x Sterile PBS for  5 minutes each 
- Add 40 µl of PLA probe mix to each cover slip 
- Incubate on parafilm in foiled small box for 1 hour at 37oC 
- Wash cover slips 3x with Wash buffer A for 5 minutes each 
- 40 µl Ligation mix added to each cover slip  
d. 5x Ligation Stock  8 µl 
e. High purity water 31 µl 
f. Ligase   1 µl (add to solution immediately before 
adding to slide) 
- Incubate on parafilm in box covered in foil for 30 minutes at 37oC 
- Wash cover slips 3x with Wash buffer A for 5 minutes each 
- 40 µl of polymerase amplification mix added 
g. 5x Amplification stock    8 µl 
h. High purity water    31.5 µl 
i. Polymerase    0.5 µl (add to solution immediately before 
adding to slide) 
- Incubate on parafilm in box covered in foil for 2 hours at 37oC 
- Wash cover slips 2 x with 1x Wash buffer A for 5 minutes each, wash cover 
slips 3x with 1x Wash buffer B for 5 minutes each 
- Add phalloidin diluted 1:10 in 1x Wash buffer B for 30 minutes, wash 2x 
with 0.01x Wash buffer B for 5 minutes 
- Dilute DAPI 1:2500 in 0.01x Wash buffer B and incubate in dark for             
5 minutes, wash 2x with 0.01x Wash buffer B for 5 minutes 
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2.17. Peptide phage display 
Peptide phage display was carried out using Peptide phage display library (12 amino 
acids) from New England Biolabs. Biopanning was used as the selection process 
which is carried out by incubating the phage displaying library onto the plate coated 
overnight with α-synuclein (target), washing away unbound phage and eluting the 
specific binding phage displaying peptides. This dodecapeptide premade library 
consists of more than 10
9
 clones. In both 7 mer and 12 mer library, the first residue 
of the peptide pIII fusion is first randomized position. Displayed peptides are 
expressed at the N terminus of the coding region of phage and are linked by a short 
linker sequence Gly - Gly - Gly - Ser. 
     
   
To avoid any sort of phage contamination, all plastic, sterile tips and glassware 
apparatus were sterilised or autoclaved. As severe contamination can lead to 
contamination in subsequent panning rounds, so all steps were carried out under 
aseptic conditions and solutions were re-autoclaved for each round. 
 
2.17.1. Panning procedure 
Panning procedure on α-synuclein was performed in two ways based on long and 
short washes. An ELISA 96 well plate was coated overnight with 1 µg/ml of WT α-
synuclein in 100 µl of coating buffer (NaHCO3 pH 6.8) and incubated overnight at 
4
0
C. The following day the coating solution was poured off and the wells were 
washed 3 times using TBST (TBS 1X (50 mM Tris pH 7.5, 150 mM NaCl) - 0.1% 
(v/v) Tween-20), the wells were then blocked using blocking buffer (3% (w/v) BSA 
in TBST) and kept on a rotator for 1 hour at room temperature. The phage library 
(10
11
 phages) was then diluted in TBST, added to the plate and incubated for 1 hour 
rocking at room temperature. The wells coated with target of interest were then 
washed quickly 10 times using TBST for quick washes whereas the wells for slow 
washes were incubated with TBST for an interval of 5 minutes for each wash to 
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remove the unbound phages. The specific bound phage particles were eluted with 
100 µl of 0.2 M Glycine pH 2.2, 1 mg/ml of BSA, incubating gently rocking for     
10 minutes and neutralized with15 µl of 1M Tris pH 9.1. Eluted phage were stored at 
4
0
Cup to 1 week until further used.  
Eluted phages were then amplified by infection of ER2378 cells and the phage 
particles were PEG precipitated. This was repeated two more times and 
approximately 10
11
 pfu of the first or second amplified eluate were used as input 
phage. 
2.17.2. Phage amplification 
The E.coli strain E2378 was streaked out onto the agar plate containing tetracycline 
(20 µg/ml) and incubated overnight at 37
0
C. 20 ml of LB (20 µg/ml) was inoculated 
with a colony picked up from above mentioned streaked plate and incubated shaking 
at 200 rpm at 37
0
C until OD600nm of ~0.05 was reached. Once such an O.D. was 
reached, cells in their early log phase were infected with 70% of the phage eluate and 
further grown for 4.5 hours. These cultures were then centrifuged at 12000 g for     
10 minutes at 4
0
C. The supernatant was then transferred to a fresh tube and 
recentrifuged. The upper portion (80%) of the supernatant was transferred to a new 
tube and 1/6
th
 volume of 20% (w/v) PEG - 2.5 M NaCl was added and mixed. The 
phage was precipitated by incubating overnight at 4
0
C, following overnight 
incubation the precipitated phages were pelleted at 12000 g for 15 mins at 4
0
C. The 
supernatant was discarded; recentrifuged briefly and the remaining liquid was 
removed. The pellet was resuspended in TBS 1X in a microcentrifuge tube and was 
centrifuged at 16,100g for 5 mins at 4
0
C. The phage supernatant was transferred to a 




 volume of PEG NaCl.  
Once again phages were pelleted by centrifuging at 16,000 g for 10 mins at 4
0
C, 
supernatant was discarded and the tube was re-centrifuged briefly to remove any 
residual liquid. This final amplified pellet was then resuspended in 200 µl of TBS 
1X. Amplified phages were stored at 4
0
C for up to 3 weeks after incubation at 65
0
C 
for 15 mins in order to kill any remaining residual bacteria.  
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2.17.3. Phage - titering 
10 mls of LB-tetracycline was inoculated with a colony of E2378 and incubated in a 
bacterial shaking incubator at 37
0
C until an OD of 0.5. 3 ml of melted LB agar was 
aliquoted in a 15 ml falcon tubes and maintained at 45
0
C in a water bath. LB plates 
containing IPTG (0.05 µg/ml) and Xgal (5 bromo 3 chloro 3 indolyl-β-D-galactoside 
(0.04 µg/ml)) were freshly prepared and kept at 37
0
C until inoculation step. 
A serial dilution was performed for both amplified and unamplified phage from all 





whereas the unamplified phage eluates were diluted from 10 to 10
4
. Once the cells 
reached an OD of 0.5, 200 µl was aliquoted into 1 ml eppendorf for each dilution. 
For infection, each tube was infected with 10 µl phage eluate, vortexed and 
incubated at room temperature for 5 mins. These infected cells were the added to      
3 ml of melted LB agar containing IPTG - Xgal. The melted agar was carefully 
poured into the plates and evenly distributed throughout the plate. After the plates 
were fully set, the plates were incubated overnight at 37
0
C. The following day, blue 
plaques were counted from the plates in order to determine the phage titre of each 
sample.   
 
2.18. Next generation deep sequencing 
2.18.1. PCR for phage DNA amplification 
Eluted phage pools were used for amplification of phage DNA. Specific primers 
were designed for Illumina HiSeq2000 multiplexed paired end read PE100 
sequencing and are shown below (table 2.6). Forward primers were ordered PAGE 
purified whereas reverse primers were ordered HPLC purified from Sigma Genosys. 
These primers were then resuspended using DNAse/ RNAse free water. 
Each sequencing reaction is read in either direction for each individual DNA and 
starts after Illumina adaptor sequences, being the sample key. The insert sequence 
length is 36 bp for 12mer library which is followed by 3 glycine spacer and preceded 
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by TCT which is not present in the wild type phage. Thus, the size of the phage 
containing insert has a size of 182 bp whereas the wild type phage on its own has a 
size of 167 bp.  
PCR reactions were prepared on ice in nuclease free tubes with 1X Herculase II 
Fusion DNA polymerase buffer (supplied with polymerase) , 0.5 M Betaine solution 
for PCR, 13.2 mM Trehalose, 500 µM dNTP, 500 nM of each forward and reverse 
primer. To this, 5 µl of phage sample was added along with 1 µl of Herculase II 
Fusion polymerase and nuclease free water up to 50 µl. 
PCR thermal cycling conditions: 
95
0
C for 1 min 
95
0
C for 15 sec 
55
0
C for 20 sec           repeated 30 times 
70
0
C for for 1 min 
70
0
C for 3.5mins  
4
0
C forever  







































2.18.2. DNA purification and quantification 
The entire PCR reaction was loaded onto a 2% (w/v) agarose gel. The amplicon of 
the correct size was gel extracted on 2% (w/v) agarose gel and 182bp band was cut 
(avoiding WT phage band 167 bp) and placed in a tube. Following excision of the 
bands, DNA was purified using gel extraction kit (#28704 Qiagen) using 
manufacturer’s instructions including recommended steps. Finally DNA was eluted 
in 40µl of nuclease free water. DNA concentration was accurately quantified on 
ultrasensitive fluorescent nucleic acid stain for double stranded DNA in solution 
using Quant-iT Picogreen dsDNA kit (#P7589, Life Technologies) following 
manufacturer’s instructions. Equal amount of each DNA based on the concentration 
were pooled together in order to obtain 5 µg of total DNA for deep sequencing. 
 
Table 2.6: Set of primer sequences: Sequence of forward and reverse primers 
designed for amplification of α-synuclein binding peptides 
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2.18.3. Deep sequencing of phage pool  
Amplicon pool was sent to Otogenetics, USA for sequencing. Data in fastq format 
was extracted and changed into excel format in collaboration with Stuart Aitken 
(University of Edinburgh) and Adam Krejci (RECAMO, Brno). Two million 
sequences were obtained from the next generation deep sequencing and these 
obtained 12 amino acid peptides were arranged in descending order on the basis of 
number of repeats obtained.  The selection of the unique peptides was performed by 
considering the incidence of highly occurring peptide sequences against α-synuclein 
in comparison to other proteins, negative control and parental library. The selected 
peptides designed with an N-terminal biotin tag and were ordered from Mimotopes, 
Victoria, Australia. 
2.18.4. Peptide protein binding efficiency 
100 ng of α-synuclein was coated onto each well of the ELISA plate (Nunc) 
overnight as well as for 1 hour in order to measure the binding efficiency of all the 
ordered peptides. The plates were then washed thrice with 0.1% (v/v) PBS-T and all 
the peptides obtained from phage screening were added at a concentration of 1 µg/ml 
to each well (50 µl in 3% BSA) in the presence and absence of 1 mM DTT. The 
peptides were incubated for 1 hour, washed thrice with 0.1% PBS-T and blocked 
using 3% (w/v) BSA. Subsequently anti-α-synuclein antibody (BD biosciences) was 
added at a dilution of 1:1000 in 3% BSA to all the wells and incubated for 1 hour at 
RT. The wells of the plates were again washed thrice with 0.1% PBS-T and HRP 
conjugated rabbit anti-mouse was added at a dilution of 1:1000 in 3% BSA. The 
plates were washed again thrice with 0.1% PBS-T and the TMB substrate was added 
to all the wells of the plates and further read at 450 nm.  
 
2.18.5. MEME analysis and co-transfection 
Alongside, all the higher occurring peptides were subjected to MEME analysis for 
identification of motifs. The interacting proteins which were identified from blast 
analysis of these motifs were cloned into pEGFP-C vector. These interacting proteins 
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after cloning were then co-transfected and transfected on its own to see its effect on 
SHSY5Y and HCT116
+
 cells. Once again the transfection was carried out in different 
ratios i.e. 0.1, 0.5 and 5 µg DNA made up in 100 µl serum free media into both cell 
lines that were seeded with same density. Also a titration of cells was carried out in 
order to see if the effect of any of these genes was cell density dependent using GFP 
itself as a control and non-transfected as the negative control. DNA was transfected 
as well as co-transfected with different proteins in several amounts until a certain 
amount of DNA showed its significant effect onto HCT116
+
 and SHSY5Y cells. 
Subsequently, cells were harvested following day, lysed in 10% Triton lysis buffer 
and incubated for 30 minutes in order to lyse the cells. The concentration of the 
protein was measured via Bradford assay and 30-50 µg of protein was run on a gel 
and was probed for α-synuclein using commercial anti-α-synuclein antibody (BD 
Biosciences). GFP-HADH transfection was carried out in 6 well dishes into 
SHSY5Y and HCT116
+
 cells with different amount of HADH DNA, GFP only as a 
control and non-transfected cells as negative control. Transfection efficiency of 
HADH gene was compared using different transfection reagents: attractene, 
lipofectamine and effectene. 
   
2.18.6. Peptide pull down assay 
To determine the binding ability of peptides identified through peptide phage display 
screening we performed peptide pull down assay described below against α-
synuclein expressing cells (figure 2.1).  
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with 20 µg/ml 
of Avidin 
Leave it on ice foe 
30 minutes 
Spin at max (16000 
g) for 5 mins at 4°C 
Collect 
supernantant 
Pre-clear lysate in 200 µl 
of 50% slurry of Sepharose 
4B (pre-washd in PBS) 
1 hr rocking 
gently at 4°C 
Centrifuge for 3 mins 
@ 4°C @ 500 g 
Collect 
Supernatant 
1 ml micobiol column 
fitted with 35 µm 
pore filter 
100 µl Streptavidin-
Agarose Beads (50% 
slurry Beads) 
3 X wash in 600µl PBS 
Add 2 µl of 5 mg/ml 
biotinylated peptides 
in 200µl PBS  
1ht rotation @ RT 
3 X Wash in 600µl 
PBS 
Add the avidin treated pre-
clear lysate  (0.5 mg per 
column)  
Make up volume to be 
200 µl in PBS 
1 hr rotation @ RT 
Empty by gravity 
4 X 600 µl PBS with 
0.2% triton X 100 
2 X wash in PBS 
Resuspend in 200 µl buffer W 
and transfer resin to centrifuge 
tube along with filter 
Centrifuge @ 500g for 
3min @ RT 
Discard 
Supernatant 
Elute by boiling the pellet in 50 
µl LDS sample Buffer (100mM 
DTT) for 5min @ 85°C 
Spin at 500g for 3 min 
@ RT. 
Collect supernatant and load 



















Figure 2.1: Peptide pull down assay: Using the cell lysate to pull out α-
synuclein by adding the cell lysate to beads pre-incubated with peptides 
found through peptide phage display screening.  
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CHAPTER 3: Development of 
monoclonal antibodies and 
Bioconjugate to canine CD20 receptor 
(a receptor, scFv model) 
3.1. Introduction 
3.1.1. Cancer 
Cancer remains one of the world’s leading causes of death in humans and the total 
economic impact of premature death and disability from cancer represents 1.5% of 
the world’s GDP, not including the direct cost of treatment of patient suffering [158]. 
In the early 1990s when the molecular basis of cancer was poorly understood, 
scientists focussed on assessing the morphology of cancer cells.  Now, research has 
expanded to study the changes occurring at a subcellular level in cancer cells and 
their environment and to explore the molecular pathways controlling the 
development and progression of cancer [159]. Biologically cancer is defined as 
abnormal growth of cells which overcome any checkpoints and finally lead to 
sequential accumulation of defects in DNA which was identified in European people 
when no treatment was available [160, 161]. The outstanding challenge in cancer 
research is the implementation of inter-disciplinary translation of rapidly growing 
knowledge of tumour biology into new anti-cancer treatment modalities as 
preclinical models have not predicted high success rate in the recent past in the clinic 
[162]. Following continuous research in the field of oncology over the past 100 
years, more than 200 types of cancer have been identified. Several phenomena 
responsible to cause cancer have been described such as mutations, oncogenes and 
tumor suppressor genes which are described below. 
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3.1.2. Concept of mutations, oncogenes and tumour suppressor gene 
Mutations are the abnormal changes in the DNA which are defined by changes in 
arrangement of a single or more base pairs of the gene. A mutation in the form of 
single pair substitution can  result in major effects and it is further classified into 
hereditary and acquired mutations depending upon the origin of the mutation. Most 
of the oncogenes are mutations of normal genes and are defined as proto-oncogenes. 
Oncogenes are defined as those genes that become active when they are not supposed 
to be active and cause unnecessary changes in the cells making it cancerous on 
occasions. Oncogenes can be mutated in such a way that they could render the gene 
constitutively active in certain condition which would otherwise be non-active as a 
wild type gene [160]. Tumor suppressor genes are genes that are known to play a 
role in maintaining cell cycle, establish DNA repair mechanisms and cause 
programmed cell death when needed called apoptosis. Tumor suppressor genes 
become problematic when mutations in some genes that are known to play role in 
several mechanisms reduce their activity and become inactive when needed. Both 
oncogenes and tumor suppressor gene mutations operate at a similar physiological 
level by driving the cancerous effects by  increase in tumor cell number via 
stimulation of such abnormal cells and/or inhibition of cell death or cell arrest [160]. 
Along with these above mentioned mechanisms, cancer cells can also have profound 
alterations in the DNA methylation suggesting epigenetic alterations may play 
important roles in cancer development and regulation [163]. Transcriptional 
reprogramming has emerged as another mechanism indicating changes in gene 
expression initiated by various transcription factors and has been studied extensively 
in endoplasmic reticulum [164]. 
3.1.3. Comparative oncology 
Comparative oncology is a fairly new discipline that plays a major role in integrating 
as well as translating naturally occurring cancers in animals into studies of human 
cancer biology and developing therapies [165].  Comparative medicine has been the 
framework from which inter species models can generate knowledge that in turn can 
be translated to impact on health and welfare. This involves the establishment of 
collaborative ventures in clinical care, surveillance and control of cross-species 
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disease, education and research into disease pathogenesis, diagnosis, therapy and 
vaccination [166]. Naturally occurring cancers in companion animals (pets) have led 
to significant investigations in studying cancer biology and drug development. The 
most frequently used animal model in past has been mice which possesses 
advantages such as short gestation period, small size and inexpensive as compared to 
other mammals. A well-known limitation in mouse models is that human tumours 
occur spontaneously whereas in most of the mice the tumours have to be induced. 
Such limitations suggest that there is a need of another animal model which presents 
similar gene interactions and similar if not same clinical outcome following 
treatment. The development of models using companion animals may overcome 
some of these limitations. 
The worldwide veterinary oncology field can offer compelling sporadic models of 
carcinogenesis in companion models (cats and dogs) that mimic certain aspects of 
cancer development such as metastasis and immune host cell interactions  [167, 168]. 
Pet owners are highly motivated to seek novel treatment options for curing cancer if 
the existing options do not meet their goals. Study of tumour biology and cancer 
therapy is not a novel concept, in fact in last 20-30 years a significant amount of 
research has been carried out in order to study the biology, several therapies in 
osteosarcoma, lymphoma, melanoma and other cancers [169-171].  
3.1.4. Mouse vs dogs as a relevant study model for humans 
One of the reasons for the failure of  some novel drugs to get FDA approval is pre-
clinical testing of the drug in the conventional pre-clinical models [172]. 
Investigations of cancer in dogs is not novel due to well-known anatomical as well as 
physiological history that dogs share with humans and several studies have been 
reported since early 1960s [173-176]. The published genome sequence analysis of 
humans and canine indicate that there is a high degree of similarity between them 
[177, 178]. The current treatment options available for naturally occurring canine 
tumours are chemotherapy, anti-angiogenic therapy and other approaches that have 
already been approved for human cancers. The dose intensity of chemotherapy and 
anti-angiogenic agents is generally lower in dogs which ultimately results in lower 
success rate [179]. This calls for urgent need for development of canine therapeutics 
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with growing interest of pet owners.  Domesticated dogs (Canis lupus) are an 
excellent animal model for studying human diseases for reasons such as phenotypic 
diversity and naturally occurring diseases of all land mammals [180]. In recent years, 
the inclusion of dog from different breeds in clinical trials provides a great cross 
sectional value that is usually higher than that obtained in the studies of inbred 
laboratory animals, reason being the genetic similarity that dogs share with humans 
[181]. Around 400 inherited diseases which are similar in development to humans 
have been characterized in dogs such as cancer, heart diseases and neurological 
disorder [182, 183]. Another advantage that dogs hold over mice is the similarity of 
tumour histology to humans and responds similarly to conventional therapies. The 
time needed for clinical trials is significantly shorter and the disease free interval 
time in dogs treated for cancer is 18 months compared to humans where the time 
interval is more than 7 years in order to assess the disease outcome [179]. 
Furthermore, tumours are difficult to be reproduced in immuno competent laboratory 
animals, thereby limiting some clinical trials which are not the case in dogs due to 
genetic similarity and immune response they share with humans. Cancer is the 
leading cause of death among dogs and naturally occurring cancer have been well 
described in several breeds of dogs [184, 185]. It has been shown on previous 
occasions that certain breeds of dogs are more susceptible to genetic diseases and 
cancers [186] and this indicates that the development of such breeds on occasions 
might cause unintentional inclusion of deleterious alleles. The lack of standard 
treatment regimens in veterinary cancer patients has compelled researchers to carry 
out clinical trials as well as research for novel therapeutic and diagnostic strategies 
[170]. The major benefit that dogs hold over any other laboratory animal models is 
that the comparative oncologists can study the novel treatment strategies in canine 
cancer model within a short time scale. 
3.1.5. Lymphoma 
Lymphoma is a malignant cancer which involves the lymphatic system and starts in 
cells called lymphocytes (B and T cells) which are one of the most important 
constituent of the immune system. Lymphoma is a very well defined cancer type and 
its tumour classification serves the purpose of providing the insights into histology, 
Chapter 3: Development of monoclonal antibodies and Bioconjugate to canine CD20 
receptor (a receptor, scFv model)                                                                                          93 
 
pathology and basic research to study the current available treatment options [187]. 
This has allowed for the development of new tools and their significant effects on the 
treatment of different types of lymphoma. There are mainly two types of lymphoma, 
Hodgkin lymphoma which is named after Dr. Thomas Hodgkin and when seen under 
microscope it is characterized by the presence of Reed-Sternberg cells. Reed-
Sternberg cells are giant cells found in biopsies which are either multinucleated or 
have a bi-lobed nucleus. The most common and other type of lymphoma is non-
Hodgkin lymphoma which has now more than 61 subtypes, out of which the most 
common ones are DLBCL (Diffuse large B cell lymphoma), Follicular lymphoma 
and Marginal Zone lymphoma. Non-Hodgkin lymphoma is the sixth most common 
cancer in UK, accounting for 4% of all new cases of cancer. Lymphoma is quite 
common in dogs accounting for one third of all canine cancers and occurs 
spontaneously as in case of humans [171]. Canine lymphoma demonstrates 
histopathological and biological features that are similar if not same to that of 
humans [188] accounts for 10-20% of all cancers in dogs. Lymphohematopoietic 
disorders are common in dogs, with non-Hodgkin’s lymphoma (NHL) making upto 
83% of all canine hematopoietic malignancies [188]. Several types of spontaneous 
canine cancers have been proposed as possible models for human cancers, reason 
being the molecular and biological similarity both species share. The treatment 
options for non-Hodgkin’s human and canine lymphoma predominantly included 
chemotherapy and radiotherapy.  
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B cells play a role in mediated immune response by producing antibodies to fight 
against diseases. Bone marrow hematopoietic cells give rise to B cells and go 
through a series of developmental changes resulting in the formation of cell types 
such as plasma cells [189]. Spleen and lymph node germinal centres are two major 
sites for activated B cell affinity maturation. These germinal centres are formed 
mainly as a result of antigen recognition by B cells, activated helper T cells and 
antigen presenting dendritic cells [190, 191]. As shown in figure 3.1, development of 
B cell lymphomas takes place at different stages of B cells i.e. from naïve B cell to 
plasma cells. The immunoglobulin idiotype present on the lymphoma B cells is 
Figure 3.1: B cell lymphoma during B cell development: Early stages of B 
cell development are associated with chronic lymphocytic leukemia and mantle 
cell lymphoma. During maturation stage in germinal centre, cancers such as 
Burkitt lymphoma, Follicular lymphoma and germinal centre diffuse large B cell 
lymphoma. Lastly during maturation stage into memory B cells cancers 
prevalent are lymphoplasmacytic lymphoma, activated B cell diffuse large B cell 
lymphoma and Marginal Zone lymphoma 
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totally distinct from their non-malignant counterparts, however regulatory approval 
has not yet been obtained for active immunotherapy for lymphoma despite the 
benefit and clinical efficacy [192]. Various B- cell differentiation antigens have been 
discovered as markers in B cell lymphoma including CD5, CD22, CD79, CD23 and 
CD25. The expression pattern of CD25, CD22, CD23 and CD5 has been described 
before in B cell lymphoma [193]. Out of the known B cell differentiation antigens, 
CD20 is highly expressed (around 75%) in different types of B cell lymphoma and 
significantly lower in T cell originated lymphoma [194]. In addition to this, 
immunophenotyping has played a major role in identifying lymphoma of B cell 
origin and further characterizing the antigenic markers. 
 
3.1.6. CD20 structure and its role in B cell lymphoma 
After understanding the significance of canine cancer as a fairly novel study model 
for immunotherapeutics, we focussed on proto oncogenic target i.e. CD20 receptor. 
As most of B cell lymphomas express CD20 and the most frequently used approved 
drug against these different types is Rituximab, the need for more effective CD20 
specific antibody still remains [195]. The identification of this target was done by 
Lee Nadler has allowed extensive research for developing therapeutic tools against 
this target. Another interesting aspect that makes CD20 a suitable target is its 
membranous expression and does not exist as free protein in the blood. However, 
there have been reports suggesting that CD20 along with CD19, CD24 and CD37 can 
be present on subpopulations of exosomes [196]. Exosomes are nanosized membrane 
vesicles which are released upon fusion of multivesicular bodies with the plasma 
membrane [197]. The extent of exosomes secretion varies depending upon the cell 
type and the observation that tumor cells release exosomes containing several tumor 
antigens can be of significant importance. More than 90% of B cell lymphoma are 
known to express this B cell receptor but the intensity of the expression of CD20 
varies depending upon the type of lymphoma [194]. CD20 is a 33 kDa tetraspanning 
transmembrane phosphoprotein which is expressed in pre B cells but the precise 
function of CD20 is still unknown [198].  It has been proposed that CD20 plays a 
major role in the regulation of B cells required for cell cycle progression [199] and 
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has also been shown to regulate calcium channel transport [200]. It is not 
phosphorylated in resting B cells but is heavily phosphorylated following mitogen 
stimulation of B cells and is found to be a dominant phosphoprotein [201]. On 
previous occasions it has been shown that CD20 can be phosphorylated by several 
kinases at unique residues which could change the functional status of CD20 under 
physiological conditions [201]. The structure of CD20 is shown in figure 3.2 and it 
has been shown on various occasions that chemical cross linking can cause CD20 to 
exist as a monomer, dimer and tetramer. 
        
 
 
In fact CD20 was the first molecule to be successful as an immunotherapeutic target. 
Rituximab is a chimeric monoclonal antibody which consist of murine variable 
regions (C2E8 mAb) and human constant regions which has been approved against 
non-Hodgkin’s lymphoma in humans [202, 203]. Also recent data shows that in 
combination with chemotherapeutic agents, Rituximab might be more efficient in 
cases of DLBCL [204]. Although antibodies such as Rituximab have been approved 
against human CD20,  it does not cross react to its canine orthologue due a single 
amino acid change in the extracellular loop [201]. Rituximab targets CD20 receptor 
in B cell related malignancies and has provided a compelling proof of concept that a 
recombinant monoclonal antibody can be used as a biologic based drug treatment 
[205, 206]. The mechanism of action used by Rituximab is based on Fab domain 
binding to the CD20 antigen on B cells and Fc domain of the antibody recruiting 
immune effector functions in order to mediate lysis of the B cell [207]. There is 
growing evidence that Rituximab can affect other disease indications such as 
Figure 3.2: Structure of CD20: CD20 is a 297 amino acids protein with 
membrane spanned four times containing smaller and larger loops of 
extracellular region. 
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rheumatoid arthritis [208], immune related indications [209-211], and in 
transplantation [212]. It is thought that Rituximab acts by eliminating B cells either 
by complement mediated lysis of cells, ADCC or causing cell death i.e. apoptosis.  
Given the widespread potential ability of Rituximab to bind to CD20 expressing 
cells, there are Rituximab “biosimilars” such as Ibritumomab and Tositumomab 
[213, 214]. These second generation antibodies have better affinity to CD20 but still 
do not bind to canine CD20, thus the need for antibody specifically binding to canine 
CD20 still remains. The fact that some patients are refractory or relapsed and also 
few might develop resistance to Rituximab; this indicates that the need for improving 
anti-CD20 modalities still remains [215]. Moreover, although Rituximab can induce 
significant anti-tumor effects but there are severe side effects associated with it and 
patients that become resistant to Rituximab have shown inefficacy of this antibody. 
Rituximab mediates direct killing of the CD20 positive cells via various mechanisms 
such as CDC and ADCC, the common side effects associated with Rituximab are 
fever, bone lesions, etc [216]. The use of live vaccines during Rituximab therapy can 
result in increased risk of developing an acute infection [217], another well-known 
adverse effect is the result of B-cell depletion after therapy which in turn can 
compromise the immune system [218]. With this B-cell depletion, the concentration 
of immunoglobulins have significantly fallen down making hard for body to develop 
any type of immune response [219]. One innovate approach for developing such 
immunotherapeutic approach towards this target could be use of canine diffuse large 
B cell lymphoma that have a similar fingerprint to the human counterpart [198].  
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This first FDA approved monoclonal antibody Rituximab binds to larger 
extracellular loop of the human CD20. Presence of amino acids alanine (170) and 
proline (172) have found to be critical for antibodies to bind to CD20 positive cells 
[220]. Extensive research has been done by few research groups on Rituximab to 
determine precisely its discontinuous epitope (170) YCYSI (173) and (182) ANPS 
(185) [221]. As shown in figure 3.3, Rituximab binds to the discontinuous epitope on 
larger loop of the extracellular domain of CD20. This non-glycosylated 
phosphoprotein spans the membrane four times and only 44 amino acid residues of 
all 297 amino acids lie in the extracellular region of CD20. The homology of the 
human and canine CD20 can be seen in figure 3.4. The efficiency of rituximab 
binding could be limiting on occasions when the lymphoma patients develop 
resistance. There could be a range of reasons for such resistance development i.e. 
overexpression of complement regulatory proteins that impair CDC [222], blocking 
ADCC via deposition of C3b complement component [223], over-expression of anti-
apoptotic proteins [224] or down regulation of CD20 which could be due to 
internalization by rituximab loss of CD20 protein [225]. 
Figure 3.3.: Detailed structure of human CD20: Tetraspanning 
transmembrane protein with smaller and larger extracellular loop containing the 
region where Rituximab binds. 
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3.1.7 Monoclonal antibodies against CD20  
Over the years, several anti-CD20 monoclonal antibodies have been under clinical 
investigations. These antibodies are either human or humanized unlike Rituximab 
which is a chimeric mAb as the aim of these mAb remains to increase the binding 
efficacy to the target and cause CDC or apoptosis of lymphoma cells. Table 3.1 







Figure 3.4: Clustalw analysis of CD20: Amino acid sequence homology 
comparison between human and canine CD20 by Clustalw analysis. 
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Ofatumumab Type I, full human Increased CDC 
and slower off rate 
FDA approval for 
CLL and phase III 
trials in NHL 
Veltumzumab Type I, humanized Slower off rate Phase I/II of 
subcutaneous 
administration in 
NHL and CLL  
Ocrelizumab Type I, humanized Increased ADCC 
and lower CDC 
Phase II in NHL 
PRO131921 Type I, humanized 
with modified Fc 
Increased ADCC Phase I/II in NHL 
AME-133v Type I, humanized 
with modified Fc 
Increased ADCC Phase I/II in NHL 




and apoptosis  




Ofatumumab, one of leading anti-CD20 fully mAb candidate that binds a unique 
epitope in the small extracellular loop of CD20 and has exceptional ability to recruit 
C1q and lyse through complement activation [226]. Interestingly results from studies 
with rituximab resistant FL have shown disappointing overall response rate (ORR), 
suggesting ofatumamab monotherapy is ineffective; however it might be effective 
when used in combination with chemotherapy [227]. Another Study from Meerten et 
al showed Ofatumumab to be highly effective when used along with CHOP 
chemotherapy in previously untreated FL patients [228]. 
 
Table 3.1: mAbs against CD20: Approved different forms of monoclonal 
antibodies against human CD20 in several types of lymphoma with different 
mechanism of action. 
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Ocrelizumab is a second generation humanized antibody derived from murine 2H7 
anti- CD20 antibody which binds to an overlapping epitope of the large extracellular 
loop of CD20 antigen compared with Rituximab. As far as efficacy of Ocrelizumab 
in comparison to Rituximab is concerned, Ocrelizumab induces two to five fold 
higher ADCC and two to five fold decreased CDC [228]. In a study carried out by 
Morschhausser et al, it was shown that in patients with relapsed/refractory FL 
following Rituximab treatment, ORR was reportedly 38% with few adverse effects, 
likely due to decreased complement activation. Due to the fact that death rates 
considerably increased, the drug was suspended in 2010; however studies (phase III 
trials) are still ongoing for use inmultiple sclerosis [192]. PRO131921 is again a 
humanized modified version of Ocrelizumab which has been developed in order to 
improve the binding efficacy to FCγRIIIa. This has entered phase II trials for the 
treatment of relapsed or refractory CLL and indolent NHL[229].   
Veltuzumab 
Veltuzumab is a humanized IgG1 generated by using the same framework regions as 
epratuzumab (humanized anti-CD22) [228]. Veltuzumab has a better activity as 
compared to Rituximab, the reason being a single amino acid change in CDR3 of the 
heavy chain and is shown to have better off rate as well as improved activity in vivo 
[229]. This humanized antibody has ORR of 44% which is comparable to that of 
Rituximab in patients with relapsed, refractory FL[230]. It is currently being 
evaluated in phase II clinical trial studies for NHL and CLL.  
PRO131921, AME133v and GA-101 
These antibodies are third generation anti-CD20 mAbs developed by modification of 
fc portion of the antibody in order to increase the affinity of the antibody and 
enhance its cytotoxic effects. Both antibodies have been under different phases of 
clinical trials and until now have proved superior to Rituximab [231]. GA-101 is a 
type II third generation antibody that has glycol-engineered Fc fragment to enhance 
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its affinity and thereby ADCC. This induced direct immune cell-mediated killing and 
in pre-clinical models has shown to be more effective than Rituximab with some 
promising results in clinical trials [232].  
Antibody fragments such as scFv and Fab have been under trials and have shown 
clinical efficacy in the trials so far. Infact one study has developed humanized scFv 
from Rituximab to retain the binding affinity onto CD20 and has succeeded in 
supressing proliferation of CD20 expressing Raji cells [233]. In another study by 
Chu et al, Fab fragments were linked to N-(2-hydroxypropyl) methacrylamide 
(HPMA) and such conjugates have effectively resulted in causing apoptosis of 
affected B cells [234]. 
 
3.1.8. AIM  
The objective of this study was to develop different antibody scaffold against canine 
CD20 and its human counterpart. With significant amount of clinical validation of 
CD20, we thought of developing antibodies and determine its binding efficiency in 
several B cell lymphomas which are known to express CD20. Another aim following 
antibody development was to develop a technology to make stable scFv tools and 
modify such tools by cloning into CpG2 to favour ADEPT to see if the affinity of the 
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3.2. RESULTS: 
3.2.1. Production of mouse anti-canine CD20 from murine 
hybridomas 
Balb/c mice were immunized with a peptide derived from canine CD20 
NCDPANPSEKNSLIQYCGS; Figure 3.5 (A) that comprise the minimal epitope 
bound by Rituximab. Hybridomas obtained following fusion were tested for activity 
against canine CD20 immunized peptide as well as canine CD20 protein. The 
hybridomas producing IgG monoclonal (NCD1.2) that recognised recombinant 
bacterially expressed canine CD20 protein (amino acids 140-190 comprising the 
extracellular domain) was sub-cloned twice by limiting dilution to obtain pure 
hybridoma population.  
The NCD1.2 (anti-canine CD20 mouse mAb) was purified with high salt using 
protein A column and the concentration of the antibody was found to be 1.38 mg/ml. 
As it can be seen in figure 3.5B, anti-canine CD20 mAb binds to cross linked 
oligomeric form of CD20 (no DTT) and also binds to the DTT reduced monomeric 
form. For determining its binding efficiency in canine B cells, we used 3132 
lymphoma cells (canine B cell lymphoma cell line provided by Lisa Pang, Roslin) 
lysed in different lysis buffer to determine optimal extraction buffer and the extracted 
lysate was separated by SDS-PAGE followed by western blot to detect endogenous 
CD20 protein. These cells were also subjected to chemical fractionation (Fr1-Fr4, as 
indicated) to isolate different cellular compartments to determine the dominant 
localization of CD20 protein in 3132 cells. The monoclonal antibody was able to 
recognize endogenous canine CD20 protein in canine CD20 expressing 3132 
lymphoma cells (Figure 3.5 C and D) and also shows that the CD20 protein is mainly 
localized within the cytoplasm. Interestingly, CD20 expression was seen in 
cytoplasm and not on the membrane which could be the case of vigorous lysis of 
CD20 expressing cells. Thus in future mild lysis of these cells could in turn show the 
expression to be membranous rather than cytoplasmic.  
Furthermore, a human CD20 construct coupled with GFP was developed by Erin 
Worrall (Hupp lab) for testing the binding ability of anti -canine CD20 mAb onto 
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human counterpart. The human GFP-CD20 construct following cloning was 
sequenced and transfected in H1299 cells. The antibody was used at a dilution of 
1:1000. As seen in figure 3.5 E and F, NCD1.2 binds to human CD20 showing it 
cross-binding to the human orthologue. The blot was also probed with anti-GFP 
antibody in order to ensure that the binding of NCD1.2 was precisely to 62 kDa GFP 
tagged human CD20. This promising cross-reactivity between canine and human 
counterpart would permit cross-species therapeutic model for development of CD20
+
 
diseases in future. Because of such cross reactivity between the species, we decided 
to measure the binding efficiency as well as investigating the binding ability of the 
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Figure 3.5.: Isolation of a mouse CD20-specific monoclonal antibody that 
can recognize human and canine CD20 protein: (A). Amino acid sequence 
of human and canine CD20 region surrounding the Rituximab epitope. The 
asterisks highlight divergence between human (hCD20) and canine (cCD20) 
proteins. (B). Immunoblotting of recombinant canine CD20 protein. Bacterially 
expressed his tagged canine CD20 protein (amino acids 140-190) was purified 
by nickel chromatography and after electrophoresis without and with DTT, 
immunoblotted with mAb NCD1.2. The laddering observed without DTT 
presumably reflects intermolecular disulphide bonds through the two cysteine 
residues. (C and D). (C). Immunoblotting of authentic endogenous canine 
CD20 protein. 3132 canine lymphoma cells were lysed with different lysis 
buffers (as indicated) to determine optimal extraction buffer to immunoblot 
endogenous CD20 protein. (D). 3132 canine lymphoma cells were subjected to 
chemical fraction (Fr1-Fr4, as indicated) to isolate compartments to determine 
the dominant localization of CD20 protein in 3132 cells. (E and F). 
Immunoblotting of human CD20 protein. Transfection of human GFP-CD20 
into H1299 cells demonstrated that NCD1.2 can bind to human CD20 (Left 
panel) with and anti-GFP monoclonal antibody as a control for protein 
expression and relative molecular mass (right panel). 
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3.2.2. Designing peptides spanning the extracellular region of CD20 
After looking at the binding ability of the antibody to canine CD20 protein and its 
human counterpart, we thought of looking at the precise binding site of antibody. For 
this reason we designed a panel of peptides for the region spanning the whole large 
loop of the extracellular domain of canine CD20 with a N terminal biotin tag. Figure 
3.6a shows sequence analysis of designed overlapping peptides, whereas figure    
3.6b shows the comparison of human and canine CD20 in the large loop of the 
extracellular region and encircled is the binding site of NCD1.2 i.e. DPANP of 
canine CD20. Figure 3.6b also shows three dimensional figure of CD20 along with 
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3.2.3. Epitope mapping of the anti- CD20 mAb  
Once the antibody was shown to bind canine CD20 and its human orthologue, 
NCD1.2 was subjected to epitope mapping to a set of overlapping biotinylated 
peptides spanning the extracellular region of canine CD20 via ELISA. The ELISA 
was performed onto the below mentioned biotinylated peptides in several titrations 
(3, 6, 15, 30, 60 125, 250 and 500 ng) and NCD1.2 was used at a dilution of 1:1000. 
A colour change was observed after adding TMB onto all the wells and absorbance 
was measured at 450 nm as it can be seen in figure 3.7, NCD1.2 binds to the peptides 
from number 32-37 (all contain DPANP), whereas it only binds very weakly to 
Figure 3.6: CD20 derived peptides and 3D structure of CD20: (a) 
Sequence analysis of the overlapping peptides deigned from the extracellular 
domain of canine CD20. Peptide immunization sequence (pep 32): 
NCDPANPSEKNSLSIQYCGS forming the loop of the extracellular domain of 
canine CD20, only peptide 38 is devoid of NCDPAN region of CD20 loop. (b) 
Canine peptide used for immunization compared with human CD20 loop 
sequence. Three dimensional structure of CD20 protein showing difference 
between human CD20 and its canine counterpart in the longer loop of 
extracellular region. 
(B) 
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peptide 38 (figure 3.7). Thus, on the basis of this, the precise epitope of the antibody 
was found to be DPANP. 
                                                                                                                       
 
                           
                                  




To visualize the binding pattern of anti-CD20 mAb onto human CD20 expressing 
cells, we performed immunostaining of mAb onto human Raji cells at a final dilution 
of 1:1000 (figure 3.8 c). As seen in figure 3.8, no spots were observed in the control 
experiment where only secondary antibody was used (figure 3.8a), spots were 
observed in the positive control staining (figure 3.8b) where 488 conjugated 
Rituximab was used. Following the control experiments, immunostaining using anti-
Figure 3.7.: Epitope mapping of NCD1.2: Epitope mapping of the NCD1.2 mAb 
onto ELISA Nunc maxisorp plate which was coated overnight with streptavidin. 
CD20 peptides covering the extracellular loop were added at a series of dilutions 
per well (3,6, 12, 30, 60, 125, 250 and 500ng) followed by blocking using 3% 
BSA. NCD1.2 was added at a concentration of 1:1000 followed by HRP 
conjugated rabbit anti-mouse as the secondary antibody.  The absorbance was 
read at 450nm after adding TMB and stopping the reaction using dilute H2SO4. 
Shown below is the precise epitope of canine CD20 to which NCD1.2 binds. 
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CD20 monoclonal antibody did not show any conclusive results. This non-conclusive 
staining pattern could be because some antibodies do not work by IF because of the 
epitope being masked or protein expressed in a different manner. 





3.2.5. Octet binding assay 
We also evaluated the relative binding affinity of the monoclonal antibody NCD1.2 
to determine whether it might have use as a potential diagnostic or therapeutic in 
future (Peter Muller, Brno, Czech Republic). The Octet red system was used for 
measuring the relative on and off rates of the antibody to the biotinylated CD20 
peptide on the solid phase. The relative Kd was defined to be 340pM, this was also 
carried out in presence and absence of DTT in the reaction, which might disrupt 
potential intra-intermolecular di-sulphide bonds in the epitope. But as it can be seen 
in the figure 3.9, no significant effect was seen on the binding reaction as the Kd was 
determined to be 310 pM (figure 3.9). However we cannot rule out the possibility 
Figure 3.8.: Immunostaining of NCD1.2 onto human CD20 expressing 
cells: Immunofluorescence staining of NCD1.2 onto CD20 expressing human 
Raji cells.  (a) AF488 conjugated rabbit anti-mouse as negative control (b) 
AF488 tagged Rituximab used as a positive control , and (c) staining with 
NCD1.2. 
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that the complex structure and oxidation of full length CD20 protein might affect the 
epitope affinity in live cells.  
 
                  






Figure 3.9.: Definition of the relative affinity of the NCD1.2 mAb towards 
the epitope peptide: (A and B). NCD1.2 was titrated into reactions containing 
canine CD20 peptide on the solid phase in the absence or presence of DTT to 
evaluate potential oxidation effects on epitope binding. An Octet RED biolayer 
interferometry system that measures binding to the sensor tip as a wavelength 
shift (in nm) in real time. The assay data were processed using Data Analysis 
(version 6.3 – Forte Bio) to obtain kinetic values as in the materials and 
methods and tabulated as Kd, Kon and Kdis.  
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3.2.6. Fluorescence polarization assay 
For further characterization of NCD1.2, we developed a fluorescent (FITC) tagged 
version of human CD20 peptide to carry out fluorescent polarization assay to 
determine the relative affinity of the NCD1.2 monoclonal antibody in comparison to 
Rituximab (Figure 3.10). Purified monoclonal antibody NCD1.2 and Rituximab 
diluted in PBS were titrated against 30 nM fluorescein-labeled peptide corresponding 
to human CD20 (NCEPANPSEKNSPSTQYCYS) in assay buffer (PBS, 0.05% 
Tween-20). Thus these above mentioned experiments confirm that the NCD1.2 Mab 
binds to both canine CD20 and its human counterpart. Rituximab was used as a 
control, however, there was no detectable binding in this assay relative to NCD1.2, 
presumably as Rituximab binds to a complex epitope on human CD20 [8]. These 
data also suggest that mAb NCD1.2 has a different epitope than Rituximab since 
NCD1.2: (i) binds to canine and human CD20 peptide (unlike Rituximab) and (ii) 
NCD1.2 binds to a linear epitope in human and canine peptide CD20 sequence 
(unlike Rituximab).  
      




Figure 3.10.: Fluorescence polarization assay: NCD1.2 and Rituximab 
were titrated into reactions containing fixed amounts of fluorescent human 
CD20 peptide (FITC; 30 nm peptide) and relative binding affinities were 
compared to each other in order to determine how the epitopes for the two 
monoclonal antibodies might differ. The data are plotted as changes in 
polarization as a function of increasing antibody concentration. 
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3.2.7. Reactivity of NCD1.2 to canine CD20 protein from clinical 
samples 
3.2.7.1. Fluorescence activated cell sorting (FACS) 
After determining the kD and relative affinity of the NCD1.2 onto the CD20 
immunized peptide, NCD1.2 was then tested onto CD20 expressing canine 
lymphoma cells as well as on tissue biopsies. The anti-CD20 antibody was evaluated 
using lymph nodal fine needle aspirates and blood samples preserved in RPMI 1640 
medium from dogs with different lymphoma subtypes using flow cytometry. On each 
sample immunophenotyping was performed according to the previously published 
procedures, in order to define cell origin and to identify the lymphoma subtype. The 
highlighted cell population subset was selected and further processed.  
 




) canine cells in 
peripheral blood (Figure 3.11A) which correlates with the study carried out by Jubala 
et al, 2005 where they show the presence of CD20 in peripheral blood as well as 
canine B cells [198]. As seen in figure 3.11 B the NCD1.2 does not bind to a subset 




), the reason being no or very 
less expression of CD20 in T cell lymphoma. In another type of B cell lymphoma i.e.  





). In figure 3.11 D, NCD 1.2 stains positive in another and the most common 
type of B cell lymphoma in dogs i.e. Diffuse Large B-cell Lymphoma (DLBCL). 
These results gave an indication that NCD1.2 mAb is highly specific to B cell 
population as no staining was noticed in T cell lymphoma. 
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Following such encouraging results obtained from FACS data, we also examined the 
expression of CD20 using NCD1.2 on formalin fixed samples obtained from tissue 
biopsies of different types of canine cancer. IHC studies were carried out in 
collaboration with our Italian collaborators (Stefano). The staining using NCD1.2 
revealed diffuse membrane staining in Diffuse Large B cell lymphomas (Figure 
3.12A) which was similar to the rabbit polyclonal antibody used for clinical 
diagnosis (Figure 3.12B). Expression of CD20 was also observed as expected in a 
range of other lymphoma histotypes of B-cell origin, including Marginal Zone 
lymphoma (Figure 3.12C), Follicular lymphoma and small lymphocytic lymphoma. 
The expected negative expression of CD20 protein in peripheral T cell lymphoma 
was consistent with our FACS data (Figure 3.12D). Collectively, this validation of 
Figure 3.11.: Expression of canine CD20 in clinical cell populations:  
The highlighted cell sample populations were isolated and processed as 
indicated in the materials and methods. Expression of CD20 (and CD21) in 
the population of cells were analyzed by FACS and include (A) peripheral 
blood; (B) peripheral T-cell lymphoma ; (C) Medium sized B-cell lymphoma; 
and (D) Diffuse Large B-cell lymphoma. 
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the full length monoclonal antibody NCD1.2 including its binding to human and 
canine CD20 protein and its expression in the correct clinical tissue (B cells), 
prompted us to clone the antibody variable regions from NCD1.2 to (i) determine 
whether it would be active as a recombinant antibody, (ii) sequence the scFv to make 
antibody sequence publically available to allow validation by other research 
laboratories. 
               






Figure 3.12.: Expression of canine CD20 protein in formalin fixed 
paraffin embedded cancer tissue: The indicated tissues were processed 
using immunohistochemistry as indicated in the materials and methods; and 
include representative images: (A) NCD1.2 in diffuse large B cell lymphoma 
(20x); (B) polyclonal anti-cd20 rabbit antibody in DLBCL (20x); (C) NCD1.2 
in marginal zone lymphoma (20x); and (D) NCD1.2 in peripheral T-cell 
lymphoma (10x) with infiltrating normal B-cells that are CD20+ highlighted 
by the arrow. The staining in brown highlights the position of the NCD1.2 
reactive protein with nuclei stained in blue. 
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3.2.8. Developing a scFv antibody phage library from hybridoma cell 
NCD1.2  
3.2.8.1. Isolation of RNA from the obtained murine spleen 
containing B cells 
RNA was isolated from mouse spleen using RNA extraction kit as well as traditional 
Trizol method i.e. phenol: chloroform method. The extracted RNA was quantified 
using Nanodrop and was further resolved on 1% (w/v) agarose gel to determine the 
quality of RNA. As shown in the figure 3.13a, good quality of RNA was successfully 
isolated using Trizol method.  Reverse transcription i.e. cDNA was prepared from 
RNA using the Omniscript Qiagen kit. This cDNA was used as a DNA template for 
first round of PCR in order to amplify variable heavy and light chain (λ and κ) 
regions. Also it was noticed that the quality of RNA differed depending upon the 
source of extraction i.e. spleen or hybridoma cells.  
3.2.8.2. First round of PCR (Amplification of variable domain of 
heavy and light chains) 
Variable heavy and light chains (λ, κ) were amplified by Polymerase chain reaction 
using mouse scFv specific primers. Several optimizations were carried such as 
increase in annealing temperature, using different types of Taq polymerase, etc. 
While carrying out PCR to amplify variable heavy and light chain domains using Taq 
polymerase, no amplification was seen with any of the primers. For further 
optimization we used additives such as DMSO to favour amplification via PCR. 
However, no difference was noticed even with additives as well as different types of 
polymerases in PCR mixture. Finally, using Phusion mater mix (NEB) turned out to 
be a breakthrough for PCR amplification with additive playing a significant role in 
diminishing non-specific bands. Also while testing the annealing temperature as well 
as number of PCR cycles ideally needed for amplification process it was noticed that 
56
0
C as annealing temperature and 25 PCR cycle were well suited for amplification 
process. Around 250 PCR reactions were performed for each of the heavy and light 
chain order to have enough of these products to generate the overlap product (scFv).  
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Also it is important to mention here that primers used in building first antibody 
library were purified by desalting method and favoured mutations via PCR 
amplification. For this reason we used HPLC purified primers and notice that overall 
mutations decrease when antibody clones were sequenced. The use of HPLC purified 
mouse scFv primers individually amplified the heavy and light chains but not similar 
ones when compared to non HPLC purified primers. For amplification of heavy 
chain, PCR reactions were carried out with each of 19 forward primers and a set of 3 
reverse primers.  However for amplification of light chain, 17 forward primers and a 
set of 3 primers were used for amplification of variable kappa light chain (Vк). 
Multiple PCR reactions and the reactions were pooled together separately for heavy 
and light chains. These reactions were then gel extracted and analysed on 1.5% gel 
and a total of 5 µg of each purified product was made. For amplification of lambda 
light chain (Vλ), a forward and a reverse primer was used for amplification followed 
by gel extraction. Figure 3.13 shows the amplification of variable light chain (figure 
3.13c) and heavy chain (3.13d). 
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These pooled PCR products were gel extracted using the gel extraction kit (Qiagen) 
and 1 µl of each of the purified variable regions was run on a 1.5 % (w/v) to measure 
the concentration of each DNA (Figure 3.14a). The concentration was measured via 
Nanodrop as well as compared to corresponding band on the hyper ladder        
(Figure 3.14).      




3.2.8.3. Second round of PCR (overlap extension PCR)  
After quantifying the amount of DNA, purified variable heavy and light chains were 
spliced together using second round of PCR. For generation of 800 bp overlap 
product, various ratios of Vк and Vλ template were examined via PCR. To start with, 
100 ng of each of the variable heavy and light (λ or к) were used to anneal together 
Figure 3.14.: Purified variable heavy and light chains: (a) Lane 1: Ladder, 
Lane 2: purified heavy chain; Lane 3: purified Vλ and Lane 4: purified Vκ. (b) 
Bioline 100 bp Hyper ladder with each band corresponding to a certain 
concentration of DNA (20-100 ng). 
Figure 3.13.: Amplification of variable heavy and light chains: (a) Isolation of 
RNA resolved on 1% agarose gel; Lane 1, 3- Hyper Ladder; Lane 2, 4: 2 and 5 µl 
of isolated RNA using new Trizol. Both subunits i.e. 18s and 28s can be seen 
after RNA isolation from the spleen of the mouse. (B) Expression of light chains 
(PCR product) from the prepared cDNA resolved at 1.5% Agarose gel. (a) Lane 
L: DNA Ladder; Lane 2: negative control; Lane 3: Vκ; Lane 4: Vλ.(C) Amplification 
of variable light chain through PCR with Phusion protein using 19 different sense 
primers (5') and 3 reverse primers (3').Lane : DNA Ladder; Lane 2-9: PCR using 
5'primers MSCVK1-MSCVK8, respectively; Lane11: DNA Ladder; Lane10-18: 
PCR using 5' primers MSCVK9-MSCVK17 respectively; (D) Amplification of  
heavy chain using 19 PCR reactions, resolved on 1.5% gel. Lane L: Ladder, Lane 
1: Negative control, Lane 2-11:  MSCVK1-MSCVK10; Lane 12-20: PCR using 
5’primers MSCVK11-MSCVK19. 
(a) (b) 
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but it was seen that there was no 800 bp band obtained. On performing PCR 
amplification using different concentrations of each variable chain, it was found out 
that 10 ng of each of the variable chain was most efficient for annealing. However 
this along with this overlap product, there was a non-specific amplification around 
1000 bp. To get rid of this non-specific band, a number of additives have been 
proven to enhance PCR amplification and minimizing other bands. Several 
optimization reactions such as a touch down PCR with 2%  (v/v) DMSO as an 
additive was found to be efficient to amplify 800 bp product and also minimize any 
other non-specific bands (figure 3.15a). Further, different types of polymerases were 
also examined via PCR with an objective to investigate if the amplification could be 
maximized by the use of different polymerases. 




A total of 120 reactions touchdown PCR reactions were performed in order to have 
enough of purified overlap PCR product i.e. around 10 µg for proceeding to next 
step. These PCR reactions were pooled together; gel extracted on 1.5% (w/v) agarose 
gel and purified using gel extraction kit. The extracted DNA was pooled together and 
once again 1µl of DNA was analysed on the gel to estimate the concentration of the 
DNA (Figure 3.15b). 
Figure 3.15.: Second round of PCR (Touch down PCR): (a) Lane 1: 
Ladder, lane II, III: 5µl PCR using 2%DMSO as an additive and no additive, 
respectively. (b) Purified PCR product Lane I, II: 1 and 2µl of purified PCR 
overlap product, respectively.  
 
(a) (b) 
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3.2.8.4. Restriction digest, Ligation of purified PCR product and 
vector DNA (pCOMB3xSS) 
Restriction digest reactions using SfiI enzyme were set up for the purified insert 
(scFv) as well as vector DNA to favour ligation. The reactions were incubated at 
50°C for 5 hours. The purified PCR product was resolved on 1% (w/v) gel, whereas 
the reaction containing vector DNA (pCOMB3xSS) was resolved on 0.6% (w/v) 
agarose gel. These products were then gel extracted and the concentration was 
determined using Nanodrop as well as hyper ladder. Each of the digested products 
was run on a 1% (w/v) agarose gel (shown in figure 3.16). These purified digested 
products were ligated together. Ligation reaction was carried out for vector DNA 
containing scFv as well as vector DNA only to check for ligation efficiency and 
percentage insert.  
As mentioned in the methods section the reactions were made up and then incubated 
at 16
0
C overnight. Following overnight ligations, purification of the ligated samples 
was carried out using mini PCR purification kit (Invitrogen) and eluted in 10 µl 
elusion buffer. The eluted mixture was divided into 5 tubes (2 µl/tube) and 
transformed into TG1 cells using electroporation technique. To each 2 µl DNA 
aliquot, 250 µl of SOC medium was added quickly to all electroporation columns 
and incubated for 1 hour at 37
0 
C. Following this, the electroporated mixture from all 





) and plated out onto LB ampicillin plates. Rest of the electroporated 
mixture was plated out on a large assay plate. Subsequently all the plates were 
incubated overnight at 37°C.   
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3.2.8.5 Library size 
The mixture plated onto the large assay plate contains the library and this library was 
scraped using LB medium, 50% Glucose and 30% glycerol. This library was snap 
frozen and stored at -80
0 
C until further used. The size of the library was calculated 
on the basis of number of colonies obtained onto the smaller 10 cm plates. A total of 
4 antibody libraries were made from mouse spleen and hybridoma cells using 
differently purified sets of degenerative primers. The size of the libraries obtained 
were 1.4 x 10
9
, 4.0 x 10
8
 and 2.6 x 10
8
 cfu /ml which were two orders of magnitude 
higher as compared to vector DNA only. Here magnitude of vector DNA indicates 
the count obtained from colonies containing self - ligated vector DNA only. 
10 colonies were grown from vector containing insert plates as well as vector only 
plates in 5 ml LB medium (100 µg/ml Amp).  Following this, miniprep (Qiagen) was 
performed for all of these colonies and the concentration of the obtained DNA was 
measured through Nanodrop. Subsequently, restriction digestion 15µl reaction of 
these clones using SfiI was performed in order to ensure that vector DNA contains 
insert. 24 out of 30 clones showed the presence of insert i.e. 80% and were further 
sequenced (for example figure 3.17).  
Figure 3.16.: Restriction digestion and ligation of scFv, pCOMB3xSS: (a) 
Restriction digestion; Lane I: Ladder, Lane II: purified pCOMB3xSS, Lane III, IV 
and VI: 1, and 5 µl of purified SfiI digested insert, respectively. (b) Lane I: 
Ladder, Lane II: Ligated scFv into pCOMB3xSS and lane III: Ligated vector DNA 
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The sequencing data of these purified DNA clones from 1
st
 library (non-HPLC 
purified primers) showed that 7 out of 10 scFvs were out of frame. However, when 
HPLC purified primers were used the clones containing insert increased to 50% in 
frame. The complementary determining regions (CDRs) and the framework regions 
(FRs) were identified from the antibody sequences. As explained above in section 
3.2.8.3, the heavy and light chains are linked together by a long serine glycine linker 
with a His tag at the end. In order to overcome the frame shift mutation which might 
have come via PCR or at any other stage, 3 more antibody libraries were developed 
using either HPLC purified primers or using spleen or using hybridoma cells. Based 
on the sequencing data obtained from all of these libraries, the one that was made 
from hybridoma cells was found to be the best one and was taken forward. The scFv 
was cloned in such a way that the OmpA sequence (sequence present in 
pCOMB3xSS just before SfiI restriction site) is followed by light chain. This light 
chain is linked to the heavy chain via a linker which has been shown below in figure 
3.18: 
 
Figure 3.17: Restriction digestion of picked colonies: Lane I: Ladder, Lane 
II-XI: Restriction digestion of miniprep purified DNA extracted from serially 
diluted vector containing insert plates, Lane 12: Ladder; Lane 13- 22: 
Restriction digestion of miniprep purified DNA extracted from serially diluted 
vector only plates, Lane 23: Ladder. 
vector 
scFv 
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Using 1µl of antibody library, OD600nm was measured and the amount of library 
needed to produce 100 copies was calculated. Subsequently the antibody library was 
grown overnight at 30
0
C, PEG precipitated and the clearly visible phage pellet was 
resuspended in PBS. A total of 4 rounds were carried out and the amount of washes 
were increased every round. Also, the concentration of the protein used in each round 
was decreased to half in order to get highly specific binding clones to the target 
CD20 peptide. The antibody library was subjected to the process of biopanning in an 
immunotube coated with CD20 peptide in order to select for CD20 binding antibody 
clones. Also during all rounds of biopanning, several titrations of the phage pools 
was carried out (as in theory, the amount of phage should decrease every round and 
the specific phage should be eluted). The dilutions of the phage was performed in 




 were prepared, 
incubated at 37
0 
C for 30 minutes and plated out on LB + ampicillin plates.             
96 colonies from round 3 and 4 were grown in 100 µl of media containing 100 µg/ml 
ampicillin and sub-cultured in 200 µl media (Amp) containing growth supplements 
in 1 ml deep well plate. These were grown until an OD of 0.6 was reached and 1 mM 
IPTG was added to each well and incubated overnight at 30
0 
C. The following day, 
Figure 3.18: scFv in pCOMB3xSS: Variable heavy and light chain connected 
by a peptide linker (L) with SfiI digestion sites at the 5’ and 3’ of light and heavy 
chain respectively. Each chain of scFv is comprised of 3 CDRs and 4 
framework regions. 
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lysis (freeze thaw protocol) was performed three times and the plate was centrifuged 
at 4000 g for 15 minutes. This supernatant contained secreted antibody without any 
phage and used as primary antibody.  
100 µl of this lysate was added to the respective well of the CD20 peptide coated 
plate and incubated for one hour at RT. Subsequently, HRP conjugated protein A 
(1:1000) was added to all the wells of the plate and the plate was then read at 450 nm 
after adding TMB. As shown below out of 96 clones, 6 of the clones showed 
significant binding as compared to other clones. The lysates were added fresh while 
performing this ELISA (figure 3.19); however when ELISA was performed the 
following day using the same lysate as the primary antibody the activity of all of the 
positive clones were close to zero. From the glycerol stocks of these antibody clones 
expression was carried out on a large scale to see if any activity was retained after 
lysis, but the results from ELISA again show that the secreted antibody was inactive. 
Thus, on the basis of results obtained from secreted antibody expression, it was 
concluded that scFv are highly unstable as the activity of the antibody was not even 
retained for 24 hours. This instability of recombinant antibody has been reported 
previously [235]. For selecting more stable and CD20 binding specific clones, 
troubleshooting in various ways was carried out such as increasing the number of 
rounds of panning, 5% milk as blocking buffer instead of 3% BSA used in earlier 
case and increasing the number of washes as well as using different reagents for 
elusion of specific binding phages.  
Chapter 3: Development of monoclonal antibodies and Bioconjugate to canine CD20 








In order to overcome this stability issue of the recombinant antibody, expression was 
optimized using different elution methods for binding phages and 8 colonies from 
output round 3 and 4 were grown in 10 ml LB media (100 µg/ml Amp) until an OD 
of 0.6 was reached. Once an OD of 0.6 was reached, 10 µl helper phage was added, 
incubated static for 30 minutes followed by shaking at 220 rpm for 2 hours. 
Following this, kanamycin (50 µg/ml) was added to the cultures and incubated 
overnight at 30
0
C. Next day the falcon tubes were centrifuged at 4000rpm for         
10 minutes and supernatant PEG precipitated, final pellet was resuspended in 200 µl 
of PBS and added to ELISA wells that were coated overnight with CD20. As seen 
below in figure 3.20, 2 colonies out of 8 showed significant activity via ELISA when 
carried out in titrations and probed using M13 antibody. The activity of these clones 
was tested again after 5 days and both clones retained activity the same as day zero. 
The stability of antibody was thus achieved when scFv was expressed on phage 
surface rather than secreted scFv antibody with no phage. As it can be seen scFv 3 
Figure 3.19: Biopanning: Analysis of 96 colonies by monoclonal ELISA: 96 
colonies were grown overnight at 370C, following day sub cultured and grown in 
200 µl LB media (100 µg/ml amp) for 2-3 hours until an OD of 0.6 was reached 
in a 1ml deep well plate. The expression was then induced by addition of 1 mM 
IPTG overnight at 300C, shaking 220 rpm. The plate was then subjected to 
freeze thaw protocol thrice and centrifuged to obtain scFv enriched lysate. This 
was added as primary antibody onto wells coated with CD20 peptide overnight. 
The binding activity was resolved using TMB and the plate was read at 450 nm.   
Chapter 3: Development of monoclonal antibodies and Bioconjugate to canine CD20 
receptor (a receptor, scFv model)                                                                                          125 
 
binds to CD20 peptide better than scFv 7 and following this both phage linked scFv 
(3 and 7) were tested and compared for activity onto peptide 32 
(NCDPANPSEKSLSIQYCGSIR) and 38 (PSEKNSLSIQYCGSIR). Interestingly 
these results showed scFv 3 and 7 bound better to peptide 38 as compared to 32, 
which was in contrast to the full length monoclonal antibody epitope which bound 
strongly to peptide 32 and weakly to peptide 38. Previously it has been shown by few 
research groups that recombinant antibody might not bind as better as the full length 
mAb, which might be due to the way epitope is exposed or could be the confirmation 







3.2.10. Bacterial and mammalian expression of scFv 
Once this optimization was successful to obtain positive phage linked scFv clones, 
we hypothesized that both of these scFv antibodies targeting CD20 could be used by 
our community as a recombinant bioconjugate in the development of 
immunotherapeutic models in canine cancer. As mentioned in methods section both 
scFv 3 and 7 were cloned into bacterial as well as mammalian expression vectors to 
determine if they could be manipulated and used in principle for future therapeutic or 
diagnostic applications. The scFv3 and scFv7 were active when fused to gIII M13 
coat protein figure 3.21. When the scFv was cloned into a mammalian expression 
Figure 3.20: Phage expressing scFv ELISA: Phage producing plaques from 
rounds 3 and 4 were grown overnight, the scFv-phage in the supernatant was 
PEG precipitated, and assayed in an ELISA using biotinylated CD20 peptide 32. 
Active scFv-phage was detected using an M13-phage antibody and binding 
activity was resolved using TMB and measured as optical density (450 nm). Eight 
representative scFv-gIII fusion phage are highlighted where two bioactive 
recombinant (3 and 7) were isolated. 
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vector that directs its secretion from CHO cells, then both scFv3 and scFv7 
supernatants were shown to produce active recombinant antibody using either CD20 
protein (Figure 3.21  i) or CD20 peptide 32 (Figure 3.21 ii).  
 
This indicates that the CHO system can be used in principle to direct the production 
of large amounts of recombinant protein for diagnostics, or therapeutics, in the 
future. Both scFv 3, 7 were expressed and the supernatants were used for performing 
ELISA onto plates coated with CD20 protein as well as CD20 peptide 32. The results 
shown in figure 3.21 demonstrate that both scFv were expressed and bound to CD20 
protein and peptide, also scFv 3 bound better as compared to scFv 7. CHO system 
has been the ideal choice for antibody expression in mammalian cells because of the 










    
Figure 3.21: Mammalian expression of scFv:  The indicated scFv (3 or 7) was 
cloned into pCDNA3.1 containing a leader sequence (amino acids MGGS) for 
targeted secretion into the media of tissue cultured CHO cells. (i) Activity was 
measured on left panel after dilution of the supernatants (1:40 or 1:80) to 
optimize activity against His-tagged CD20 protein; (ii) right panel the optimized 
supernatants of scFv-3 and scFv-7 were assayed against biotinylated CD20 
peptide as indicated in the materials and methods. Antibody scFv binding to 
antigen was detected using peroxidase conjugated protein A and resolved with 
TMB-based ELISA at an OD of 450nm. Controls included media only or PBS. 
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Alongside bacterial expression was carried out into pTRCHisB, the antibody 
expression was followed by purification using a Ni-NTA column. The antibody was 
used at a dilution of 1:40, 1:80, 1:160 and 1:320 onto CD20 extracellular protein 
(figure 3.22). 
 







Figure 3.22: Bacterial expression of scFv (ELISA): (a) Binding efficiency 
of purified scFv 3, 7 onto GST-CD20 and extracellular CD20-His tagged with 
all controls. (b) Titration of extracellular CD20 was added to fixed amount of 
scFv (500 ng/well) and absorbance read at 450nm after addition of TMB. 
(a) 
(b) 
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3.2.11 Sequence analysis of scFv 3, 7 
Both scFv were sequenced and the amino acid of each has been shown below in the 
figure 3.23 upper panel. All three CDRs and four FRs have been shown, with 
variation only in light chain in CDR1 and CDR2 region between the scFvs. In theory 
both scFv should have same sequence throughout as both scFvs are isolated from a 
single hybridoma cell. Interestingly we notice here that both scFvs have been 
obtained from a single hybridoma cell and the variability was only seen in the light 
chain CDRs whereas the heavy chains were totally identical. To further prove this, 
we designed primers using the initial sequence of each light chain. The PCR was 
performed with three different cycles (20, 25 and 30 cycles) and as it can be seen in 
the figure 3.23 lower panel both light chains were amplified using the designed 
primers from different scFv.  
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3.2.12 scFv-CpG2 Bioconjugate 
Bacterial production was evaluated after creating a CPG2-bioconjugate with an aim 
to determine whether the scFv scaffolds would be suitable for ADEPT (antibody 
directed enhanced pro-drug therapy) type immunotherapeutics. CPG2 is 
Carboxypeptidase G2, originally derived from Pseudomonas that has been used to 
convert Nitrogen mustards into potent DNA cross-linking agents. CPG2 was cloned 
into pHISTEV at NcoI and NotI sites to create pJGS101. The scFv-3 and scFv-7 were 
cloned into pcDNA3.1-his/ lacZ with CPG2 cloned into the KpnI - EcoRI sites of the 
vector. The anti-CD20 scFv - CPG2 bioconjugates were relatively insoluble in 
bacteria (Figure 3.24 C, left panel). However, we optimized the production of soluble 
scFv-CPG2 fusion proteins that permitted affinity purification of the protein (Figure 
3.24 C, right panel). The purified scFv-3:CPG2 and scFv-7: CPG2 fusion proteins 
were tested for activity on the CD20 derived peptides. We notice that both scFv 
actively binds with a proposed epitope defined by the overlapping binding towards 
peptide 32 and peptide 38 derived from CD20 protein (Figure 3.24 D). These latter 
data suggest that although the CPG2 - scFv fusions have the potential to be used as a 
bioconjugate, bacterial expression systems might not be the optimized source of 
protein for future trials in canine cancers. CHO cells might remain the standard 






Figure 3.23: Sequence analysis of scFv 3 and scFv 7: (a)The amino acid 
sequences of the light chain and heavy chain framework and CDR regions are 
as indicated. The CDRs of the light chain are highlighted in red, since the 
sequences diverge in CDR1 and CDR2 of the two light chains, but are identical 
in the CDR3 of the light chain. The full amino acid sequence of scFv-3 and scFv-
7 including the linker is highlighted. (b) RT-PCR using primers directed to the 
divergent light chains (from CDR1 to Framework 4) of cDNA scFv-3 and scFv-7 
from NCD1.2 hybridoma cell line to establish that the light chain mRNA for scFv-
3 and scFv-7 are both expressed to similar levels indicating that the hybridoma 
produces two light chains with an identical CDR3. The size of the CDR1-FR4 
PCR product is approximately 300 bp and the ladder is Hyperladder (Bioline). 
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Figure 3.24: Bioactivity of recombinant scFv-3 and scFv-7 secreted from 
CHO cells and produced in bacteria as a CpG2-bioconjugate: (A) The 
indicated scFv (3 or 7) was cloned into pCDNA3.1 containing a leader sequence 
(amino acids MGGS) for targeted secretion into the media of tissue cultured 
CHO cells. (i) Activity was measured on left panel after dilution of the 
supernatants (1:40 or 1:80) to optimize activity against His-tagged CD20 protein; 
(ii) right panel the optimized supernatants of scFv-3 and scFv-7 were assayed 
against biotinylated CD20 peptide 32 as indicated in the materials and methods. 
Antibody scFv binding to antigen was detected using peroxidase conjugated 
protein A and resolved with TMB-based ELISA at an OD of 450nm. Controls 
included media only or PBS. (B). A schematic of the scFv-3 and scFv-7 CPG2 
fusion protein. (C). Bacteria were grown and scFv-3 or scFv-7 CPG2 
bioconjugates were induced with IPTG. Following lysis with 100 mM or 1 M NaCl 
lysis buffer, the samples were separated into soluble and insoluble fractions. 
These fractions were mixed with SDS loading buffer, were separated on an SDS 
gel, and stained with Coomassie blue. The Left panel (i) displays the solubility 
(S) or insolubility (I) of scFv-3 and scFv-7 from bacterial expression systems in 
lysis buffer containing the indicated NaCl concentrations. The arrow highlights 
the position of the scFv-CPG2 fusion protein. The NI lane represents the amount 
of soluble scFv- 3 recovered from the S fraction after nickel chromatography, 
which was negligible. The right panel (ii) shows the relative purify of the scFv-3 
and scFv-7 (and scFv-8 as a control antibody) after lysis using stabilizing lysis 
buffer (as in Methods) and followed by nickel affinity chromatography. The 
relative expression and purity of CPG2 alone is shown by comparison to 
highlight its enhanced yield relative to the scFv-CPG2 fusion. The insolubility 
remains a problem from bacterial expression systems, as the total synthesis of 
scFv-CPG2 and CPG2 alone is relatively similar using whole cell lysis buffer 
(right panel (iii). (D). Bioactivity of affinity purified scFv-3 and scFv-7 from 
bacteria. The normalized affinity-purified scFv fractions (from Figure 3.23 C) 
were assayed for binding to the indicated canine CD20 peptides (peptide 32 and 
peptide 38) where the core epitope resides (in gold shade). scFv-3 : CPG2 was 
more active than scFv-7:CPG2 on both peptide 32 and peptide 38. The 
enhanced activity of scFv-3:CPG2 as a bioconjugate is consistent with its 
enhanced activity when secreted as a single chain from CHO cells (Figure 3.23 
A) and when fused to M13 gIII protein (Figure 3.23 C). 
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3.2.13 Yeast expression and purification of scFv3-CpG2 
To further increase the affinity of the scFv.CpG2 conjugate, we cloned conjugate 
into yeast expression vector with an aim of improved antibody secretion. Yeasts are 
eukaryotic micro-organisms provide an advantage of additional protein folding 
pathways and can be rapidly grown on yeast growth media [236]. In this case only 
scFv3 was considered and was carried out in collaboration with Eva, Brno, Czech 
Republic.  
Expression 
scFv was expressed on a small scale (20 ml) as well as large scale (1 litre) in the 
yeast strain Pichia pastoris. Single colony was inoculated in 25 ml of BMGY in a 
250 ml baffled flask. The colony was grown overnight (approximately 16-18 hours) 
at 28-30
0 
C in a shaking incubator (250 rpm) and the cells reach an OD600 of 2-6 
which indicates the cells will be in the log phase. The cells were centrifuged at 1500-
3000 x g for 5 minutes at RT. The supernatant was discarded and cell pellet was 
resuspended to an OD600 of 1.0 in BMMY medium to induce expression 
(approximately 100 ml). The culture was placed in a 1 litre flask and the flask was 
covered with 2 layers of sterile cloth and returned to incubator to continue growth. 
100% methanol was added to a final concentration of 0.5% methanol every 24 hours 
to maintain induction. At each of the time point i.e. 0, 6, 12 , day 1, day 2 , day 3 and 
day 4; 1ml of the expressed culture was transferred to a 1.5 ml microcentrifuge tube. 
These samples were then used to analyse the expression levels and determine the 
optimal time post induction to harvest. These were then spun down at maximum 
speed in a table top microcentrifuge for 2-3 minutes at room temperature. For 
secreted expression, the supernatants were analysed via Coomassie staining as well 
as functional assay such as ELISA (figure 3.25 A, B).  
Purification 
Cell pellet was resuspended in sucrose buffer (30 mM Tris/HCl, 20% sucrose, adjust 
pH to 8.0). The cells were kept on ice with a dropwise addition of 500 mM EDTA to 
1 mM and incubated on ice for 5-10 minutes with gentle agitation. The cell 
suspension was spun down at 8000 x g for 20 minutes at 4
0
C. The cell pellet was 
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resuspended in buffer B (100 mM NaH2PO4, 10 mM Tris/HCl, 8 M urea, adjust pH 
8.0). The cells were sonicated at an amplitude of 10 (3x 15seconds) on ice. The cells 
were centrifuged at 10,000 x g for 20-30 minutes at room temperature to pellet the 
cellular debris. 1 ml of 50% Ni- NTA to 4 ml lysate and mixed gently by shaking at 
4
0
C for 60 minutes. This lysate –Ni-NTA mixture was loaded onto a column with 
capped bottom outlet, bottom cap was removed and flow through was collected. The 
column was washed with 100 mM NaH2PO4, 10 mM Tris/HCl, 8 M urea, adjust the 
pH to 6.3. The protein was then eluted in 100 mM NaH2PO4, 10 mM Tris/HCl, 8 M 
urea, adjust the pH to 4.5. The samples were then analysed by Coomassie staining 
and ELISA (figure 3.25 A, B).   Thus in conclusion, the results indicate that yeast 
expression of scFv3-CpG2 does not yield a great amount in comparison to bacterial 
and mammalian expression as shown in 3.2.10.  
     
                       
(A) 
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Figure 3.25: scFv3-CpG2 expression, purification in Pichia pastoris (A) 
Coomassie staining 10µl of expressed, purified scFv3-CpG2 along with IFITM 
scFv-CpG2. Lane I: uninduced scFv, Lane 2,3,4 : induction day3, 2 and 1 
respectively; lane 5: wash, lane 6, 7 and 8: purified fractions 3, 2 and 1 
respectively and lane 9: IFITM scFv. (B) Binding activity of purified scFv3-CpG2 
onto CD20 peptide (immunization peptide) as well as CD20 protein with IFITM 
peptide and EGFR as negative controls respectively. The overall data suggests 
that the scFv3- CpG2 construct was purified and ran at ~70 kDa and with activity 
higher onto the peptide as compared to the protein which correlates with our 
earlier data. 
(B) 
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3.3 Discussion 
Experimental animals have long been a part of clinical research as a model for 
studying drug effects, signalling pathways etc. but choosing the right one turns out to 
be an important factor.. The emergence of companion therapeutics has also led to the 
development of the first approved anti- CD20 mAb for use in canine lymphoma 
[237] and additional mouse monoclonal antibodies are being generated to CD20 thus 
creating a competitive landscape [238]. Canine non-Hodgkin’s lymphoma is the most 
common type of malignancies in dogs, accounting for 24% of all reported neoplasm 
and dogs are affected during their middle and later stages in life [188, 239]. CD20 
was an interesting target choice due to the fact that it is expressed in premature and 
growing B cells whereas not present in terminally differentiated B cells (i.e. plasma 
cells) [240]. Here we develop an antibody against canine CD20 that is indeed 
capable of binding to its human counterpart. Having established that NCD1.2 can 
bind to both human CD20 and its canine counterpart we set out to investigate 
whether or not we could increase its affinity towards using different antibody 
scaffolds. 
Using FACS, Jubala et al demonstrated that CD20 is present in abundance in most 
canine B cell lymphomas [198]. However it was also demonstrated that the 
predominant forms of CD20 were present in both normal and malignant B cells, 
whereas hypophosphorylated forms of CD20 were seen only in normal canine B cells 
[198]. Against this membranous target, Rituximab was the first monoclonal antibody 
approved, followed by few more with either modifications in CDR or binding to a 
different epitope. Not all the antibodies have gained clinical significance due to high 
toxicity or re-occurrence of tumor. Another reason as to why this target becomes an 
interesting choice is that although these cells are normal B cells, the stem cells that 
give rise to new B cells do not express CD20 [241]. This means that when the cells 
are targeted by any therapy, B cells that die after therapy can be replaced with CD20 
negative cells (figure 3.26). Replacement of B cells is necessary as B cell lymphoma 
is clonal in nature and thus many of cells are present in such populations. 
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Due to the fact that Rituximab does not bind to its canine counterpart, the need for 
antibodies that can bind to canine CD20 still remains from the veterinary oncology 
point of view. A mouse was immunized with canine CD20 peptide 
(NCDPANPSEKNSLSIQYCGS) and on testing the monoclonals, NCD1.2 was 
found to bind CD20 protein as well as CD20 in canine B cell lymphoma cells. 
Although full length monoclonal antibody can induce anti-tumor effects via several 
mechanisms, accessibility to the tumor still remains an issue in some cases due to the 
size of an antibody. For all such purposes, the aim of this project was to screen 
hybridomas obtained after mice immunizations with canine extracellular portion of 
CD20 onto canine CD20 as well as its human counterpart (figure 3.10) for future 
inter-species application, measuring the kD of the antibody NCD1.2; to show the 
Figure 3.26: Regeneration of B cells: Normal B cells are targeted by different 
B cell therapies but these B cells are replaced by stem cells following therapy 
and these B cells do not express CD20. 
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binding efficiency of the NCD1.2 onto CD20 protein in canine lymphoma cells, 
lymphoma tissues in different types of B cell lymphomas. Results from 
immunohistochemistry (figure 3.12) show that the antibody stains positive for B cell 
lymphoma whereas results obtained were negative when tested for T cell lymphoma 
(CD20
-
). It is important to mention that T cell lymphomas are devoid of CD20 [242] 
and thus for this T cell lymphomas became an ideal model to demonstrate the 
specific binding efficiency of NCD1.2. The data obtained from FACS using NCD1.2 
onto canine lymphoma cells correlates with our IH results and prove that NCD1.2 
binds to only B cell lymphoma which express CD20. Interestingly, we noticed that 
NCD1.2 does not bind to CD20 positive cell line (Raji cells) via IF whereas the data 
from FACS and IH showed significant binding to the target tissue. The data suggests 
that performing IF on living cells using NCD1.2 might result in a better outcome 
which in turn can be useful for in-vivo immunotherapy. The only drawback we 
consider with this NCD1.2 is the dog anti-mouse response upon administration to 
dogs, for this reason we thought making a recombinant antibody or dogizing the 
antibody might be of great advantage. Ongoing work in this project is being carried 
out to caninize NCD1.2 antibody for administration in dog patients. 
Further the aim of developing a scFv library to build single chain antibody scaffold 
by amplification of variable heavy and light chains and cloning into a phagemid 
vector was met. We used phagemid vector for cloning the scFv into due to the fact 
that they possess better transformation efficiencies and well assembled after the 
addition of helper phage M13KO7. Once the library was made from the dog spleen 
as well as from hybridoma cells, only 40% of the clones had the scFv in frame (i.e. 
light chain- linker- heavy chain). In order to overcome these frame shift mutations 
which have been on occasions shown to occur due to PCR error or purity level of the 
primers, another library was made from hybridoma cells using HPLC purified 
primers and the obtained library had 60% clones in frame. 5 positives were obtained 
after selection using the process of biopanning (figure 3.20) but the stability was 
always an issue with the secreted scFv as they did not even retain activity for          
24 hours. In order to overcome the stability issues, more rounds of panning were 
carried out; different blocking buffers were used onto the immunotube, expressed in 
a different strain of E.coli. Finally, following a number of troubleshooting steps, the 
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ultimate solution came from the colonies from output sets which were grown in      
20 mls, PEG precipitated and used as antibodies (phage linked scFv) onto ELISA. 
These resuspended phage scFv retained activity even after a month at 4
0
C when they 
were tested on ELISA.  
The outcome of this experiment resulted in two scFvs with one binding better than 
the other (named as scFv3 and 7, figure 3.22). The sequencing data of both scFv 
revealed that there was a difference in the CDR3 region of the light chain whereas 
the heavy chain sequence was exactly the same. It was surprising due to the fact that 
both scFv come from a single hybridoma so they should code for the same sequence. 
Also to prove this we performed RT-PCR to amplify the light chain using the 
primers designed from the sequence of the light chain of both scFv (figure 3.23 lower 
panel). Previously only on one occasion it has been shown where an anti-DNA 
hybridoma codes for two different kappa light chains [243]. On the basis of ELISA 
results, it was shown that scFv 3 exhibited greater binding capacity to CD20 peptide 
as well as CD20 protein. Not much has been published in the literature as to what 
percentage of variation in the light or heavy chain could be expected from a single 
hybridoma cell. Cloning the core scFv into an ADEPT bioconjugate system or can be 
secreted into active form from CHO cells was another of our research for increasing 
the affinity of antibody and to build a scaffold suitable to deliver in humans.  As it is 
well known that scFvs are highly unstable and some manipulations, mutagenesis 
being one of them have proved to be effective in improving the stability of the 
antibody [244]. From future immunotherapeutic point of view, we thought it was 
better to clone the scFv into an ADEPT system as it can be delivered as an antibody 
enzyme conjugate followed by prodrug administration. We used CpG2 as an enzyme 
to be linked to scFv and expressed in bacteria to look for antibody secretion. As 
shown in figure 3.24D, not much antibody was secreted after lysis but following 
optimizations we managed to pull out scFv – CpG2.  
Furthermore, scFv-CpG2 conjugate was cloned into pICZalpha and its expression 
was carried out in yeast.  The expression was determined at various time points and 
1ml of media was taken out each day until proceeded with purification. scFv- CpG2 
conjugate was clearly visible on the gel and its activity was determined onto CD20 
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peptide via ELISA using IFITM1 as a control peptide. With such results obtained 
with antibody scaffolds we are currently in the process of developing full length 
recombinant antibody using scFv sequence. Thus we show the efficacy of 
monoclonal antibody NCD1.2 and using this hybridoma we also developed several 
antibody scaffolds for optimizing the binding affinity. Based on our results we 
conclude that NCD1.2 binds to canine CD20 as well as to its human counterpart and 
in future could be useful from both veterinary once it has been dogized and human 
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CHAPTER 4: Developing monoclonal 
antibodies and assays to biophysically 
characterized α-synuclein  
4.1. Introduction  
4.1.1. Immunotherapy as tool for treatment of neurodegenerative 
diseases  
The concept of immunotherapy in neurodegenerative disease evolved from Dale 
Schenk’s work on Aβ vaccine targeting Alzheimer’s disease (AD) [245] which 
further encouraged development of immunotherapy based approaches towards 
Parkinson’s disease (PD). The self-assembly of proteins and peptides into amyloid 
fibrils is the characteristic of more than 20 human diseases, including Parkinson’s 
disease (PD) and Alzheimer’s disease (AD) [246]. In case of PD, insoluble amyloid 
fibrils are the final detrimental product formed from monomeric species, whereas 
oligomeric assemblies are transitory phase species. The best example of such a 
transitory protein from monomeric to amyloid fibrillar structure is α-synuclein that 
becomes aberrantly folded in Parkinson’s disease, a disease which still does not have 
medical cure. From a therapeutic point of view, the need for antibody/drug 
conjugates still remains that can target α-synuclein at different stages before the 
amyloid fibrils are formed. It has been reported on few occasions now that although 
fibrillar structures are the main characteristics of α-synuclein related 
neurodegenerative disease the oligomeric form of α-synuclein remains the main toxic 
form [247-249]. Intriguingly, antibodies have been developed that selectively bind to 
the conformational epitope exposed in the target i.e. oligomeric species. Also 
recently it has been shown that the oligomerization of α-synuclein is not a pre-
requisite for aggregation and the aggregates rather develop through sequential 
assembly of assembly of monomers [250]. One study has highlighted the fact that N-
terminal acetylated form of α-synuclein does not form dimers, trimers, etc or higher 
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molecular weight proteins but can alter the conformational state of the monomeric 
form [251]. It is surprising that the antibodies have been developed against either 
oligomeric form of the protein or fibrillar species but it still remains a massive 
challenge to develop such biological tools that can target both species.  
Both active and passive immunizations have proved to be effective in degrading 
accumulated α-synuclein and toxic aggregates via autophagy or macrophage 
activation [252]. In the recent past, antibodies targeting oligomeric species of protein 
have been isolated but their mechanisms of action are still not very well understood. 
However, on one occasion it has been demonstrated that anti-α-synuclein antibodies 
reduce α-synuclein pre formed fibrils which are known to induce inclusion bodies i.e. 
lewy bodies (LBs) and rescue synaptic or neuronal loss in primary neuronal cultures 
[253]. On another occasion it has been shown that multivalent IgM with 10 
independent sites selectively bound to oligomers due to exposure of multiple 
epitopes in the oligomeric assemblies [254]. It is also important to identify the 
precise region on the protein which is embedded in fibrils and exposed in the case of 
oligomers. Consequently, following intense research in this field only one antibody 
has managed to enter clinical phase I trial (AFFITOPE) by Affiris. Although 
antibodies have been shown to bind oligomeric species, their ability to target proteins 
in other fibrillar structural forms still remains a concern. Here we isolated anti-α-
synuclein antibodies with an aim to target α-synuclein at different stages of 
transitions from monomeric form to fibrillar form in PD and also develop peptide 
aptamers via peptide phage display screening to identify interacting proteins using 
next generation deep sequencing (Chapter 5).    
4.1.2. Current available treatment  
Although the etiology of PD is still not very well understood, indicators such as the 
formation of aggregates, fibrils and loss of dopaminergic neurons have become an 
ultimate target for PD therapies. All the therapies used in the case of PD treatment 
have a similar goal which is to induce dopamine with minimum side effects. The 
treatment for PD patients is divided into several categories. Multiple clinical trials 
have demonstrated that Levodopa provides the best symptomatic benefit for 
Parkinson’s disease by increasing dopamine concentration in the brain and shows 
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less risk of developing hallucinations, impulse control disorders as compared to 
dopamine agonists [255]. Levodopa induces dopamine by aromatic amino acid 
decarboxylase and are usually administered with peripheral aromatic amino acid 
decarboxylase (AADC) inhibitor such as carbidopa or bensarazidenin order to reduce 
the side effects [256]. However, dopamine based treatment therapies have been 
effective in PD patients below 60 years of age and are known to cause less 
dopaminergic motor complications. From experimental therapeutic treatment, 
vaccine developed by Affiris has been under clinical trials and has shown promising 
results against α-synuclein. In most available clinical I and II trials, entacapone and 
tolcapone significantly reduced off time (mechanisms based on improved 
medication) and several adjuvants have been shown to reduce off time and avoid 
severe side effects [257]. There still remains a concern over the effect of Levodopa 
with or without agonists based on its mechanism of action on neurons. However, for 
advanced PD patients, Levodopa and different agonists may fail to provide 
satisfactory control, thus for such patients surgical therapies become an alternative 
option. Another drug that has shown promising results over the years is Phenserine; a 
derivative of physotigmine which has shown to improve cognition in various 
experimental paradigms in rodents as well as dog models.  
4.1.3. Parkinson’s disease 
Parkinson’s disease is the second most common disorder affecting all ethnic groups 
and both genders which is characterized by loss of pigmented neurons in substantia 
nigra of the midbrain [258]. The characteristic features of progressive neurological 
disorder were first described by James Parkinson in 1817. The epidemiological 
studies have indicated there are a number of factors which might increase the risk of 
developing Parkinson’s disease which might be environmental factors, industrial 
chemicals, pesticides, herbicides, toxins [259]. Parkinson’s disease occurs in both 
familial and sporadic forms; however sporadic form of PD is more common. 
Parkinson’s disease is often described either as a movement disorder or as an 
idiopathic disorder, thus it is known to cause issues with movement, autonomic 
dysfunction and neuropsychiatric problems. Under normal circumstances, the 
proteins that are not folded properly are directed to the waste disposal mechanisms 
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such as ubiquitin-proteosomal degradation.  However in cases where such proteins 
are not degraded tend to form thread like structures which further lead to formation 
large proteinaceous masses that might disrupt the normal functioning of the 
surrounding tissues [260-263].  
Although extensive research has been carried out for years now, the definitive 
markers are still not very well described and thus the hallmark of the disease is 
marked by formation of inclusion eosinophilic lewy bodies in PD patients. However 
it is important to note that lewy bodies are not specific to PD but also found in AD as 
well as dementia with lewy body disease. Parkinson’s disease is characterized by 
presence of abnormal intracytoplasmic aggregates of lewy bodies and lewy neurites 
in axons and neurons respectively. These inclusion bodies are present in specific 
regions of the brain and vary in shape, frequency and size [264]. The reported 
components of lewy bodies include synphilin-1, ubiquitin and various ubiquitin 
related enzymes [265, 266]. However the major component of LBs is an aggregated 
form of presynaptic protein i.e. α-synuclein and is relatively well characterized 
marker available for PD related patients. The classical brainstem lewy bodies are 
spherical, a dense core surrounded by a halo of 10 nm wide radiating fibrils. 
Moreover, abnormal accumulation of α-synuclein is not only observed in PD but also 
in dementia with lewy bodies, multiple system dystrophy and lewy body variant of 
AD [267, 268]. For this reason, such diseases are described as α-synucleinopathies 
[269, 270]. It has been shown that 3-4% neurons in the substantia nigra show 
presence of lewy bodies in PD patients, irrespective of disease severity [271].  
4.1.4. Genes involved in PD 
Some of the identified genes that underlie familial form of PD include two autosomal 
dominant genes: leucine rich repeat kinase, α-synuclein and three autosomal 
recessive genes: parkin, DJ1 (PARK 7) and PTEN induced putative kinase-1(PINK1) 
[272]. Also, there have been ubiquitin related and other genes reported in a few cases 
of PD but the importance of such genes is still not very well understood. With an 
ultimate aim of understanding the whole mechanism responsible for cause of 
Parkinson’s disease, it is important to link environmental factors and disease 
associated genes which could result in the modification of associated molecular 
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pathways. Although the role of above mentioned genes has been identified in PD 
traits but it is still unknown whether genes apart from α-synuclein have any role in 
formation of lewy bodies. Parkin mutations have been found mainly in PD patients 
below the age of 30 and such mutations have led to the dysfunctioning and loss of 
dopaminergic neurons [273]. Parkin is a 465 amino acid protein and is known to be 
an E3 ubiquitin ligase which is well known for proteosomal degradation.  In fact it 
has been shown that mutation in Parkin gene affects its ability to perform 
ubiquitination and also its ability to degrade the protein in proteasome [273]. DJ1 
mutations have been associated with autosomal recessive PD [274] and it has been 
implicated in oxidative stress.           





Figure 4.1: Mechanism of neurodegeneration: Misfolding of the protein could 
be a result of either genetic mutation in either α-synuclein, DJ1, Parkin and 
UCHL-1 or due to toxins. Normally misfolded protein is degraded by 
mechanisms such as Ubiquitin proteosomal pathway. In PD patients, this 
misfolded protein leads to the formation of lewy bodies which avoids cell death 
due to mitochondrial dysfunction and ultimately the ability to produce dopamine 
is lost resulting in neurodegeneration [7].  
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As explained by Dauer and Przedborski in 2003, accumulation of misfolded protein 
is the key event in PD neurodegeneration. Mutations can either lead to change in the 
confirmation of protein causing it to misfold or damage the ability of cellular 
machinery to destroy misfolded and degraded protein. In fact mutations in different 
parkin genes have been reported on various occasions but it is still not known 
whether these mutations are the ultimate cause of lewy body formation [275, 276]. 
4.1.5. Synuclein family 
Synucleins are 15-20 kDa proteins which make up synuclein family consisting of 
three different types: α - synuclein, β - synuclein and γ - synuclein. All three types 
are well known to be expressed in the brain [267, 277] and share 55-60 % similarity 
among themselves. Α-synuclein was first identified as a precursor protein for non-
amyloid beta component of Alzheimer’s disease [278].  Synucleins are characterized 
by a N-terminal amphipathic domain consisting of a consensus motif of KTKEGV 
which facilitates their lipid binding properties [279]. The highly conserved N 
terminal domain is a common feature among all synuclein members and is known to 
be characterized by two helical domains separated by KTKEGV [280]. Out of all the 
three members of synuclein family, only α-synuclein is known to be present in lewy 
bodies which means both β and γ-synuclein have not been found in formation of 
inclusion bodies [281, 282]. The most common missense mutation reported until 
recently has been A53T which was first reported in an Italian American family, 
another one being A30P first identified in a German family in α-synuclein gene and a 
third mutation at residue 46 has been reported recently (G46L) in Spanish kindred 
[283]. After years of vast genetic research on α-synuclein gene (SNCA), another 
breakthrough was made in analysing SNCA in PD patients where triplication of the 
gene was identified in a family called the Iowa kindred [284]. As it can be seen in the 
figure 4.2, α-synuclein is the longest gene among synuclein family (14 kDa in 
length) and it has been shown that all three types of synuclein are expressed in brain 
[277]. 
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Following the sequence analysis of different types of synucleins, distribution of all 
three types has been well studied and characterized. As seen in figure 4.3, the relative 
expression of synucleins in several tissues as well as their distribution throughout 
brain parts has been shown by northern blot analysis [1-3]. No or little expression of 
β synuclein in brain tissues might be an indicative of relative amino acid sequence 
variation among the synuclein family [285].  
 
Figure 4.2: Sequence analysis of synuclein family: The sequence 
comparison of α, β and γ synuclein. α-synuclein is 140 amino acids in length 
and is the largest among the synuclein family, whereas β and γ synuclein are 
143 and 127 in length respectively. The difference in the amino acid sequence 
is marked by white colour and the sites for mutation have been indicated i.e. 
A30P and A53T.   
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Α-synuclein is a 140 amino acid protein accounting for 1% of the total amount of 
cytoplasmic protein. It is comprised of a amphipathic N-terminal domain, a 
hydrophobic non-amyloid component (NAC) domain and an acidic C terminal 
domain [286]. The protein is thought to lack a proper secondary structure and exist as 
an unfolded coil in aqueous solution. It has been shown that α-synuclein is expressed 
in two different forms i.e. free and membrane bound (plasma membrane or vesicle 
bound) [287]. It is mainly expressed in neurons of neocortex, hippocampus, 
substantia nigra, cerebellum and is also expressed to a certain degree in red blood 
cells, kidney, liver, etc [288]. On the basis of membrane association, it is known to 
Figure 4.3: Expression of synucleins among different tissues: The relative 
expression of all three types of synuclein genes in pancreatic, kidney, skeletal 
muscle, liver, lung, placenta, brain and heart tissues (top panel). Expression of 
synucleins in thalamus, subthalamic nucleus, substantia nigra, hippocampus, 
corpus collasum, caudate nucleus and amydgala parts of brain. This expression 
pattern is based northern blot analysis [1-3]. 
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have a role in synaptic neurotransmission and dopamine release [289]. The precise 
function of α-synuclein is still unknown but it is known to interact with other 
proteins for regulation of neurotransmission and also known to act as a chaperone 
involved in the process of folding of synaptic proteins [290, 291]. It has been shown 
previously that α-synuclein binds to a 90 kDa cytoplasmic protein synphilin-1 which 
might play an anchoring role for transporting α-synuclein to interact with 





4.1.7. α-synuclein in Parkinson’s disease 
α-synuclein pathology in the brain stem in PD patients is thought to be responsible 
for motor symptoms limbic and neocortical areas of brain [293]. Detection of α-
synuclein in enteric nervous system as a biomarker of PD in gastrointestinal (GI) 
tract has been suggested. Interestingly, detection of α-synuclein aggregates in colon 
biopsies have been seen much before PD diagnosis using other symptoms [294]. For 
the removal of misfolded and abnormal proteins, ubiquitination and autophagy 
lysosome are the most common pathways. In the ubiquitin-proteasome misfolded 
proteins are polyubiquitinated and guided through a series of enzymes to proteasome 
for degradation. Lysosomes maintain the activity of various enzymes, both of these 
pathways are known to be affected in PD as the immunoreactivity of both 
proteosomal and lysosomal degradation markers were found to be reduced compared 
N-terminal Cterminal






Figure 4.4: Detailed structure of α-synuclein: α-synuclein contains N-terminus 
which is the amphipathic domain (sites for mutations), non-amyloid β component 
(NAC) domain and acidic tail towards the C-terminus. 
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to age matched controls [295]. α-synuclein oligomers have been reported in PD 
patients possessing SNCA triplication [296], A30P [297]  as well as in recently 
identified E57K [298] mutations.  It has been established that recombinant α-
synuclein under defined conditions can lead the formation of insoluble aggregates 
and possess similar morphological behaviour to the disease affected forms of α-
synuclein [299-301]. 




4.1.8. Controversial state of native α-synuclein  
Several spectroscopic and structural studies such as NMR have been carried to 
determine the structural status of native α-synuclein. It has been shown that this 
unfolded protein is structurally disordered under physiological conditions [302, 303]. 
To support this fact, work carried out by Davidson et al proved that α-synuclein is 
highly disordered in solution; however striking conformational change was seen 
from disordered structure to α helical upon lipid binding. A number of proteins have 
been identified in lewy bodies and lewy neurites using light microscopy such as 
ubiquitin and neurofilaments [304-307]. On contrary to α-helical state, another study 
has shown that conformational state of α-synuclein changes from random coiled to β-
pleated sheet [308, 309]. The structural changes occurring in α-synuclein leading to 
PD is shown in figure 4.5. 
Figure 4.5: Structural changes in α-synuclein in PD: Misfolding of α-
synuclein which is natively unfolded in nature causes it to be partially folded 
initially. This intermediate form further leads to the formation of oligomers which 
comprise of both soluble and insoluble. Some oligomers lead form large 
clusters i.e. protofibrils and lastly these protofibrils form insoluble fibrillar 
structures.  
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The role of α-synuclein in cell membrane dynamics suggests that when α-synuclein 
binds to the lipid membranes, it changes its conformation from disordered structure 
to α-helical secondary structure [280, 310]. This highlights the importance and role 
of lipid binding to α-synuclein in synaptic terminals which might be useful to study 
the dynamics of the protein in more details. It has been shown that the conformation 
of α-synuclein can be affected by various factors such as low pH, storage conditions 
and high temperature which can cause α-synuclein to be aggregated and fibrillated 
[311]. Several models have been created to show α-synuclein under certain defined 
conditions can lead to change in the structure of the protein  [312] but fundamental 
question still remains as to what forces drive this mechanism of structural change. 
With extensive research on the morphology of α-synuclein, it has been well 
demonstrated that conformational change in the modulation of α-synuclein could be 
due to a variety of factors such as pH and temperature conditions in vitro, α-
synuclein interacting with other proteins in brain models, etc. On previous occasions, 
there have been models that show protein aggregation in-vitro under certain 
conditions suggesting that the protein is amyloidogenic [313-315]. Few properties 
assigned to α-synuclein in native state are: (i) unfolded, disordered structure 
(demonstrated by CD), (ii) stable to heat denaturation, and (iii) aberrant SDS binding 
ability leading to unusual mobility onto SDS PAGE [302].  It still remains to be 
determined whether the unfolded disordered orientation of protein contributes 
directly or indirectly in the formation of lewy bodies.  
4.1.9. AIM 
Our experimental aim was to determine the precise native state and secondary 
structure of α-synuclein in different conditions by native gels and Circular dichroism 
respectively. Also, due to its aberrant nature we planned to develop monoclonal 
antibodies to look at the expression pattern of α-synuclein in neuroblastoma cells as 
well as in parts of brain and kidney. The final aim of this project was to measure co-
localization of α-synuclein using co-transfection of α-synuclein constructs and PLA 
in α-synuclein expressing cells.     
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4.2. RESULTS 
4.2.1. Expression and purification of WT α-synuclein  
To begin with, α-synuclein was cloned in pT7-7 vector (by Vikram Narayan, Ball 
lab) and results were confirmed by restriction digestion and sequencing. 
Subsequently, the expression of recombinant α-synuclein was carried out in one litre 
culture volume. The filtered lysate was passed through the His trap column and each 
of the fractions following IMAC purification was collected, snap frozen in liquid 
nitrogen and stored at -80
0
C. Each of the fractions obtained after elusion was stored 
and alternative fractions were run onto a SDS gel and Coomassie stained. As it can 
be seen in the figure 4.6 below, highly purified fractions could be seen from fraction 
17 to fraction 38 with no contaminating bands and thus was pure enough to carry out 
further experiments for studying protein in detail and also to immunize mice for 
antibody development.  
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As seen above that the purified recombinant α-synuclein was found to run at a size of 
14 kDa on a 12% SDS gel. Due to its controversial and still unknown precise native 
form, we decided to run the purified protein on 8% native gel which involved 
different buffer recipes including sample preparation (described in section 2.11). The 
prepared samples contained no SDS, were not boiled and also no DTT was added to 
the sample buffer as described in section 2.11.  These conditions made sure that the 
protein was run in its absolute native state. The gel was pre-run at 4
0
C for 1 hour at 
50V; the samples along with BSA as a control were loaded onto the gel and ran at 
50V, followed by 100V for 3-4 hours. The gel was then either stained using instant 
blue (Expedeon) or Coomassie stained for 1 hour followed by destaining. 
To determine firstly the optimal running temperature of native gels we first ran 
native gels at 4
0
C and RT. As seen in the figure 4.7 (top left panel), native gel needs 
to be run at 4
0
C for bands to be clearly visible. Also we notice here that the protein 
runs at a size of 140 kDa clearly higher than its monomeric form. For this reason we 
thought of looking at the effect of different temperature conditions and thus we 
incubated purified protein overnight at different temperature conditions. The protein 
was incubated at 4
0
C, RT and 37
0
C for 24 hours and the samples were then run at 
4
0
C on a native gel. The gel image shows the protein still ran at 140 kDa so it is not 
temperature dependent (4.7 top right panel). Subsequently, we incubated protein 
overnight with different concentrations of SDS (0.05%, 0.1%, 0.5% and 1%) at 4
0
C. 
The results show that the protein collapses down to different oligomeric forms of 
protein after addition of SDS (4.7 lower right panel). This mechanism indeed 
correlates with known interactions of α-synuclein with lipids [316]. 
Figure 4.6: Purification of recombinant α-synuclein: 10 µl of each alternative 
purified fractions following IMAC purification of recombinant α-synuclein after 
expression in pT7-7 vector were ran on a 12% SDS gel. The top section of the 
figure show the purified fractions from 1-34 and the bottom half shows the 
fractions from 36- 60. The bottom right panel shows load before purification, 
wash and flowthrough. Purified recombinant α-synuclein runs around 15 kDa on 
a SDS gel. 
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Figure 4.7: α-synuclein on a native gel: The left panel of the figure shows 
running of different fractions of purified WT α-synuclein on a native gel at 
different temperatures i.e. RT (upper left panel) and 40C (lower left panel). 
As seen the protein does not run properly when ran at RT, whereas when 
the gel was run at 40C purified WT α-synuclein runs at ~140 kDa which 
suggests it might be an oligomer.  The BSA was used as a control in all the 
experiments which runs at 66kDa. The top right panel shows α-synuclein 
where it was incubated overnight at different temperatures and the gel was 
ran at 40C where no disruption of oligomer was seen. The lower right panel 
shows collapsing of the purified WT α-synuclein oligomer after an overnight 
incubation with (0.05%, 0.1%, 1% SDS).   
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Due to such intriguing results obtained with SDS, we thought of looking at the effect 
of different detergents such as Triton-X100, Tween 20 on the purified WT protein. 
Figure 4.7 lower right panel shows the effect of SDS when incubated with the 
purified WT α-synuclein overnight causes the collapse to a size of monomer. 
However when incubated for specific number of hours (0.5 - 6 hours) SDS did not 
fully collapse it down to a monomer (figure 4.8a). Similarly the right panel of figure 
4.8a shows the extent to which α-synuclein collapses down from its oligomeric state 
after addition of different concentrations of SDS. Moreover, while analysing the 
effect of different detergents such Triton, Tween-20 and DMSO no change in the 
oligomeric state of this protein was seen (figure 4.8b). In the bottom right panel 
(figure 4.8b), we ran different amounts of purified α-synuclein with and without SDS 
as well as boiled sample with no SDS. One of the prepared samples was boiled in 
order to see the effect of high temperature on this protein. The overall results from 
native gels indicate that temperature does not affect α-synuclein in any case whereas 
SDS plays a role in degrading the oligomeric state of α-synuclein to a monomeric   
14 kDa size protein. Moreover to rule out the possibility that freezing and thawing of 
recombinant α-synuclein could cause α-synuclein to aggregate on a native gel, we 
ran fractions after IMAC purification before and after freezing. Here we notice that 
freeze thaw does not affect the oligomeric state of the protein at all due to which the 
state of protein remains oligomeric. 
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Figure 4.8: Recombinant purified α-synuclein in different conditions 
on native gel: (A) Left panel shows the time scale for which purified α-
synuclein incubated with 0.1% SDS (0.5, 1, 2, 4 and 6 hours) along with 
BSA as a control. The right panel shows purified α-synuclein after 
incubation with different concentrations of SDS (0.1%, 0.05%, 0.025%, 
0.012%, 0.006%, 0.003% and 0.001%). (B) Effect of different amounts of 
SDS (left panel); Tween and Triton-X100 (right panel) with an incubation 
period of 30 minutes on recombinant α-synuclein with BSA as a control 
(C) Effect of different amounts of DMSO onto α-synuclein(left panel). 
The right panel shows 5, 10µl of purified protein, protein with 0.1%, 
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4.2.2. Biophysical studies of α-synuclein 
After determining the native state of α-synuclein using native gels, we performed 
some biophysical studies with purified α-synuclein. Biophysical studies with α-
synuclein have indicated dynamic flexibility with respect to its dynamic structure 
[317]. Gel filtration studies from our group earlier have indicated that α-synuclein 
acts as an oligomer (tetramer). In order to look at the native state of the protein in 
more detail, we used a differential absorption technique called as Circular dichroism 
(CD) onto this controversial protein. We also measured CD onto a critical micelle 
concentration of SDS onto α-synuclein in solution.  
Circular dichroism works on the basis of factors such as purity level of the protein 
should be quite high, presence of Tris-HCL as chloride ions in the buffer can give 
false signals. As seen in the above figure 4.6, although the purity of purified protein 
was quite high with no contaminating bands, the storage buffer for protein used was 
Tris that contains high amount of salts. As this condition is not suitable for carrying 
out CD, we performed a buffer exchange of the purified α-synuclein into phosphate 
buffer with no chloride ions. To start with, we performed buffer exchange into 
phosphate buffer at different pH to see which desalting/ buffer exchange is best 
suited for the protein. Using fraction 28 of the purified protein (figure 3.8), we 
performed buffer exchange using Zeba desalting columns (Thermo scientific) into 4 
different pH (6.2, 6.8, 7.2 and 7.8) of phosphate buffer. The buffer recipe and 
different amount of ingredients needed for maintaining pH have been shown and 
described below: 
Components of phosphate buffer for buffer exchange 
            Phosphate buffer: 1 M  K2HPO4, 1 M  KH2PO4 
 pH 1 M K2HPO4 vol. 1 M KH2PO4 vol. 
6.2 19.2 80.8 
6.8 49.7 50.3 
7.2 71.7 28.3 
7.8 90.8 9.2 
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100 ml of each pH solution was prepared and 1 ml of fraction was divided into 25 ml 
each halves to perform buffer exchange at four different pH. Desalting protocol was 
followed according to the manufacturer’s protocol (Thermo scientific). 50 µl of 
phosphate buffer was added as stacking buffer at the final elusion step from the 
beads. After final elusion for each pH, 10 µl of the protein following buffer exchange 
with BSA as a control to measure protein concentration was run onto a 12% SDS gel 
(figure 4.9A). Subsequently, two of the buffer exchanged samples (pH 6.8 and pH 
7.8) were run in three different amounts (5, 2 and 1 µl) along with titrations of BSA 
(4, 2 and 1 µg) onto a SDS gel in order to compare the amount of protein lost after 
buffer exchange (figure 4.9B).  




Figure 4.9: Purified recombinant α-synuclein after buffer exchange:       
(A) 10 µl of each sample obtained after buffer exchange into different pH 
phosphate buffer solutions (6.2, 6.8, 7.2 and 7.8) along with same amount of 
non-desalted purified protein. (B) 5, 2 and 1 µl of buffer exchanged pH 6.8 and 
pH 7.8 samples with 5 µl of non-desalted purified α-synuclein onto 12% SDS 
gel. 4, 2 and 1 µg of BSA run alongside as a control. Α-synuclein runs at 14 
kDa on a SDS gel.  
(A) 
(B) 
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Further we decided to run these samples on a native gel to see the effect of different 
pH of phosphate buffer on the state of purified recombinant buffer exchanged α-
synuclein. We notice here that this protein in phosphate buffer runs at the same size 
(~ 140 kDa) as it does when it was in Tris buffer even at different pH. Figure 4.10 
shows 5 μl, 2 μl and 1 μl of buffer exchanged α-synuclein at pH 6.8 and pH 7.8 runs 
at ~140 kDa with BSA as a control onto a native gel. Buffer exchange using Zeba 
desalting columns offers rapid desalting and maximum protein recovery.  




Determination of concentration of buffer exchanged α-synuclein 
The precise concentration of the protein was determined by reading absorbance at 
280 nm and using the molar extension coefficient of the protein. Phosphate buffer 
was used as a blank; the absorbance was read at 280 nm and was found to be 0.0006. 
Subsequently, absorbance of α-synuclein at 280 nm was found to be 0.6052. These 
values along with the molar extension coefficient were used to calculate the 
concentration of the protein on the basis of Beer-lambert law.   
Figure 4.10: Buffer exchange of recombinant α-synuclein:  Buffer 
exchange of α-synuclein into 10 mM phosphate buffer, pH 6.8 and 7.8. 5, 2 
and 1 µl of buffer exchanges sample along with 1 and 2 µg of BSA was run 
onto a 12% native gel.   
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Absorbance = ε c l 
ε = Epsilon, c= concentration of the protein in aqueous solution (mol dm
-3
), and 
l = length of solution the light passes through (cm) 
                        
                                             
 
4.2.3. Circular Dichroism 
After determining the concentration of the protein, samples were then prepared for 
Circular Dichroism (CD). Three parameters were taken into consideration while 
using JASCO CD spectropolarimeter which are: path length, band width and data 
pitch. We performed CD onto three different samples: (i) recombinant purified α-
synuclein in phosphate buffer (no SDS), (ii) α-synuclein incubated overnight with 
SDS (0.1%) and (iii) α-synuclein incubated with SDS for 10 minutes (0.1%). The 
samples were subjected to dilutions based on the CD spectral behaviour which is 
explained below:   
The selected wavelength range for CD was chosen from 185 to 285 nm, path length 
of 1 nm, data pitch of 0.1 nm and band width changed depending upon quick or a 
slow scan. The instrument settings were adjusted by following the instructions from 
the manual (Jasco) and the instrument was turned on 30 minutes before use. CD 
cuvette was cleaned with ethanol before use; air dried and holds a capacity of not 
more than 400 µl of sample. Phosphate buffer (400 µl) was added to the clean 
cuvette and CD was measured using a quick scan with a band width of 100 nm/ 
minute. Following this, another three scans were performed on the same sample with 
a band width of 20 nm/minute. On running the phosphate buffer on its own on a CD 
spectrum machine, it was no change noted in the far UV CD spectrum in the whole 
range from 185-285 nm. This indicated that there was no chiral structure induced by 
phosphate buffer which in turn could lead to the formation of structures. This 
followed by CD spectral analysis of recombinant α-synuclein in phosphate buffer. 
               0.6 = 5960 x c x 1 
                         
Concentration of α-synuclein =     1.006 mg/ml 
 
Chapter 4: Developing monoclonal antibodies and assays to biophysically characterized α-
synuclein                                                                                                                                161 
 
This protein (1.006 mg/ml) when passed through the CD gave a high signal to noise 
ratio and thus the protein was passed through CD analysis with several lower 
concentrations. The final diluted concentration of the protein was 0.027 mg/ml and 
three different scans were performed in the same wavelength range from              
185-285 nm. As reported in literature, the UV spectrum shows a typical unfolded 
disordered structure at neutral pH at 25
0
C. The spectrum has an intense minimum in 
the vicinity of 195 nm, with absence of any characteristic bands in the wavelength 
range of     220 to 260 nm (figure 4.11). This demonstrates the negative spectrum 
which in turn indicates the right circularly polarized component of plane polarized 
light absorbing more than the left component showing a negative CD spectrum. The 
data was interpreted using several algorithm based programs on spectrum software 
Dichroweb after calculating the mean residue weight using the formula shown 
below: 
               
 
 
                         
 
Figure 4.11: Circular Dichroism spectra of recombinant α-synuclein: 
Sample was prepared in 10 mM phosphate buffer with a pH of 6.8 at a final 
concentration of 0.02 mg/ml. The molar ellipticity was measured at 250C in a 
0.1 cm path length in a wavelength range from 185-285 nm.    
Mean reside weight (Daltons) = Molecular weight of the protein  
                                                   (Number of amino acid residues – 1) 
                                      MRW = 104.02 
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Subsequently, for performing CD onto SDS α-synuclein the cuvette was cleaned 
with SDS made in phosphate buffer and air-dried after cleaning with ethanol. The 
cuvette was then filled with phosphate buffer containing SDS (0.000125%) and 
passed through the CD spectrum to see if SDS was sticking to the cuvette and giving 
any false signals which could lead to formation of chiral structures. A quick scan 
followed by three timely scans was performed for the spectral analysis in a 
wavelength range from 185-285 nm. The curve from the SDS phosphate buffer 
indicates that the circular polarized radiation gives a similar spectrum as obtained 
using phosphate buffer with no SDS. This spectral analysis made sure that SDS by 
itself neither had any effect on phosphate buffer nor induced any chiral structure. 
Following this, CD spectrum analysis of the second sample i.e. α-synuclein 
incubated overnight with SDS was carried after dilution to a final concentration of 
0.06 mg/ml with a final SDS concentration of 0.00006%. A quick scan was 
performed at 100 nm/ min in vicinity absorption wavelength range of 185-285 nm, 
followed by three timely scans at a band width of 20 nm/min. As it can be seen in 
figure 4.12B, interestingly the protein in presence of SDS gives an unexpected 
spectrum with a negative peak at 205 nm and a strong positive peak at 190 nm. This 
suggests a transition of conformation of the protein from unfolded disordered 
structure to some folded form due to addition of SDS. This structural transition might 
provide an insight into association of α-synuclein with lipids in the synaptic area for 
future research. Due to such compelling results, we performed CD on α-synuclein – 
SDS (0.00006%) in phosphate buffer with an incubation period of 10 minutes. Here 
we notice that both negative and positive peaks are similar but stronger as compared 
to the samples with overnight SDS (figure 4.12b). From this data we can conclude 
that SDS has potential ability to change conformation to a significant amount of 
ordered secondary structure of the protein.  
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On the basis of data obtained from CD spectral experiment, we thought of 
determining the type of secondary structure that the protein attains after addition of 
SDS. In order to do this, we used DICHROWEB which provides a user friendly 
interface and platform for a range of popular secondary structures with use of several 
algorithms and reference database. Out of all the 5 available algorithm programs, we 
used CDSSTR and CONTIN which are known to produce most reliable data in 
comparison to other available database [318].  The files from the CD spectral 
software are uploaded onto the DICHROWEB website, input units selected as 
millidegrees and the wavelength range from 185-285 nm. The analysis program as 
mentioned was selected as CDSSTR with a reference set optimized for 190-240 nm 
and an output unit of mean residue ellipticity. For additional information, MRW 
(104), protein concentration (0.06 mg/ml) and path length (0.1 cm) was mentioned as 
well. Following submission of the data onto the software, it was found that 78% of 
the total structure was α-helical which was divided into two types based on the 
modified helical structures. From secondary structure analysis, helix structures per 
100 residues were 5.426 with an average helix length per segment of 14.280. Infact 
CD studies have indicated earlier that α-synuclein natively occurs as a tetramer under 
Figure 4.12: Circular Dichroism of recombinant α-synuclein incubated 
with SDS: Samples were prepared in 10 mM phosphate buffer, pH 6.8 at a 
final concentration of 0.06mg/ml and SDS (0.00006%) was added overnight 
(a) and freshly added SDS (b) SDS incubated overnight. The ellipticity of the 
samples was measured at 250C in a 0.1 cm path length in a wavelength 
range of 185-285 nm. 
 
(a) (b) 
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non denaturing conditions [319]. Thus on the basis of CD spectral analysis we show 
that α-synuclein from a natively unfolded disordered structure attains a highly α-
helical secondary structural conformation with an addition of SDS. This data 
prompted us to develop different tools and assays that in turn could be useful to 
target as well as study this protein in more detail. 
 
4.2.4. Development of antibodies binding to WT α-synuclein 
With such intriguing data obtained from the native gels and biophysical studies of 
WT α-synuclein, targeting this aberrant protein by various biological tools could be 
indeed useful from PD treatment point of view. Thus developing tools that can target 
this protein in different states could turn out to be more than useful from various 
aspects such as understanding the behaviour of α-synuclein in its native state as well 
as its controversial monomeric or oligomeric expression in cells. To begin with, we 
developed monoclonal antibodies using standard hybridoma technology against this 
target (described in section 1.3). Two immunization cycles were carried out in Balb/c 
mice with α-synuclein to isolate antibody producing cycles (in Morbvian Biotech, 
Brno, Czech Republic).  Following hybridoma technology, the monoclonals after 
growing were tested for activity onto recombinant protein. All the positive clones 
were grown and were tested for IgG via Dot blot using IgG specific secondary 
antibody.  The supernatants from the clones that were found to bind WT protein in 
ELISA were tested for the IgG isotype via dot blot (figure 4.13). From the first batch 
of immunization, clone 2E12 was found to be positive for IgG (1.1) and similarly in 
case of 2
nd
 batch; 2E4 was found to be positive for IgG (3.1). These antibodies have 
been referred to as 1.1 and 3.1 from here on for further experiments.   
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4.2.5. Binding efficacy of monoclonal antibodies to α-synuclein 
Following dot blot analysis, we tested all the monoclonal antibodies (18 mAbs 
including IgM and IgG) onto WT α-synuclein as well as a set of overlapping peptides 
designed from the WT protein. The ELISA plates were coated with 200 ng of protein 
overnight and antibody serum from positive clones was added in 5 different titrations 
(neat, 1:2, 1:5, 1:10 and 1:50) to the coated ELISA plates. As shown below, 4 out of 
18 mAbs showed binding to the WT protein (figure 4.14a). Out of these positive 
ones,  2 of the antibodies were found to be IgM and other two were identified as IgG. 
After analysing the binding potential of these antibodies on the WT protein, we 
performed another ELISA where we titered α-synuclein against fixed amount (1:20) 
of these 4 positive antibody supernatants in duplicates (figure 4.14b). This was done 
in order to determine the precise amount of WT protein needed for different 
Figure 4.13: Dot blot of individual clones to test for IgG isotype.  2 batches 
of immunizations carried out, from the 1st batch of α-synuclein binding clones, 
clone 2E12 was found to be a positive clone for α-synuclein as well as IgG 
isotype. In the 2nd batch clone 2E4 was found to bind recombinant α-synuclein 
as well as positive for IgG isotype. 
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antibodies to bind, commercial anti-α-synuclein antibody (BD Biosciences) was used 








Figure 4.14: ELISA onto WT α-synuclein (a) Activity of 18 monoclonal 
antibodies (including all IgGs and IgMs) obtained after mice immunizations with 
WT α-synuclein onto purified WT α-synuclein. 4 out of 18 bound to α-synuclein 
(mon.1.1, 2E4, 1H1 and 5B4). The titrations were performed for the monoclonals 
onto 500ng of the WT protein coated onto each well of the ELISA plate. (B) 
ELISA showing binding of the positive monoclonal antibodies onto titered WT α-
synuclein. The protein was diluted from 500 ng to 25 ng and as it can be seen in 
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Following this, in collaboration with Borek Vojtesek’s lab we purified the antibodies 
that showed significant binding activity, stored in sodium azide and also HRP 
conjugated the antibodies. Further on, we performed an ELISA onto α-synuclein to 
see if the HRP conjugated antibodies still retained the activity.  A titration of the 
purified monoclonal antibodies was performed onto 200 ng of the WT protein coated 
onto each well of the ELISA plate. Monoclonal antibody 2.1 was added as a negative 
control onto the ELISA, whereas mAb 1.1 (IgG) and 3.1 (IgG) bound to protein 
along with IgM (4.1). The results indicate that all positive clones even after HRP 





4.2.6. Epitope mapping of the anti-α-synuclein antibodies 
After determining the activity of all the monoclonal antibodies onto WT α-synuclein, 
we performed epitope mapping in duplicates on the set of overlapping peptides 
derived from WT α-synuclein to determine the precise epitope of each antibody.  
Epitope mapping was performed for all 4 mAbs that bound to the wild type α-
Figure 4.15: Activity of HRP conjugated antibodies onto purified WT α-
synuclein: ELISA demonstrating activity of 4 different monoclonal antibodies (1 
mg/ml) after conjugation to HRP onto recombinant α-synuclein in several 
titrations (1:1000, 1:2000, 1:4000, 1:8000, 1:16000 and 1:32000).  
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synuclein. The 140 amino acid sequence was divided into 9 short overlapping 
peptides to determine specific residues that could be critical in antibody binding. The 
sequence of the designed overlapping peptides is mentioned below: 
          
The epitope mapping for all antibody clones was performed onto the set of peptides 
and all IgGs binding efficeincy to the peptides has been shown below (figure 4.16). 
The results indicate that out of 18 monoclonal antibodies only 2 bound to peptide. 
Out of the above 4 positive clones (shown in above ELISA results figure 4.14), only 
two show binding to the peptide i.e. 2E4 (3.1) which has been identified as an IgG 
and the other one being 6C8 which is identified as IgM. It is also important to 
mention  that mAb 1.1 obtained from first batch of immunization binds to same 
epitope as IgM. Although IgM provides an advantage of targeting different epitopes 
exposed because of its multimeric nature, but it is not possible to recombinantly 
express which hampers its potential abilty to be a therapeutic tool. Interestingly, one 
of the commercial antibody (BD Biosciences) was also subjected to epitope analysis 
and has been found to bind to the same epitope as the 2E4 Ab (IgG). Also, another 
interesting fact to be noticed was that IgM (6C8) binds to a different epitope in 
comparison to 2E4 mAb and does not bind to endogenous α-synuclein in cells.  
This differential binding of these mAbs might be due to the fact that epitope is either 
being masked in someway or presented differently to the antibody. The epitope of 
positive clones lie in region between residues 100 – 125 of the WT α-synuclein and 
                 
              Peptides sequences 
 
5  SGSGEQVTNVGGAVVTGVTAVAQK 
 












4  SGSGEGVVHGVATVAEKTKECVTN 
 
9 SGSGDNEAYEMPSEEGYQDYEPEA 
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The common residues present in both peptide sequences are ‘GAPQE’ which could 
be critical for both antibody binding to α-synuclein. These residues form the end of 
non-amyloid component (NAC) domain which is known to be important in protein 
aggregation along with acidic tail of α-synuclein.  
 
1. MDVFMGLSKAKEGVVAAAE            2. VAAAEKTKQGVAEAAGKTKE 
3. GTKEGVLYVGSKTKEGVVH              4. EGVVHGVATVAEKTKECVTN 
5. EQVTNVGGAVVTGVTAVAQK          6. AVAQKTVEGASIAAAATGFV 










































1 2 3 4 5 6 7 8 9
5B4
Epitope mapping of positive clones (9 peptides)
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4.2.7. Cell model to study α-synuclein oligomeric state 
After determining the binding efficiency of the above mentioned monoclonal 
antibodies using ELISAs, we thought of looking at their efficacy for binding onto 
purified recombinant protein using western blot. A titration of recombinant WT α-
synuclein was carried out and detected using IgGs at a dilution of 1:20 that were 
found to bind WT protein using ELISA (figure 4.17A). Also, alongside we decided 
to look at the expression of α-synuclein in dox repressible SHSY5Y cells 
(neuroblastoma cell line) to look at the precise size of α-synuclein within cells. As it 
can be seen in figure 4.17A, all three IgG antibodies could detect purified 
recombinant α-synuclein (14 kDa). Out of three antibodies, it is important to mention 
here that 5B4 did not bind to any of the derived α-synuclein peptides; however it 
binds to the protein using ELISA as well as immunoblotting.  
The other part of the figure shows the detection of α-synuclein in SHSY5Y cells, 
where addition of doxycycline (dox) relatively supresses α-synuclein within these 
cells (figure 4.17B). Another interesting aspect of this figure is the band formation 
around 57 kDa which indicates formation of aggregates within the cells, whether it 
forms lewy bodies within these cells or not is still controversial. Also doxorubicin 
did not affect the oligomeric state of α-synuclein, however monomeric state was seen 
to be reduced. Infact it is these types of oligomers that are the more toxic form 
causing neurological disorder rather than aggregates (lewy bodies) [320].       
Figure 4.16: Epitope mapping of all the positive clones that bound to 
WT α-synuclein Top half of the figure shows the epitope mapping of all the 
monoclonal antibodies that bound to recombinant α-synuclein. Epitope 
mapping was performed onto a panel of overlapping peptides designed from 
the protein sequence onto WT protein. The region that the epitope for all 
antibodies lie is outlined i.e. peptide 7, 8 and 9.  
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4.2.8. Different Lysis methods, Fixing of immunoblot 
Further on, we used another neuroblastoma derived SHSY5Y cell line that expresses 
lower amount of α-synuclein. Following harvesting of cells from 10 cm petri dishes, 
we performed lysis in different lysis buffers (RIPA, Urea, Hypotonic and triton) to 
find out the most efficient way of extracting α-synuclein from SHSY5Y cells. 
Subsequently, Bradford assay was used to measure the total protein concentration 
and 50 µg of total protein was run onto a 12% SDS gel. All four differently lysed 
samples were loaded in duplicates onto a SDS gel and following the transfer of bands 
onto nitrocellulose membrane, membrane was divided into two halves.  
Generally while visualizing immunoblot the monomeric band of α-synuclein is 
usually lost or retained in very low amount due to washes. For this reason we looked 
at the effect of paraformaldehyde (PFA) on SHSY5Y cells to see if monomeric band 
could be retained after fixing the blot. First half of the membrane was fixed with 
0.4% paraformaldehyde to see if the monomeric form could be retained via a fixing 
Figure 4.17: Binding efficiency of IgGs onto α-synuclein: (a) Binding of all 
IgG (5B4, 2E4 and 1.1) at a dilution of 1:1000 onto a series of titrations of 
recombinant WT α-synuclein (50, 25 and 10 ng of protein) via immunoblot. (b) 
Expression level of α-synuclein in neuroblastoma cell line SHSY5Y (probed with 
commercial anti-α-synuclein antibody), effect of dox in repressing α-synuclein 
monomer.  
(A) (B) 
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solution and other half was not fixed with PFA. As seen below in the figure 4.18, the 
oligomer as well as the monomer was retained after lysis except when hypotonic 
buffer was used where only monomer was retained. The figure indicates that 
hypotonic lysis is not efficient to extract the oligomeric α-synuclein from SHSY5Y 
cells. Also it can be seen that the intensity of the monomer band (~14 kDa) obtained 
after fixing with 0.4% PFA was quite high as compared to the one not fixed at all 
(figure 4.18). Fixing blots with PFA has previously been shown on various cell lines 
to fix the bands and intensify them [321]. This can indeed be useful for studies such 
as post-translational modifications, etc where the critical changes in monomeric state 
are to be visualized via immunoblot.  
      
 
 
           
     
 
Figure 4.18: Different types of lysis of SHSY5Y cells: Lysis of SHSY5Ycells 
was carried out in 3 different types of lysis buffers – RIPA 
(radioimmunoprecipitation assay lysis buffer), Urea, Hypotonic and Triton 
buffer. The cells were lysed for 30 minutes and then centrifuged at 13,000 rpm 
for 5 minutes. (a) Lysis of SHSY5Y cells and blots were straight away blocked 
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4.2.9. Immunofluorescence 
For further characterization and in-vitro application of anti-α-synuclein antibody, we 
performed immunofluorescence (IF) onto α-synuclein expressing SHSY5Y cells. 
The protocol followed for IF is described in section 2.2. Here we demonstrated 
binding potential of antibody 3.1 as well as 4.1 to α-synuclein using commercial 
antibody as the positive control and secondary antibody (AF488) only to demonstrate 
background staining. The antibodies were used at 1:500 and we notice here that 
antibody 3.1 binds in a similar way as commercial antibody (1:1000). Moreover, no 
staining pattern was seen with antibody 4.1 which gave background similar to the 
secondary antibody control. Based on our earlier finding, mAb 4.1 binds to 
recombinant α-synuclein but does not bind to α-synuclein within cells, this result 
correlates with our IF result as we do not see any staining pattern with 4.1. Antibody 
1.1 did not detect α-synuclein within cells via IF (data not shown). However mAb1.1 
bound to α-synuclein within cells when observed via immunoblotting which in turn 
might be useful along with 3.1 to study α-synuclein in brain tissue models. The 
staining pattern of monoclonal antibodies binding to α-synuclein in SHSY5Y cells is 
shown in figure 4.19. The figure distinctly shows DAPI cellular staining, green in 
form of antibody binding and merged images. 
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Figure 4.19: Characterization of mAb 3.1, 4.1 onto SHSY5Y cells via 
immunofluorescence: Commercial anti-α-synuclein antibody (BD biosciences) 
and secondary antibody were used as positive and negative control respectively. 
The antibodies were used at a concentration of 1:500 commercial antibody used 
at a final concentration of 1:1000. 
 DAPI: blue stain, Green: green fluorescent light and RGB: red green blue merge 
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4.2.10. Immunohistochemistry 
With intriguing and contrasting results obtained with mAb 1.1 and for its further 
characterization along with antibody 3.1, we also looked at the presence of α-
synuclein in different tissues by IHC on brain as well as kidney tissues. This was 
performed in collaboration with Rudolf Nenutil, Brno, Czech Republic onto 
deparaffinised tissues. We also performed tissue staining studies with antibody 2.1 
but it was found to be negative in all the cases which correlates with our ELISA and 
immunoblotting results obtained above. It has been shown on previous occasions that 
α-synuclein is present in most of tissues including kidney, colon, lymph node and 
parts of brain. Immunohistochemistry was performed on formalin fixed tissues of 
normal brain and kidney samples. We stained a range of tissues such as Henle’s loop, 
skin mast cells, brain gray matter and kidney glomerulus and proximal tubules. The 
purified antibodies were used at a concentration of 1:1000 in both cases.  
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Figure 4.20 depicts that both antibodies 1.1 and 3.1 stain in a similar manner, we see 
no or very less staining in the kidney glomerulus, as well as skin melanocytes. 
However we notice that there is positive staining observed in the case of neurites and 
dendrites of brain gray matter in both cases, moreover there is a strong granular 
staining obtained in skin mast cells as well as in epithelium of Henle’s loop. In some 
tissue samples we see a very weak binding which might fade away with higher 
antibody dilution and no staining was noticed while characterising Ab 4.1 onto tissue 
Figure 4.20: Immunohistochemistry on brain and kidney tissues: Staining of 
parts of brain and kidney to look for presence of α-synuclein as well as to 
determine the binding potential of monoclonal antibodies. A. Henle’s loop, B. 
skin mast cells, C. brain matter and D. kidney glomerulus and proximal tubules. 
The fixed tissues were stained with 3.1 and 1.1 and the presence of α-synuclein 
was demonstrated in all mentioned tissues.   
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samples. In the recent past intensive research has been carried out mainly in the brain 
region, reason being that the significant role that this protein plays in Parkinson’s 
disease where its accumulation leads to the formation of lewy bodies. However 
within different tissues expression pattern of α-synuclein varies, for example it is 
expressed in cytosol of brain cells as well as in nucleus of mammalian neurons [288, 
322]. These results prompted us to look at the expression pattern of α-synuclein in 
cells using several assays described below. 
4.2.11. Co-localization of α-synuclein  
4.2.11.1. Development of distinct constructs of α-synuclein 
Even after tremendous amount of research on α-synuclein, the protein’s state is still 
controversial as it is considered as a monomer by some research groups whereas it is 
thought to be aggregated by other research groups. Thus extensive research still 
needs to be performed to determine the precise state of this protein in neural cells. 
For such studies, we thought of cloning WT α-synuclein in two different mammalian 
expression vectors containing distinct tags and to look at their effects against each 
other as well as onto endogenous α-synuclein in SHSY5Y cells and HCT116+ cells. 
Primers were designed for PCR cloning of α-synuclein into pMCherry C1 (cherry 
tagged), pEGFP-C1 (GFP tagged) and confirmed via restriction digestion of colonies 
after transformation. The plasmids were then sequenced in order to make sure the 
plasmids contained α-synuclein with no mutation. Subsequently, after maxiprep of α-
synuclein containing plasmids we transfected both constructs in different amounts in 
both above mentioned cell lines. After determining the concentration of total protein 
following lysis we ran 50 μg onto 12% SDS gel. From all the data obtained within 
these experiments, we show that the amount of Cherry tagged α-synuclein needed is 
more than three times to show the same expression level as GFP tagged α-synuclein. 
Moreover we detected transfected as well as endogenous α-synuclein in cells via 
commercial antibody (BD Biosciences) as well as antibody 3.1 (figure 4.21a, b).  
Chapter 4: Developing monoclonal antibodies and assays to biophysically characterized α-




      
 
As seen in figure 4.21, Cherry tagged α-synuclein was transfected in different 
amounts (0.5 and 1 µg) with empty cherry vector as a control and immunoblotted 
with anti-α-synuclein commercial (BD Biosciences) as well as 2E4 (IgG 3.1). The 
results indicate that when transfected constructs were immunoblotted using 
commercial antibody, a band around ~ 42 kDa was seen indicating the presence of 
cherry tagged α-synuclein along with a lower molecular weight product around         
~ 35 kDa which might be indicative of cleaved cherry tag with α-synuclein within 
the cells. Similarly when this blot was probed using mAb 3.1, 1 µg of DNA was 
found sufficient for antibody to detect but 0.5 µg was found to be very low for 
detection. However, another observation in the figure 4.21a is the detection of 
endogenous α-synuclein in SHSY5Y cells by commercial antibody which always 
detects a band around 55 kDa. This is still not acknowledged by some research 
groups believing it could be due to sequence homology with another protein. 
(a) (b) 
Figure 4.21: Transfection of α-synuclein constructs in SHSY5Y cells: (a) 
Transfection of Cherry tagged α-synuclein (C syn) in two different amounts (1 
and 0.5 μg), Cherry empty vector control and no transfection control. (b) 
Transfection of GFP tagged α-synuclein in two different amounts (1 and 0.5 μg), 
GFP empty vector control and no transfection control. Both blots were probed 
separately with commercial as well as mAb 3.1.    
Chapter 4: Developing monoclonal antibodies and assays to biophysically characterized α-
synuclein                                                                                                                                179 
 
Although 3.1 has the same epitope as commercial antibody, it does not give a 
characteristic band around 55 kDa but it showed a band around 35 kDa which could 
be a different form of α-synuclein occurring within cells. Similarly immunoblotting 
with commercial antibody for GFP tagged α-synuclein transfection showed a band at 
40 kDa and cleaved GFP tagged α-synuclein around 35 kDa and 30 kDa (figure 
4.22b). Antibody 3.1 detects GFP tagged α-synuclein as well but not in any of the 
cases mAb 3.1 was able to detect cleaved products. 





Further on, transfection of both constructs was performed in HCT116+ cells. The 
transfected samples included empty vectors, each construct along with empty vectors 
and both Cherry as well as GFP tagged α-synuclein. The transfected samples were 
immunoblotted for α-synuclein (commercial Ab) as well as for GFP. Based on this 
result, it appears as if either GFP tagged α-synuclein is being stabilized by cherry tag 
or more cleaved products are formed due to transfection of both α-synuclein 
constructs. For deeper understanding of α-synuclein interaction, we also used these 
constructs for Fluorescence resonance energy transfer –fluorescence lifetime imaging 
Figure 4.22: Transfection of α-synuclein constructs in HCT116+ cells: 
Transfection of GFP and Cherry tagged α-synuclein into HCT116+ cells: GFP 
empty vector, Cherry empty vector, GFP tagged α-synuclein, Cherry tagged α-
synuclein, GFP tagged α-synuclein with cherry empty vector, Cherry tagged α-
synuclein with empty GFP vector, GFP tagged α-synuclein with Cherry tagged 
α-synuclein and non-transfected as a control. These samples were 
immunoblotted using commercial antibody and anti-GFP antibody. 
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microscopy (FRET-FLIM). However we did not see a significant difference in the 
radioactive decay half-life of Cherry α-synuclein with respect to GFP tagged α-
synuclein. Based on our results we think that this might again be due to lower 
intensity of Cherry tagged α-synuclein. This model with significant optimizations in 
transfectable amount could be further useful to demonstrate oligomerization of α-
synuclein in cells.  
4.2.11.2. Proximity Ligation Assay (PLA) 
Another well characterized technique for visualization and quantification of protein –
protein interaction that has gained significant importance in the recent years is 
proximity ligation assay (PLA). To further prove co-localization of α-synuclein we 
used PLA technique to visualize its interaction pattern. This Duolink assay uses two 
primary antibodies selected from two different species such as a mouse and a rabbit 
antibody. The secondary antibodies contain a unique oligonucleotide sequence 
attached to them. When the proteins are in close proximity to each other, 
oligonucleotides are ligated together by a ligase to form a circular loop template. 
This template is then subsequently amplified by polymerase and the detection signal 
is obtained through complementary labelled probes.  This amplification reaction is 
visible in the form of distinct spots using a fluorescent microscope. Due to the 
robustness of this technique and controversial state of α-synuclein, we thought of 
studying interaction of α-synuclein with itself i.e. to see if it forms oligomers within 
SHSY5Y cells. We employ PLA technique to study oligomerization in two different 
sets of SHSY5Y cells i.e. lower and higher expression of α-synuclein. Here we 
modify the standard protocol (Veronika Brychtova from Borek Vojtesek laboratory, 
Brno, Czech Republic) and prepare anti-α-synuclein Ab (3.1) directly linked to a (-) 
probe and similarly anti-α-synuclein Ab linked to a (+) probe. Due to direct linkage 
of probes to primary antibody, secondary antibodies were not required in the 
experiment.  
Firstly mAb 3.1 was buffer exchanged using Zeba column into PBS to remove 
sodium azide that might interfere in conjugation process. The antibody was 
concentrated down and the concentration was measured on Nanodrop.  Succinimidyl 
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6-hydrazinonicotinate acetone hydrazone (SANH) solution was prepared and stored 
in the dark just before use.  SANH is a heterobifunctional protective linker used to 
introduce hydrazinonicotinimide functional groups into proteins including antibody 
and has been used extensively for labelling of biomolecules [323]. The antibody was 
conjugated to SANH (1:25) with gentle shaking in dark for 2 hours at room 
temperature. Following antibody conjugation, mixture was buffer exchanged once 
again into 1X conjugation buffer on a ZEBA column to remove any unconjugated 
product. To prepare oligo linked antibody, aldehyde modified DNA (oligonucleotide) 
was mixed with SANH activated antibody in 1X conjugation buffer in a ratio of 3:1 
(oligo: SANH linked antibody). To assist the conjugation reaction, 10 mM aniline 
was added as a catalyst and finally incubated for 2 hours 30 minutes at RT in dark.  
Using Zeba columns oligo-SANH linked antibody was buffer exchanged into PBS to 
remove any unconjugated products. The final concentration of the both probes linked 
to antibody was determined using Nanodrop.  
Further on, using these antibody linked to probes we performed PLA onto SHSY5Y 
cells along with controls. After fixing and permeabilising the cells, the coverslips 
were blocked using 3 % BSA for 45 minutes. For setting up the controls for this 
experiment, mAb 3.1 linked to – probe, mAb 3.1 linked to + probe and no antibody 
i.e. only BSA. Subsequently, mAb linked to – probe was added along with mAb 
linked to + probe onto the coverslip. The dilutions maintained throughout for 
antibody linked probe was 1:250 in each case. Figure 4.23 shows PLA onto SHSY5Y 
cells that express higher amount of α-synuclein (Dox repressible). Here upon 
visualizing PLA results under fluorescent microscope we notice that in controls 
containing either – probe or + probe only few spots were seen which corresponded to 
background staining count. However upon addition of both probes i.e. antibody 
linked to – probe as well as + probe, we see that the amount of spots obtained in this 
case were significantly higher as compared to the individual probe controls as well 
BSA control (figure 4.23).  
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Similarly while visualizing the data from PLA on SHSY5Y cells (low α-synuclein) 
we once again notice that spot formation in case of PLA with both probes is quite 
high as compared to controls (figure 4.24). This data correlates with above 
mentioned PLA results obtained on higher α-synuclein expressing cell line. These 
Figure 4.23:  Proximity ligation assay (PLA) on higher α-synuclein 
expressing cell line (SHSY5Y): PLA using antibody 3.1 showing DAPI only, 
green and merged (left to right) containing – Row 1 shows PLA using antibody 
lined to – probe only, row 2 shows PLA using antibody linked to + probe only, 
row 3 shows PLA using antibody containing both probes and row 4 shows PLA 
with no probe attached as a control. 
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results indicate that α-synuclein might be self-interacting and forming oligomers 






Figure 4.24:  Proximity ligation assay (PLA) on lower α-synuclein 
expressing cell line (SHSY5Y): PLA using antibody 3.1 showing DAPI only, 
green and merged (left to right) containing – Row 1 shows PLA using antibody 
lined to – probe only, row 2 shows PLA using antibody linked to + probe only, 
row 3 shows PLA using antibody containing both probes and row 4 shows PLA 
with no probe attached as a control. 
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Thus here we show using PLA that it is likely that α-synuclein is interacting with 
itself in SHSY5Y cells.  Interestingly, the staining pattern of antibody seen was not 
similar as in the case of IF. In the case of IF staining pattern indicated that the 
antibody binds to the membrane of the cell whereas in case of PLA the staining 
indicated binding pattern all over the cell which might be due to exposure of epitope 
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4.3. Discussion 
In this study we demonstrated the secondary structure of native α-synuclein and also 
potential efficacy of anti-α-synuclein antibodies against aberrantly folded protein (α-
synuclein) in PD via in-vitro assays. Parkinson’s disease is a highly prevalent 
neurodegenerative disorder which is characterized by accumulation of protein 
inclusion including α-synuclein and ubiquitin like proteins [324]. This disease is 
characterized by loss of dopaminergic neurons and is marked by the presence of lewy 
bodies similar to few other diseases such as LBD [325]. Protein aggregation in 
various neurodegenerative disorders is due to aberrant folding of the proteins which 
can lead to formation of oligomers and ultimately insoluble fibrillar structures. This 
phenomenon of protein accumulation which leads to formation of lewy bodies and its 
toxicity effects could be due to various reasons such as (i) impairment of ubiquitin-
proteosomal pathway, (ii) chronic endoplasmic stress and (iii) glutamate receptor 
dysfunction [326]. A study carried out using transgenic mice expressing WT α-
synuclein indicated loss of dopaminergic neurons characterized by formation of lewy 
bodies. α-synuclein can act as a pathogenic agent spreading from one cell to another 
throughout the course of PD by various mechanisms. Possible mechanisms involved 
in intercellular transfer of α-synuclein include secretion, exocytosis and recently 
found extensions called nanotubes (tunnel like structures between two cells) [327]. 
Exocytosis is the most common mechanism for α-synuclein to leave the cells which 
is supported by its intraluminal vesicular localization [328], whereas the precise role 
of tunnelling nanotubes (TNTs) is still being investigated. Inhibition of such 
mechanisms through antibodies or peptides can indeed play a major role in treating 
PD. Potential treatment strategies developed and ones under process with different 
mechanism of action target oligomers by either making these oligomers in soluble 
form or disrupting the already formed oligomers. Although the function of α-
synuclein is still unknown, it is known to be enriched at presynaptic terminals where 
it promotes the assembly of SNARE machinery (Soluble N-ethylmaleimide sensitive 
factor attachment protein receptor). Α-synuclein has been widely accepted as a 
structurally unfolded intrinsically disordered protein in its native state [329, 330], 
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however a few studies have suggested α-synuclein occurs as a α-helically tetramer in 
its native state [319, 331].  
Interestingly, the results with native state of synuclein have always been conflicting 
and not always replicated and thus its physiological form is still questioned. Thus in 
order to study the physiological state of this protein in detail, we expressed and 
purified the recombinant construct for α-synuclein.  In order to avoid any potential 
breakdown of any physiological assemblies by detergent, we initially ran the 
recombinant purified WT α-synuclein on a native gel under different conditions. 
Here we notice that α-synuclein runs at a higher molecular weight i.e. ~140 kDa 
whereas no monomeric form (14 kDa) was identified. However, when WT α-
synuclein was run on a SDS gel we noticed that all the oligomeric protein was 
degraded down to a monomeric protein which compelled us to look at the effects of 
different detergents. Among all detergents (SDS, Triton X-100, tween-20 and 
DMSO), only SDS was seen to collapse the protein to a monomer with as low as 
0.01% final concentration causing the collapse. It has been shown on various 
occasions that secondary structure of α-synuclein can be affected by boiling of 
sample, pH changes, etc.  A study carried out using Gel filtration on native α-
synuclein in brain cytosol as well as recombinant α-synuclein without any boiling or 
detergents showed this protein occurs as a folded tetramer which correlates to the 
earlier results [319, 332].  
In fact CD spectral studies have indicated that protein possesses α helical secondary 
structure i.e. containing 65% α - helical, 17% turns and 8% unfolded calculated using 
DICHROWEB [309, 333]. The conformation of native form α-synuclein has always 
been a topic of debate and so is its secondary structure in lewy bodies (inclusion 
bodies).  Another study on secondary structural analysis via CD spectrum has 
indicated that unfolded disordered conformational state of α-synuclein could be 
transformed into partially folded intermediates subjective to changes in pH and 
temperature [312]. It has also been shown by CD experiments; α-helicity is increased 
from 3 to 80% upon binding of α-synuclein to phospholipid bilayers [280]. Our CD 
data indicates that α-synuclein is structurally unfolded and disordered in its native 
state in the spectra range of 185 nm to 285 nm. Interestingly we see that after 
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addition of SDS (0.00006%) to WT α-synuclein α-helicity was attained from an 
unfolded disordered secondary structure based on the algorithms from 
DICHROWEB. Among all the algorithms used, α helical structures were best 
estimated by CONTIN method using SP175 as the reference set. In addition to this, 
using CONTIN we looked at the percentage increase in the α-helicity from a native 
unfolded protein after addition of SDS overnight as well as fresh. The reason behind 
adding SDS overnight as well as fresh was to look at the stability of the structure and 
also to analyse the percentage change in other types of secondary structures. Figure 
4.25 depicts a pie chart that shows percentage of occurrence of different types of 
structure in native α-synuclein with and without SDS. Based on analysis using 
CONTIN algorithm, native α- synuclein is 63% disordered, 7% helical, 4% stranded 
and 26% other structures. However, overnight and freshly added SDS induces 
structural changes which increase α helicity of the protein from 7% to 38% and 67% 
respectively. This structural variability induced due to addition of SDS is an 
indicative of interactive ability of α-synuclein with lipids. 
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Figure 4.25: Structural analysis of recombinant α-synuclein after CD 
spectral analysis: Using CONTIN as algorithm in DICHROWEB website, 
percentage of different types of structures was determined for each data set.  
(a) Native α-synuclein with no detergent showing 63% to be structurally 
disordered, 7% helical, 4% stranded and 26% turns. (b) α-synuclein with 
overnight SDS appears 37% to be structurally disordered, 38% helical, 12% 
stranded and 13% turns and (c) α-synuclein with fresh SDS incubation  
appears to be 22% structurally disordered, 67% helical, 1% stranded and 10% 
turns by software analysis. 
(a)
(c) (b) 
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From PD studies point of view, this protein becomes misfolded and leads to 
formation of insoluble oligomers which have become the ultimate hallmark of PD 
patients and a suitable target for therapies. With multiple approaches aimed at 
targeting different steps along aggregation pathway and different toxicity levels are 
being examined in basic laboratory research and pre-clinical studies [326].  For this 
reason, we immunized mice with recombinant α-synuclein to obtain monoclonal 
antibodies and tested against a panel of antigens as well as on recombinant protein. 
Interestingly one of the antibodies (2E4- 3.1) has the same epitope as the commercial 
antibody from BD Biosciences and two of mAbs (1H1 and 5B4) bind to the 
recombinant protein but not to any of the derived peptides. We also determined the 
activity of all these mAbs onto recombinant α-synuclein by immunoblotting as well 
as onto α-synuclein expressing neuroblastoma cell line (SHSY5Y). Also, fixing of 
the blotting membranes after Immunoblot transfer with PFA intensified the 
monomeric band which correlates with the published results [321]. Following testing 
and epitope mapping of antibodies on recombinant α-synuclein and a panel of 
peptides respectively, we immunohistochemically detected the presence of α-
synuclein in several brain tissues as well as kidney organs. α-synuclein is principally 
known to be expressed in brain but also expressed in low concentrations in all other 
tissues except in liver.  Moreover, we demonstrated the binding potential of mAb 3.1 
(2E4) via immunofluorescence and it was found that antibody stains in a similar 
pattern to that of commercial antibody in α-synuclein expressing cells.  
Previously, there have been attempts to understand the mechanism involved in the 
formation of oligomerization of α-synuclein in neuronal cells. For studying the 
behaviour of α-synuclein in cells we developed two constructs of α-synuclein with 
different tags onto each (GFP and Cherry) via cloning. The aim was to investigate 
the effect of both constructs onto each other as well as their effect on endogenous α-
synuclein via transfection into SHSY5Y cells. We demonstrated that GFP α-
synuclein was stabilized by cherry tagged α-synuclein (figure 4.21), however we did 
not see any signs of oligomerization of tagged α-synuclein occurring within the cells. 
Also, increasing the transfection amount of Cherry tagged α-synuclein DNA might 
be useful for studying α-synuclein interaction in cells.  
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To further study α-synuclein’s self-interaction we used PLA to illustrate that α-
synuclein indeed interacts with itself; however it remains to be determined what 
stable state this protein attains in cells and if it contributes to lewy body formation. 
PLA is a useful technique to microscopically visualize protein-protein interaction 
occurring within cells [334]. While analysing PLA onto SHSY5Y cells, we see spots 
(indicator of PLA signal) throughout the surface of cells indicating self-interaction of 
α-synuclein in SHSY5Y cells (high and low α-synuclein expressing cells). Thus 
these assays in future could be more than useful tools to demonstrate self -interaction 
of a protein occurring within cells or possibly even in tissues using well 
characterized antibodies. Moreover, our results with monoclonal antibodies 
developed against α-synuclein indicate that these antibodies could be a useful tool 
following further characterization from future therapeutic point of view for PD 
patients. Finally, antibody development combined with novel assays demonstrated in 
this research in turn could provide a major breakthrough in studying proteins 
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CHAPTER 5: Peptide phage display 
screening against α-synuclein 
5.1. Introduction 
5.1.1. Phage display 
With continuous success and efficacy of immunotherapy over the years against 
intracellular proteins such as tau [335, 336], Huntingtin [337] and α-synuclein [338] 
in neurological diseases, new era immunotherapeutic challenges are highly 
demanding in order to be implemented in humans. One such approach towards 
clinical success is developing new tools not only distinct from available ones but also 
possess higher efficacy towards the target. Phage display is one such promising 
selection approach that uses a combinatorial library containing random peptide 
sequences displayed on surface of bacteriophage. The advent of phage display has 
allowed a physical linkage between phenotype and genotype.   
              






Several groups have demonstrated the display of random peptides on the surface of 
phage and binding peptides using phage display have been identified to various 
biomolecules [339-341] . The most common display systems used for peptide phage 
display include filamentous phage in which peptides are fused to either minor coat 
protein (p3) or major coat protein (p8); this in turn ultimately determines the valency 
of the library. However, pharmacokinetics studies with peptides have always shown 
an area of concern and often contributes to its disadvantages, to overcome some 
issues such as low immunogenicity the ability of peptides is improved by making 
them oligomeric [342]. Oligomerization of the peptides could in turn act by  
increasing the selective binding to the target protein, for example dimeric peptide 
against EpoR and TpoR [343]. The trouble with current available immunotherapeutic 
tools for synucleinopathies is the extent to which biologics can induce any significant 
reduction in α-synuclein oligomers. Since α-synuclein is only 140 amino acids and 
intrinsically disordered i.e. lacking a stable 3D structure, peptide specifically binding 
to a pocket in the protein could be a useful tool for molecular imaging.   
5.1.2. Need for peptides binding to α-synuclein 
Selection process of peptides binding to a target is performed by a process called 
biopanning which involves incubation of combinatorial library with the target of 
interest in an immunotube or ELISA 96 well plate. Such screening can be easily 
performed due to the availability of commercially available peptide libraries such as 
7 mer and 12 mer Ph.D. libraries from New England Biolabs (NEB). A cyclic 
peptide library has shown its importance in reducing the toxicity of α-synuclein and 
resulted in prevention of dopaminergic neurons in the PD model [344]. α-synuclein 
is prone to misfolding, aggregation and can ultimately lead to ER stress, 
accumulation of lipid, mitochondrial dysfunction and finally cell death [345, 346]. 
Figure 5.1: Peptide phage display: Each phage displaying a distinct peptide 
sequence (peptide library) added to target of interest onto 96 well plate. 
Unbound phages washed away during biopanning and specific bound phages 
eluted and re-amplified for next round. The specific peptides are then 
sequenced and tested via different assays onto target protein. 
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There is evidence supporting the importance of non-amyloid component (NAC) 
domain in aggregation and cytotoxicity of α-synuclein [347]. Infact the GAV motif 
(residues from hydrophobic region 66 to 74) which is comprised of hydrophobic 
residues is known to be critical for α-synuclein fibrillation [348]. Several mouse 
models have been developed to study synucleinopathies for determination of high 
levels or mutant forms of α-synuclein. These models focused more on investigating 
whether or not α-synuclein results in loss of dopaminergic neurons and also 
demonstrate that its aggregation is necessary for formation of lewy bodies in animal 
models. Due to such pathological properties of α-synuclein, it might be useful to 
develop peptide aptamers to target this protein that occurs in various forms. These 
tools are developed with an aim of targeting fibrils at early stages rather than mature 
fibrils as the former is mainly involved in neuronal cell death whereas the later might 
play a protective role in some cases [349].  
An advantage of combinatorial peptide phage display screening is that it can provide 
novel peptide sequences that can bind to many proteins expressed within cells 
because of its diversity. The issue with other available technologies is their inability 
to identify millions of sequences straight from the phage pools, also restricted to 
number of sequences that can be identified and their difficulty to interpret data. 
Phage display is no longer limited by sequencing constraints as it is now possible to 
sequence millions of peptide sequences by technologies such as -next generation 
deep sequencing, etc. These binding peptides might have capability of inducing 
conformational change in the protein and ultimately result in disruption of aggregates 
and fibrillar forms.  Agents that can interact with aggregate forms of α-synuclein 
could be very useful not only in studying the mechanism of α-synuclein aggregation, 
lewy body formation but also from a diagnostic as well as a therapeutic development 
for PD patients. Since experimental studies have indicated that α-synuclein’s amino 
terminal repeats play a role in its binding ability to lipids [292], developing peptides 
to this region could in turn have a significant potential for understanding its 
biophysical properties. These peptides could be delivered to the target site by linking 
it to a macromolecule that does not induce any major side effects and also does not 
affect peptide binding ability.  
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5.1.3. AIM 
The aim of this study was to screen and identify peptides using peptide phage display 
technology that bind specifically to α-synuclein. Here we used Ph.D. 12 mer library 
from NEB for screening against α-synuclein using the selection process of 
biopanning. Binding peptides derived from the amplified pools of phage bound to 
peptide were sequenced and identified via next generation deep sequencing (NGS) 
and ultimately test for their ability to dissociate monomers and preventing 
aggregation. The identified peptides were then analysed for binding onto 
recombinant WT α-synuclein as well as neuroblastoma cell line (SHSY5Y) 
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5.2. Results: 
5.2.1. Peptide phage display againstα-synuclein 
Peptide phage display technology which involves displaying of randomized peptide 
sequences onto phage is widely employed for selection of specific binding peptides 
to a target immobilized onto an ELISA plate. This technique provides an advantage 
of presence of millions of peptide sequences on the surface of phage particles; this 
demonstrates the diversity of library. The Ph.D. 12 mer commercial phage library 
stock from NEB was sequenced in order to identify the repetitive sequences as well 
as to determine the diversity of library before subjecting the library to biopanning. 
Based on our earlier studies carried out on MDM2 (by Anne Sophie Huart, Hupp 
lab), it has been demonstrated that Ph.D. 12 mer library has different level of 
diversity with high number of repetitive sequences (Anne Sophie Huart, personal 
communication, 2013). For this reason before proceeding with our screening 
experiments onto α-synuclein we determined the diversity of peptides by determining 
cumulative copy number in the peptide phage library. As it can be seen in the figure 
5.2 a, uniqueness of the peptide sequences in peptide phage library before screening 
for mdm2 protein is quite low with cumulative number of copies exceeding over 
100,000. However, diversity of another stock of new Ph.D. 12 mer library used for 
screening against α-synuclein in comparison to the above mentioned library was 
quite high as not more than 100 repetitive numbers of copies were noted following 




























Due to the ease of availability of commercially made peptide phage display libraries, 
screening of peptides onto a target can be performed quickly by the process of 
biopanning which is demonstrated below in figure 5.3. Two rounds of biopanning 
were performed onto recombinant α-synuclein in an ELISA well. The non-specific 
phages bound to the well were washed away by performing stringent washes and the 
Figure 5.2: Comparison of Cumulative number of copies in phage 
library prior to use for biopanning: (a) Diversity of P.h.D 12 mer library 
used for screening onto mdm2 protein (b) Diversity of P.h.D 12 mer library 
used for α-synuclein screening. Each based on identification of unique 
sequences within the library 
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specific ones were eluted in appropriate elusion buffer. A fraction of all phage pools 
after elusion were stored for the subsequent round of panning as well as for PCR 
amplification to have enough DNA to further proceed for sequencing. Several 
controls such as incubation of library with blank wells and incubation with different 
proteins were used in the following experiments to remove any non-specific, 






Amplification of phage by infection into E.coli ER2378 was necessary from each 
round in order to amplify the specific binding clones by multiplying the copy number 
Figure 5.3: Biopanning protocol for peptide library screening onto target 
of interest: (a) PhD 12 mer peptide phage library containing different peptide 
sequences pentavalent in nature onto the phage. (b) Biopanning i.e. addition 
of library onto α-synuclein coated plate, (c) washes to get rid of non-specific 
phages followed by elusion of specific phages and (d) amplification in E.coli 
for subsequent round of panning and PCR for amplification of phage pool DNA 
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of specific clones. Few sequences might be over-expressed within the commercial 
library itself which could in turn cause their amplification in all the rounds of 
panning after re-infection into E.coli cells. For this reason, the phage DNA was 
amplified using PCR from the eluates obtained from each round of panning to 
minimize chances of amplified based bias obtained in sequencing data. A recent 
review described a few peptide sequences that have been known to amplify 
independent of target, thus these sequences are suspected as a non-specific binder 
[350]. Thus all the binding peptide sequences were selected if they were minimally 
expressed in the parental library in comparison to α-synuclein. In recent years, a 
number of web tools including databases and programs have been developed in the 
field of peptide phage display to analyse sequencing data. Based on the published 
data, it has been shown that 12 mer library binds better to the targets which require a 
chain of few amino acids that can fold into structural elements [351]. It is therefore 
not surprising to get high variability in the amount of peptide sequences as in theory 
peptide might bind to different hotspot residues distributed all over the surface of a 
protein. Using Next generation deep sequencing as a sequencing tool, we identified 
numerous peptides against αsynuclein following phage display. 
5.2.2. Identification of peptides binding to α-synuclein  
5.2.2.1. Abundance Method 
The number of repetitions of each peptide against α-synuclein is referred to as 
iteration number. Iteration of each peptide sequence was determined as a percentage 
within each sample set to be able to compare it to the other proteins (controls) via 
sequencing numbers. The advent of MEME software enabled us to identify several 
motifs containing identical sites within the selected peptide sequences. These 
selected peptides were passed through MEME software in order to identify different 
motifs containing identical amino acids. From all the peptides identified, 20 different 
motifs were identified on the basis of occurrence of several repetitive amino acids in 
all the selected peptides. As shown in the table 5.1 below, ‘GDGDNSVLKPGNW’ 
peptide was identified in 41 sites, another motif ‘EITHPGWSTVTH’ in 35 sites and 
thus these consensus peptides were further categorized.  
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Using this commercially available 12 mer Ph.D. peptide phage display library, 
peptides binding to recombinant α-synuclein were selected following DNA 
amplification. DNA was amplified from each phage pool that was stored following 
every round of panning, gel extracted and concentration of each DNA was measured 
as mentioned in section 2.17. The purified amplicons were pooled together in equal 
concentrations in order to obtain a total of 5 µg for Next generation sequencing 
(NGS) to obtain the list containing all possible peptide sequences. These combined 
phage pool DNA containing a combination of phage linked peptide DNA was 
sequenced and data from NGS was obtained in FASTA format. Along with α-
synuclein, screening was also carried out on a panel of proteins such as ZNF, npm 
and reptin. The data was converted from FASTA into xlsx format and further sorted 
out in an excel sheet. A total of approximately 1 million distinct peptide sequences 
present in the 12 mer library based on various combinations were derived from next 
generation deep sequencing data.  
5.2.2.1.1. Iteration number of each peptide 
Firstly, the identified peptides were arranged in decreasing order based on the 
iteration number of each peptide binding to a specific protein. For selection of 
peptide binding to α-synuclein, only peptides that showed at least two fold higher 
occurrence as compared to other proteins, controls as well as parental library were 
further characterized. As mentioned earlier in section 2.17 screening was performed 
in the form of fast washes and slow washes to obtain highly specific α-synuclein 
binding peptides. A control was used in each case to determine the background score 
and it was noticed that count obtained for the binding peptides obtained was 
significantly higher in slow wash as compared to fast wash. During different rounds 
of biopanning, the count obtained in case of slow washes was significantly higher as 
compared to fast washes which indicate better amplification of specific ones. Also, 
the total number of peptide sequences obtained in slow washes was less as compared 
to fast washes which might give an indication of amplification of non-specific 
peptide sequences in subsequent rounds in fast washes. Moreover in order to remove 
any false positives, the peptide library was first added to the well containing blocking 
buffer only (3% BSA) and then added to the well containing the protein of interest. 
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This could also in turn indicate that most of the plastic binders would remain bound 
to the plastic and remaining library could be subsequently added to the well coated 
with the target protein. A comparison of α-synuclein binding peptides based on 
different consensus sites obtained from slow washes along with different controls 











5.2.2.1.2. Comparison of selected peptides (Fast wash vs Slow wash) 
As it can be seen in table 5.1, the iteration number of binding peptides to α-synuclein 
was at least more than two fold higher as compared to the parental library, other 
proteins and control. Each peptide sequence was associated with its sample identity 
and iteration number. Following the comparison of binding peptides between 
different proteins, we further defined the behaviour of peptides based on their 
percentage occurrence in different rounds including unamplified round. As seen in 
table 5.2, iteration number of peptides is expressed in terms of percentage in round 
one before amplification (unamplified), round one amplified and round two 
amplified. One common feature noted among all peptides was the higher counts 
observed in round one amplified of slow washes as compared to fast washes. For 








197 27515 186 202 373 
EITHPGWSTVTH 
 
356 16146 521 374 759 
SSWWHHLVADRV 
 
32 2474 35 26 66 
SALKGLFPADHH 
 
124 3268 916 708 219 
MADVRHPGGFFF 
 
0 6 0 0 0 
Table 5.1: Iteration number of peptides: Peptides with higher iteration number 
against α-synuclein compared with iteration number against parental library, 
nmp, ZNF350 and control. For example, GDGNSVLKPGNW has an iteration 
number of 27515 against α-synuclein which is more than 8 fold compared to 
parental library and other proteins. 
                 Chapter 5: Peptide phage display screening against α-synuclein                          201 
 
peptide GDGNSVLKPGNW, the total iteration number for this peptide was 47270. 
Using this total number, percentage of occurrence of this peptide in different rounds 
was determined in fast and slow washes. Similarly for other peptides amplification 











We also determined iteration number of peptide GDGNSVLKPGNW selected 
against α-synuclein in comparison to several other proteins, parental library and 
control. It is important to mention here that against all proteins and control the same 
library was used and the same protocol was followed. Figure 5.4 shows this peptide 
had a total occurrence of 77 % when tested against α-synuclein. The numbers 
obtained were comparatively low against other proteins i.e. 8%, 5%, 1%, 2% and 7% 
in npm, control, parental library, ZNF and reptin respectively.  
peptide from motif FR1ua FR1 a FR2 SR1ua SR1a SR2 
GDGNSVLKPGNW 
 
3.5 0.19 1.45 1.08 59.2 12.5 
EITHPGWSTVTH 
 
2.85 0.85 2.24 5.57 17.1 4.5 
SSWWHHLVADRV 
 
2.47 0.1 1.97 1.7 30.5 27.9 
SALKGLFPADHH 
 
1.8 10.6 6.5 1.33 11.6 4 
MADVRHPGGFFF 
 
9.1 0 9.1 0 54.5 9.1 
Table 5.2: Selected peptides iteration number in percentage: Each 
peptide with higher iteration number was expressed in percentage in 
both rounds of panning in slow as well as fast washes.  
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Following the selection of peptides on the basis of their iteration number, we 
performed MEME analysis to identify different consensus sites present in the 
selected panel of peptides.  All selected peptides on the basis of abundance were 
scanned through this software and a list of motifs was obtained containing extent of 
variability observed between sequences. A total of 20 sets of motifs (shown below in 
figure 5.5) showing abundance of each amino acid were identified and ones with 






Figure 5.4: Percentage distribution of peptide GDGNSVLKPGNW: 
Percentage distribution of GDGNSVLKPGNW against α-synuclein along with 
other proteins, blocking buffer as controls. This peptide has an occurrence of 
peptide against α-synuclein is 77% whereas it is lower than 10% against all 
other proteins and control. 
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5.2.2.1.3. MEME analysis and identification of interacting proteins: 
Motif 1  2.2e-352 
 41 sites 
 
 
Motif 2  8.4e-309 
 35 sites 
 
 
Motif 3  3.0e-161 
 21 sites 
 
 
Motif 4  2.7e-061 
 10 sites 
 
 
Motif 5  4.9e-019 
 4 sites 
 
 
Motif 6  6.6e-019 
 5 sites 
 
 
Motif 7  5.4e-018 
 5 sites 
 
 
Motif 8  7.8e-010 
 3 sites 
 
 
Motif 9  8.0e-007 






 3 sites 
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The most statistically significantly identified motifs against α-synuclein using 
MEME analysis are mentioned below in table 5.3. E value is the statistical 










Table 5.3 shows number of identical sites present in each motif identified by passing 
filtered sequences through MEME analysis. This indicates that even after filtering 5 
fold, few peptide sequences are highly dominating when visualized by MEME for 
example GDGNSVLKPGNW was identified in 41 sites after MEME. For further 
characterization of 12 mer GDGDNSVLKPGNW peptide, we directed and scanned 
this peptide to protein blast (pBlast- NCBI) in order to identify different proteins 
containing similar motifs which might interact directly or indirectly with α-
synuclein. The proteins were selected only if they were associated with α-synuclein 
(Parkinson’s disease), synucleinopathies or any other neurological disorder. Using 
blast analysis a total of 15 proteins were identified based on sequence alignment and 
the list containing all fifteen proteins is mentioned below: 
Discovered motif E-value Number of sites 
GDGNSVLKPGNW 2.2e-352 41 
EITHPGWSTVTH 8.4e-309 35 
SSWWHHLVADRW 3.0e-161 21 














HD 6.6e-019 5 
Table 5.3: Discovered motifs containing maximum sites: Selected top 6 
motifs showing e-value and number of sites that it contains among all 
sequences identified against α-synuclein 
Figure 5.5: MEME analysis: All selected peptides were passed through MEME 
software to identify identical amino acid residues present within the peptide 
sequences. All peptides with high iteration number against α-synuclein were 
considered in this case  
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protein FAN isoform 2- 0.9kb  
Protein O mannosyl transferase 2- 2.2kb 
Thrombopoietin receptor precursor- 1.9kb 
Hydroxyl-coenyme A dehydrogenase, mitochondrial isoform 1 precursor- 0.8kb   
Aminopterin induced protein 1 precursor- 1.47kb 
Gap junction beta 4 protein- 0.67kb 
Ornithine carbamoyltransferase, mitochondrial precursor- 1kb 
Progestin and adipoQ receptor family member 9- 1.1kb 
Protein Smaug homolog 1 isoform 2- 1.8kb 
ADAMTS-like protein 5 precursor- 1.4kb 
Killer cell lectin like receptor subfamily member 1-0.8kb 
Rho GTPase activating protein 25 isoform d -1.8kb 
Alpha-1B-glycoprotein precursor-500bp 
Indolethylamine N methyl transferase isoform 2-786bp 
ATP binding cassette sub family D member 2- 2.2kb 
 
 
All the identified genes that were associated with their expression in brain are 
described briefly below. Factor associated with neutral sphingomyelinase activation 
(FAN) is an adaptor protein belonging to the BEACH family and is found in a 
variety of tissues [352]. Thrombopoietin (THPO) is a protein encoded by THPO gene  
playing a central role in normal megakaryocytopoiesis and thrombopoiesis [353]. 
This protein becomes highly relevant as its expression in brain is releaved and can be 
highly useful in exploring its association with α-synuclein.  Hydroxyl-coenyme A 
dehydrogenase is a mitochondrial enzyme belonging to dehydrogenase family and its 
protective role in PD has been shown before [354]. It functions in mitochondrial fatty 
acid oxidation by catalysing oxidation of 3-hydroxyl CoAs [355]. Gap junctions have 
always been present in a higher amount in brain and various organs for cell to cell 
communication. Ornithine carbomoyltransferase is an enzyme that cataylses the 
reaction between carabomoyl phosphate and ornithine to form citrulline and 
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phosphate. Its role and importance in brain has been determined to some extent in 
sparse fur mouse [356]. ADAMTS (a disintegrin and metalloprotease with 
thrombospondin motifs) was identified as another protein via phage display and are 
predicted by structural domains to be extracellular matrix proteins [357]. 
Primers were designed for cloning these above mentioned genes into mammalian 
expression vectors i.e. pMCherry (N, C terminus) as well as pEGFP (N, C terminus) 
vectors and ordered from Sigma Aldrich. Neuroblastoma cell line derived cDNA was 
used as template to amplify these genes. A gradient PCR was performed for all genes 
with a temperature range from 62 to 85
0 
C. The PCR amplification of some of these 
above mentioned genes is shown below in figure 5.6. The cloning results were 
confirmed via restriction digestion of miniprep purified DNA obtained after 
transformation. Once the genes were confirmed via digestion, they were sequenced 
(Sanger Sequencing, Source Bioscience, Cambridge) and maxiprep purified 
(Qiagen).  The successfully cloned genes from the whole panel were hydroxyl acyl 
co-enzyme A (HADH), thrombopoietin and GAP junction β-4.  
   





5.2.2.1.4. Transfection of cloned genes identified by phage display  
To investigate the interaction level of these identified proteins with α-synuclein we 
planned transfection of these constructs into SHSY5Y cells and to look at their effect 
on endogenous α-synuclein. Out of the whole panel of identified genes we managed 
to successfully clone three genes, namely, GAP, thrombopoietin and HADH and thus 
we proceeded further with these genes. These three cloned genes were further 
characterized by transfection into SHSY5Y cells which contain endogenous α-
synuclein. The following day the cells were lysed in 10% triton lysis buffer for       
30 minutes and concentration was measured via Bradford assay. As shown in figure 
5.7a below, 5 μg of hydroxyl acyl co-enzyme A dehydrogenase (HADH) resulted in 
the collapse of synuclein oligomeric protein into monomer i.e. 15 kDa. However no 
difference in α-synuclein state was noticed as an effect of GAP as well as 
thrombopoietin transfection in different amounts when immunoblotted with anti-α-
synuclein antibody. The transfected lysed samples were once again ran on 10 % SDS 
gel and probed with anti-GFP antibody at a dilution of 1: 2000 in 5 % skimmed milk 
to determine the efficiency of transfection with empty GFP vector as a control.       
50 μg of these lysates was run on 10 % native gel to confirm HADH effect onto 
endogenous α-synuclein that was obtained on SDS gel. The blots were again 
immunoblotted with commercial anti-α-synuclein antibody (BD Bioscience) and a 
distinct effect of HADH was seen on a native gel as a smear appeared (2
nd
 lane figure 
5.7c). This indicated that screening for peptides using peptide phage display might 
assist in identifying interacting proteins. This new finding could indeed be useful in 
studying HADH role in PD as well as its interaction with α-synuclein in brain 
models.        
Figure 5.6: PCR amplification of identified genes: Gradient PCR of genes 
within a temperature range of 62-850C. The genes included GAP, Ornithine, 
Progestin, Smaug, ADAM-TS, Killer T cell, Rho GTPase, Alpha-1β 
glycoprotein and thrombopoietin. 5 genes out of 9 amplified, gel extracted and 
restriction digested to clone into vector. 
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Following such encouraging results, we performed similar experiments to reproduce 
HADH effect but on every occasion the results varied which gave an impression that 
the effect of this protein might be cell density dependent. Following on, we 
transfected different amounts of GFP - HADH with an empty vector control in 
SHSY5Y and HCT116
+
 cells. Also, cells were grown at different densities to see the 
effect of cell density in induction of GFP - HADH change onto endogenous α-
synuclein. The transfection was then performed in SHSY5Y, HCT116
+
 cells and 
immunoblotted for α-synuclein as well as GFP. Interestingly on this occasion a faint 
band appeared in all different densities ~ 40 kDa in SHSY5Y cells (figure 5.8).  
Similarly the samples were immunoblotted using anti-GFP antibody (1: 2000) to 
determine the transfection efficiency. In all experiments performed it was noticed 
that HADH effect was seen only if concentration was atleast 5 μg. Even though 




Figure 5.7: Transfection of GAP, Hydroxyl coenzyme A (HADH), 
thrombopoietin and empty vector control into SHSY5Y cells (50 μg): (a) 
Immunoblotted for α-synuclein, (b) Immunoblotted for GFP and (c) all 
samples on native gel and probed for α-synuclein. α-synuclein oligomer 
formation around 55 kDa and monomer at 14 kDa. 
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HADH has an effect on endogenous α-synuclein directly or indirectly. Also a few 
genes while selecting from BLAST analysis were not considered due to their large 
size, thus only genes less than 2.5 kb in length and are known to be in relation with 
α-synuclein or ND were selected.    






Figure 5.8: GFP-HADH transfection in SHSY5Y and HCT116+ cells: (a) 
HADH transfection in cells maintained at different densities, left panel shows 
transfected samples in SHSY5Y cells (rectangular box shows HADH effect 
on α-synuclein) whereas right panel shows transfected samples in HCT116+ 
cells. Both blots were immunoblotted for α-synuclein. (b) Same samples (left 
panel- SHSY5Y and right panel- HCT116+ cells) but immunoblotted with 
GFP antibody to visualize the transfection efficiency. 
(a) 
(b) 
                 Chapter 5: Peptide phage display screening against α-synuclein                          211 
 
5.2.2.2. Percentage based method for identification of binding 
peptides 
Following this abundance method used for the selection of peptides binding to α-
synuclein, another method was employed in order to identify peptides based on total 
count of each peptide against a panel of proteins. The sum total of the each peptide 
was carried out i.e. total peptide count in parental library, controls, npm, reptin, 
ZNF350 and α-synuclein. After determining the total peptide count, percentage of 
each peptide was calculated in the relevant protein i.e. α-synuclein. For example, 
peptide GDGNSVLKPGNW gave a total of 47,270 (total of this peptide count in 
parental library, npm, ZNF350, α-synuclein, reptin and control).  This total for each 
peptide was inclusive of all rounds i.e. round one unamplified, round one amplified 
and round two amplified. Subsequently, total of GDGNSVLKPGNW peptide in all 
rounds of α-synuclein screening was calculated and was found to be 36,361. Thus 
using these total counts, percentage of this peptide against α-synuclein was 
calculated i.e. 77%. Similarly, percentage of iteration number for all the peptides 
following screening procedure was calculated against α-synuclein. For selection of α-
synuclein binding peptides, percentage of peptide exceeding 70% were filtered out 
and further characterized. The top 32 peptides were selected based on the percentage 
occurrence against α-synuclein and are shown below in table 5.4. Interestingly some 
peptides showed iteration number only against α-synuclein and not in other proteins 
and control. 
       sequence sum AAA   control α   synuclein α synuclein 
(%) 
  GDGNSVLKPGNW 47270 197 2618 36361  77% 
  DGAYWVSSLGLR 9740 36 705 6803 70% 
  LSVHLPVVDSPN 8139 40 628 5786 71% 
  HVIQSIREFRFT 4400 19 279 3143 71% 
  LSGHDRNNWHNM 3065 6 175 2178 71% 
  SQLKPILAWANS 2834 20 235 2048 72% 
  DGTASIPVSQTS 2834 16 136 2006 71% 
  SSLLTFYPIGVS 1856 8 80 1373 74% 
  FEPSAPSNVPGS 1860 15 83 1351 73% 
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  GNSAWQINSLTD 1581 11 82 1237 78% 
  FEDPRTWWVTHL 1688 5 132 1231 73% 
  ELVGGLHFWGST 1623 2 105 1205 74% 
  KVSSTGGLSPYT 1403 7 61 1090 78% 
  MRSATLGDWSVT 1405 6 93 1079 77% 
  YSLGLRVDTQGY 1497 4 83 1072 72% 
  WPSSGVNPAQGS 1258 7 58 990 79% 
  KCCWPAVLPDSI 1090 4 70 853 78% 
  KCCFSTTVMEPK 1084 5 75 830 77% 
  INFTPDRSTRDM 1062 0 46 793 75% 
  GNCKSYSPTFTL 946 6 58 711 75% 
  DSYYIATSAMAG 820 0 39 677 83% 
  KLWDLGLGPIET 829 3 52 671 81% 
  YSLGPDVKLERY 771 4 36 621 81% 
  NGEKIAWRTLSL 622 3 208 478 77% 
  GGDGADRRSSFA 11 0 0 11 100% 
  LPYKIPQTFFNI 11 0 0 11 100% 
  MISISGTDYAHP 11 0 0 11 100% 
  SHACWWDECTGS 11 0 0 11 100% 
  VLGLPVTFSIRA 11 0 0 11 100% 
  GDGNSVLKPGNQ 10 0 0 10 100% 
  IGVPRVIAVEVS 10 0 0 10 100% 
  LDFSRGQGLPRK 10 0 0 10 100% 
  NHAYIGLAFDRP 10 0 0 10 100% 
  NTFPLTGHPYTT 10 0 0 10 100% 
  NTRTQAYIPVIP 10 0 0 10 100% 
  RNESPGMVFPAS 10 0 0 10 100% 
ICFFAHSGSPRC 
 
26 0 0 25 96% 
GSPDLDFTYAKT 
 
25 0 1 24 96% 
FEVQSLHPKRLY 
 
21 0 1 20 95% 
  GDGNSVLQPGNW 21 0 0 20 95% 
NTRWFDHRAPSD 
 
19 0 0 18 95% 
LTGLMAAVGLKS 
 
18 0 0 17 94% 
 DPAVGITDATLP 
 
18 0 0 17 94% 
HVSRSLHQTSPV 
 
18 0 0 17 94% 
TSNWSLSGPTLN 
 
18 0 0 17 94% 




17 0 0 16 94% 
SSGLVHGYRAWN 
 
17 0 0 16 94% 




These above mentioned 32 peptides identified through peptide phage display were 
designed containing N-terminal biotin tag were ordered from Mimotopes, Victoria, 
Australia.  The N terminal biotinylated tagged peptides were resuspended in 200 μl 
DMSO to a final concentration of 5 mg/ml. Subsequently, these peptides were tested 
for their binding efficiency against purified recombinant α-synuclein. ELISA was 
performed in two different formats. Firstly, one 96 well ELISA plate was incubated 
with streptavidin overnight whereas the other plate was incubated for just one hour 
with streptavidin as the designed peptides were biotinylated. The following day 
peptides were added onto the washed wells for one hour and subsequently the wells 
were blocked with 3% BSA. Further on, α-synuclein was added to the wells for 1 
hour, washed 3 times with PBS-T and incubated with secondary antibody (1:1000 
rabbit anti-mouse Ab) for another 45 minutes. On reading the plates it was found out 
that none of the peptide showed binding to WT α-synuclein. 
Secondly, activity of all the peptides was determined onto α-synuclein coated plates. 
Once again one of the plates was incubated overnight whereas the other one was 
incubated for just 60 minutes with WT α-synuclein at room temperature to see if the 
incubation time and temperature affect the peptide protein interaction. There was a 
significant difference noticed in the interaction level of the peptides with WT α-
synuclein when the plates were coated with α-synuclein for 1 hour and overnight for 
the same. It was seen that the peptides did not show any interaction with α-synuclein 
when the plate was coated overnight with WT α-synuclein. However, when α-
synuclein was coated for 1 hour, peptide 20 (SHACWWDECTGS) showed 
significant binding in comparison to other peptides when the plate was read at       
450 nm (figure 5.9a). This binding difference could be due to various factors such as 
change in the conformation of the protein due to overnight incubation, temperature 
Table 5.4: Peptide occurrence in percentage against α-synuclein: 
Percentage calculation of each peptide against α-synuclein based on total count 
of peptide against all proteins, parental library and control (including slow and 
fast washes).  
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dependency, buffer solubilized, etc. To further validate this peptide, we performed 
another ELISA to measure the effect of DTT (+/-) along with random selected 
peptides out of the panel onto α-synuclein. As seen in figure 5.9b, peptide 20 binds to 
WT α-synuclein in absence of DTT whereas there was no interaction observed after 






While understanding the structure of binding peptide SHACWWDECTGS, we notice 
that interestingly this peptide contains two cysteine residues which could explain the 
reason of DTT effect on its interaction with the protein. The disulphide bond 
between the cysteine residues present at position 4 and 10 in the peptide was reduced 
with the action of DTT which is expected based on the chemistry of the molecule. 
Figure 5.9: Peptide- protein interaction ELISA: (a) Activity of all 32 peptides 
onto ELISA plate coated with recombinant α-synuclein for 60 minutes. (b) 
Activity of selected panel of peptides (2, 19, 20, 29 and 30) in presence and 
absence of 1mM DTT. Left panel of 5.9a shows binding in absence of DTT 
whereas the right panel shows binding in presence of DTT. 
(a) 
(b) 
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This peptide was cloned in a GFP and Cherry tagged (N and C terminal) vectors for 
mammalian expression.  The primers were designed in such a way that they 
amplified GFP or Cherry sequence containing the peptide sequences and re-cloned 
into the digested purified vectors.  The primers designed for cloning of these peptides 
into plasmids have been mentioned below: 
Primers for cloning of the peptides into cherry and gfp tagged vectors (N and C 





GDGNSVLKPGNW CHERRY C 
FORWARD AGEI 
 





GDGNSVLKPGNW CHERRY C REVERSE 
KPNI 
5’ GGT ACC TCA CCA GTT GCC GGG TTT CAA 
AAC GGA GTT GCC GTC GCC GCC GGA GCC 




SHACWWDECTGS  CHERRY C  
REVERSE KPNI 
5’ GGT ACC TCA AGA CCA TGT ACA CTC ATC 
CCA CCA ACA GGC GTG AGA GCC GGA GCC 




SHACWWDECTGS  GFP  C   REVERSE   
KPNI  
5’ GGT ACC TCA AGA CCA TGT ACA CTC ATC 
CCA CCA ACA GGC GTG AGA GCC GGA GCC 




GDGNSVLKPGNW   GFP  C   REVERSE   
KPNI 
5’ GGT ACC TCA CCA GTT GCC GGG TTT CAA 
AAC GGA GTT GCC GTC GCC GCC GGA GCC 




GDGNSVLKPGNW CHERRY N 
FORWARD HINDIII  
 
5’ GC AAG CTT ATG GGC GAC GGC AAC TCC 
GTT TTG AAA CCC GGC AAC TGG TGA GGT 





SHACWWDECTGS  CHERRY N 
FORWARD HINDIII 
5’ AAG CTT ATG TCT CAC GCC TGT TGG TGG 
GAT GAG TGT ACA TGG TCT TCC GGC TCC 




CHERRY N REVERSE NOTI  
 




GFP  N REVERSE NOTI  
 




Table 5.5: Primers to clone identified peptides: Primers containing 
restriction sites for cloning of peptides binding to α-synuclein identified by 
NSG into cherry and gfp tagged vectors (N and C terminal).                                
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These primers were used to amplify gene (cherry/ GFP sequence) from the empty 
vectors pMCherry C, N and pEGFP N, C terminal vectors. The amplified genes were 
double digested and cloned into digested above mentioned vectors. The sequencing 
data from cloning indicated point mutations in the peptide sequences which might be 
due to cloning of small fragments i.e. small peptide (12 amino acid chains) into 
plasmids. Since the cloning of the peptides was not successful on this occasion we 
went on to perform peptide pull down assay as means of another way to identify the 
activity of identified peptides. 
In order to see the effect of all the peptides onto α-synuclein in SHSY5Ycells we 
performed peptide pull down assays to see if the binding peptides could pull down α-
synuclein from α-synuclein expressing SHSY5Y cell line. The pull down was carried 
out in three different ways based on pre-clearing described here. Before proceeding 
with peptide pull down 10 mg of total fresh lysates was prepared from SHSY5Y cells 
grown in 10 cm petri dishes. We performed avidin treatment for 30 minutes to pre 
clear the SHSY5Y cell lysate. Firstly no pre-clearing was carried out using avidin 
and the lysate was immediately added to streptavidin beads incubated with peptides. 
Here we do not see any binding with some of the peptides i.e. peptide 1, 2, 9, 12, 13, 
18, 19, 25, 26, 29, 30 and 31.  As seen in figure 5.10a, remaining peptides (peptide 3, 
4, 5, 6, 7, 8, 10, 11, 14, 15, 16, 17, 20, 21, 22, 23, 24, 27 and 28) pulled down 
oligomeric α-synuclein. Secondly, peptide pull down was performed after lysing the 
cells for 30 minutes followed by pre-clearing the lysate using sepharose beads for 30 
minutes. Interestingly here we see only peptide number 17, 22, 24, 26, 29, 30, 31 and 
32 manage to pull down endogenous α-synuclein from the cell lysate. Lastly,           
20 μg/ml avidin was added along with lysis buffer before lysing the cells for 30 
minutes and only peptide 2, 5, 24, 28, 29, 30, 31 and 32 did not pull down α-
synuclein (figure 5.10c). The difference noticed in all three different cases could be 
due to the manner in which the peptide is exposed during the incubation of α-
synuclein expressing lysate. Also, further validation of these peptides is necessary to 
prove their binding ability to α-synuclein.  









Figure 5.10: Peptide pull down assay:  (a) No pre clearing step involved in 
peptide pull down i.e. lysate straight away added to beads containing peptides. 
(b) Lysis for 30 minutes followed by pre-clearing using avidin for 30 minutes 
before adding to peptides, and (c) lysis together with pre-clearing for 30 minutes, 
followed by addition to peptides onto beads for pull down. All the samples were 




                 Chapter 5: Peptide phage display screening against α-synuclein                          218 
 
5.3. Discussion 
Phage display provides a useful technique for display of numerous distinct peptides 
onto its surface and the process of biopanning has enabled selection of peptides 
binding specifically to a protein. Peptides have an advantage of greater stability as 
compared to antibodies and via phage display they have routinely been found with 
high specificity to bind to different proteins with kD values from 3 nm to 5 μM 
[358]. In our experiments we subjected Ph.D. 12 mer library to the process of 
biopanning and carried out two rounds in order to select for highly binding peptides 
to α-synuclein. With the availability of NGS, two rounds of panning are usually 
enough to identify specific binding peptides as NGS has capability of generating data 
using extracted DNA out of the phage pool and can also be easily interpreted. Thus 
we carried out two rounds for identification of all binding peptides from the library. 
For increasing the amount of controls in our experiment and to obtain highly specific 
peptides binding to α-synuclein, we performed screening in a 96 well plate that 
contain α-synuclein, npm, ZNF350 and reptin. The phage pools stored from each 
round before and after amplification of peptide sequences. The DNA from the phage 
pools was gel extracted, purified and total of 5 μg was sent for next generation deep 
sequencing. NGS is capable of analysing millions of sequences reducing the number 
of selection rounds required and eliminates artifacts that arise during PCR or 
selection process [359, 360]. Following NGS we used two different methods with 
help of Adam Krejci (RECAMO, Brno, Czech Republic) to isolate all binding 
peptides identified from screening. With advancement in NGS it is not necessary 
anymore to carry out more selection rounds and binding peptides can be easily found 
out based on its iteration number.  
As shown in our experiments NGS can also be useful in identifying proteins 
interacting with α-synuclein and ultimately their role in PD. Using NGS we 
determined the iteration number for each peptide against α-synuclein and associated 
controls. It is important to mention here that deep sequencing of DNA from phage 
pools after single round of biopanning gives sufficiently positive phages. 
Furthermore, increasing the number of rounds on occasions possess a risk of losing 
some promising clones that propagate slowly [361]. Since other types of available 
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deep sequencing techniques have an error rate of >1%, NGS is capable of sequencing 
millions of peptide sequences from a single pool with minimum error. The peptides 
based on their iteration number were then arranged in decreasing order from top to 
bottom and were compared against parental library, other proteins and control. On 
looking at the binding ability of these peptides to α-synuclein, only one peptide 
SHACWWDECTGS showed binding to WT α-synuclein with no detectable activity 
among other peptides. Due to the presence of two cysteine residues in this peptide, 
we looked at the effect of strong reducing agent i.e. DTT and as expected the binding 
was diminished after its addition. Figure 5.11 illustrates secondary structure of 
SHACWWDECTGS with marked cysteine residues responsible for diminishing the 
activity of peptide after addition of DTT. DTT reduces the disulphide bonds and thus 





Consensus sites were found after subjecting all peptides to MEME analysis and each 
motif containing identical sites has been shown in figure 5.5. Moreover the most 
common peptide obtained via both methods was ‘GDGDNSVLKPGNW’, however 
unfortunately this peptide did not bind to α-synuclein via ELISA. This phenomenon 
Cysteine 
Figure 5.11: Secondary structure of SHACWWDECTGS: Illustration of 
SHACWWDECTGS peptide secondary structure built using pymol. Cysteine 
residues within the peptide which affect the activity of this peptide binding to α-
synuclein after addition of DTT have been indicated.  
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could be due to variety of reasons such as exposure of α-synuclein in a different 
manner; however this peptide turned out to be a useful tool in order to identify 
interacting proteins. Interestingly upon scanning this peptide to BLAST analysis, this 
motif identified a panel of proteins that appear to be either interacting with α-
synuclein or involved in ND. The list of interacting proteins is shown in table 5.5 and 
the sequence analysis of cloned genes along with designed primers is shown in 
appendix IV.  
In conclusion to this chapter, we have successfully demonstrated that different stocks 
of same peptide library from NEB can cause substantial loss in the diversity of 
library. The peptide phage display screening against α-synuclein could indeed serve 
a dual advantage, firstly to identify peptides binding to various domains of proteins 
and secondly to identify interacting proteins that can assist in studying protein’s role 
in relevant disease. As it has been shown that α-synuclein self-associates into 
oligomeric state and plays a key role in driving PD, it becomes a promising target for 
such peptide based therapies. As noticed in this chapter 15 interacting proteins were 
found out using a scan of a single peptide identified through screening, out of which 
we validated three of the interacting proteins. Thus future work of this project will 
focus more on identifying interacting proteins by means of identified motifs and 
validating them against endogenous α-synuclein. Following sufficient validation of 
the peptides, these tools could in turn be a useful tool in blocking several signalling 
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CHAPTER 6: Summary and future 
work 
6.1. CD20 as an intriguing target in canine B cell Lymphoma 
Developing biologics especially monoclonal antibodies seems to be the likely way 
forward to combat various diseases including cancer. The acquisition of monoclonal 
antibody technology by various pharmaceutical companies is an indication of 
continuously growing interest in the field of antibody therapeutics. Here we 
developed several types of tools against two totally distinct targets that behave 
aberrantly in two different diseases. The reason for choosing CD20 and α-synuclein 
as targets for therapy is their high level of expression in B cell lymphoma and 
Parkinson’s disease respectively. CD20 is a non-glycosylated transmembrane 
phosphoprotein expected to display a loop of 40 amino acids between third and 
fourth transmembrane helical loop. Due to the well-known fact that this protein is 
only expressed on growing B cells and not expressed on terminally differentiating 
plasma cells  [240], we developed antibody tools to have a net effect on CD20 
expressing lymphoma cells. CD20 is mainly expressed in B cell lymphomas and not 
in T cell lymphoma which correlates with our finding.  
It is now very well known that dogs develop cancer spontaneously in a similar 
manner to that of humans, for example B cell lymphoma. Rituximab is the first 
generation antibody approved against B cell lymphoma in humans, however it does 
not bind to its canine counterpart. Following Rituximab, even second generation 
antibodies against human CD20 have failed to bind to canine CD20. Here we 
develop a monoclonal antibody (NCD1.2) against canine CD20 that binds to larger 
loop of extracellular region and determine its binding efficiency in canine lymphoma 
cells, tissues via FACS, IF and IHC. Also we demonstrate NCD1.2 binds to its 
human counterpart by Fluorescent polarization assay, immunofluorescence, etc. 
Following on we also developed scFv (variable heavy and light chains) via antibody 
phage display in different scaffolds to increase affinity of the antibody. We also 
show two different kappa light chains were produced from a single hybridoma cell, 
this has only been reported on a single occasion previously against an anti-DNA 
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hybridoma. We also demonstrate the technique to obtain stable clones from the 
process of biopanning i.e. phage linked to scFv is stable as compared to scFv alone. 
We also performed bacterial as well as mammalian expression of two scFvs (3 and 7) 
to test the affinity of the antibody. Finally we cloned scFv into CpG2 for ADEPT 
cloning, carried out yeast expression and purification. As another approach we also 
developed recombinant IgG using scFv 3 sequences with canine Fc region to avoid 
any anti-canine responses and determine its binding efficacy on recombinant CD20 
using IFITM1 as a negative control. One of the promising ELISA results using 
recombinant canine IgG onto canine extracellular CD20 using HRP conjugated   




Thus we develop a monoclonal antibody that has promising potential for therapeutic 
approach for canine B cell lymphoma and hopefully could be translated into humans. 
Along with full length, several scaffolds of scFvs were constructed that could be 
useful in future for deep penetration into tissues. With such promising results we 
hope to take this antibody forward by caninizing followed by imaging in canine B 
Figure 6.1: Recombinant dog IgG binding efficacy: Recombinant IgG 
following expression in CHO cells onto extracellular CD20 and IFITM1 as a 
negative control protein. As seen above one of the clone binds better to CD20 in 
comparison to IFITM1. 
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cell lymphoma models and determine its dosing effects from veterinary therapeutics 
point of view.  
6.2. Biophysical studies and developing aptamers to α-synuclein 
Secondly, another intriguing target chosen was α-synuclein which is known to be 
aberrantly expressed in PD against which antibodies have not managed to pass 
through the clinical trials stage due to non-availability of animal models. Infact 
recently α-synuclein aggregates have been found in colon biopsies of PD patients,  it 
is proposed that protein aggregation begins before other factors become visible 
which in turn can serve as a diagnostic marker [362]. Since aggregation of this 
protein is responsible for formation of insoluble protein aggregates i.e. lewy bodies, 
the need for antibody targeting this protein still remains. Passive immunotherapy 
might indeed be the way forward for treatment of PD patients if α-synuclein is 
targeted at early onset of disease. To start with we cloned, expressed, purified α-
synuclein and ran fractions onto native gels to determine its native state. After 
looking at the effect of various detergents we show that α-synuclein is collapsed after 
addition of SDS and runs around 140 kDa on a native gel and at 14 kDa on a 10% 
SDS gel. Moreover to confirm its oligomeric nature as well as secondary structure 
we used CD and on this basis we can conclude that this protein is structurally 
disordered. However, in presence of SDS α-synuclein attains helical structure. Here 
we developed monoclonal antibodies against α-synuclein and tested via ELISA, IHC 
on recombinant protein and tissues respectively (chapter 4). Such antibodies in future 
will be tested on PD brain tissues to visualize the binding pattern and distribution of 
α-synuclein throughout brain in PD patients. 
For gaining deeper understanding into controversial state of α-synuclein, we 
developed two constructs of α-synuclein and studied them via transfection, FRET-
FLIM and IF in cells. Subsequently using PLA we show that α-synuclein 
oligomerizes within cells, however it remains to be demonstrated if this contributes 
to lewy body formation within cells. We also developed peptide aptamers against α-
synuclein by subjecting 12 mer Ph.D. library to the process of biopanning. Using 
NGS we interestingly identified peptides binding to α-synuclein via sequence sorting 
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in comparison to controls. Identified peptides were tested via ELISA as well as 
peptide binding assay onto recombinant α-synuclein and SHSY5Y cells respectively. 
One of the identified peptide was found to bind α-synuclein via ELISA, however no 
binding was reported in presence of 1 mM DTT. These above mentioned findings 
indicate that peptide aptamers could be useful tools with high potential that can be 
further translated into conjugation or cell model study. 
 
6.3. Conclusion 
In conclusion, biologics, especially antibodies and peptides have revolutionized the 
available treatment regimens for many diseases including cancer. For 
oligomerization studies, techniques such as PLA, FRET-FLIM and also developing 
two different constructs of target protein might prove to be efficient with significant 
optimizations. Similarly with advancement in screening techniques along with next 
generation sequencing, specific peptides binding to a protein can be identified and 
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CHAPTER 7: APPENDICES 
Appendix I: scFv construction 
 
Clustalw analysis of human and canine CD20 
 
Biopanning (4 rounds) 


















Figure 7.1: ELISA (4 rounds of biopanning): ELISA of input phage pools 
obtained during 4 different rounds of biopanning onto CD20 peptide 32 coated 
plate 
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Sequencing data obtained from antibody library from spleen 
As shown in figure 3.25, two different kappa chains were isolated from anti-CD20 
antibody library made using single hybridoma cell. However while sequencing 
clones from a library made using mouse spleen, significantly higher amount of 
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Appendix II: Recombinant dog IgG activity 








Figure 7.2: Vector construction (Mologics): pICZα vector (3.6kb) 
construction for cloning of scFv.CpG2 by addition of XhoI site in collaboration 
with Mologics. 
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Recombinant IgG (dog Fc) onto CD20 peptide (32 and 38) 


















Figure 7.3: Dog IgG ELISA: Binding efficiency of two isolated clones of 
recombinant dog IgG was estimated via ELISA using TMB as a substrate 
solution onto ELISA plate coated with CD20 peptide (32 and 38).   
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Figure 7.4: Identified protein constructs transfection: Transfection of 
proteins (thrombopoietin, GAP, HADH and α-synuclein) identified via 
BLAST scanning of peptide sequence into SHSY5Y and HCT116+ cells. 
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Appendix IV: Peptide phage display screening identified peptides 
Identified peptides following MEME (whole) 
 


















          
GDGNSVLKPGNW 197 131 537 373 530 86 684 27515 5913 
GDGNSVLKQGNW 0 1 1 0 0 0 1 19 9 
GDGNSVMKPGNW 0 0 1 1 0 0 1 21 9 
GDGNQVLKPGNW 0 0 2 1 1 0 0 20 7 
GDGNWVLKPGNW 0 0 2 1 1 0 0 20 7 
GDGNSMLKPGNW 0 0 0 0 0 0 0 5 1 
GDGNSALKPGNW 0 0 1 1 1 0 0 24 6 
GDGNSVLKPGNC 0 0 0 0 0 0 0 28 1 
GDGNSELKPGNW 0 0 0 0 0 0 0 9 3 
GDGNSVLKAGNW 0 0 1 0 0 0 1 16 1 
GDDNSVLKPGNW 0 0 0 0 0 0 0 2 1 
GDGNSVLKTGNW 0 0 0 0 0 0 5 32 12 
GDGNSVLKPGDW 1 0 3 0 1 0 1 65 12 
WDGNSVLKPGNW 0 1 1 0 0 0 0 12 3 
GDGNSVLKPWNW 0 0 0 0 0 0 0 11 1 
GDGNSLLKPGNW 0 0 3 0 0 0 2 19 7 
GDGNSGLKPGNW 0 0 0 0 1 0 0 38 7 
GDGNSVLKLGNW 0 0 0 0 0 0 0 11 1 
GDGNSVLKPGIW 0 0 0 0 0 0 0 5 1 
GDGNSVLKSGNW 0 0 0 0 1 0 0 25 1 
GDVNSVLKPGNW 0 0 0 0 0 1 1 18 5 
GDGNSVLKPGHW 0 1 2 0 3 0 3 85 21 
GDGNSVLKPVNW 0 0 0 0 0 0 1 11 4 
VDGNSVLKPGNW 0 1 0 1 1 0 1 4 3 
GYGNSVLKPGNW 1 0 2 1 0 0 2 27 8 
GDGNSVLKPGYW 0 0 1 0 1 0 2 66 11 
GDSNSVLKPGNW 0 0 0 1 0 0 0 4 1 
GDGNSVLKPGNQ 0 0 0 0 0 0 0 7 2 
GDGNSVLKPGSW 0 0 2 0 0 0 1 5 1 
GDGNSVLKPGTW 0 0 0 0 0 0 1 8 3 
GDGTSVLKPGNW 0 0 0 0 0 0 0 3 2 
GAGNSVLKPGNW 0 1 1 0 0 0 0 23 8 
GDGNSVLKPGNL 1 0 0 1 0 0 0 21 3 
GVGNSVLKPGNW 0 0 1 0 0 0 1 22 5 
GGGNSVLKPGNW 0 0 0 0 0 0 0 12 1 
GDGNSVLQPGNW 0 0 0 0 0 0 0 18 2 
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GDGNSVLNPGNW 0 0 2 1 0 0 0 19 8 
GDGNSVLTPGNW 0 0 0 0 0 0 0 5 1 
GDGNSGLKPGDW 0 0 0 0 0 0 0 4 1 
EITHPGWSTVTH 356 295 1500 759 1067 799 2115 16146 4264 
EITHPCWSTVTH 0 0 2 0 1 1 0 17 7 
EITHPGWQTVTH 0 0 1 1 1 2 3 14 5 
EITHPGWSTVMH 0 1 1 0 1 0 5 7 7 
EITHPGWSTVKH 1 0 2 3 0 1 4 26 2 
EITHPGWSTVTQ 0 0 0 1 0 0 1 4 1 
EITHPGWATVTH 0 0 1 0 0 0 0 16 3 
EITYPGWSTVTH 0 0 0 0 0 0 0 1 1 
EIIHPGWSTVTH 0 0 0 1 0 0 0 5 1 
EITHPGWSTVTY 0 0 0 0 1 1 0 3 2 
EITHPGWSNVTH 0 0 3 0 2 6 1 20 5 
EITHPGWSTVRH 0 0 0 0 0 0 1 2 1 
EITHPGWSTATH 0 0 0 1 0 1 1 3 3 
EITHPGWPTVTH 0 0 1 0 0 0 0 5 1 
EINHPGWSTVTH 1 0 2 0 1 0 2 16 10 
EITHPGWSTVSH 0 0 1 1 0 0 2 13 1 
EITNPGWSTVTH 0 1 1 2 1 0 2 12 4 
EFTHPGWSTVTH 0 0 0 1 0 0 1 5 1 
EITHPGWSSVTH 0 0 0 0 0 0 1 6 2 
EITHHGWSTVTH 1 1 0 0 0 0 1 11 5 
EITHTGWSTVTH 0 0 8 0 1 1 4 12 7 
EITHPGWSTVPH 0 0 0 0 1 0 1 4 3 
EITHLGWSTVTH 1 0 0 1 2 0 1 9 2 
EITHPGWSTLTH 0 0 1 1 1 2 5 11 5 
EITHSGWSTVTH 0 0 0 0 0 1 2 4 1 
EITHPVWSTVTH 0 0 2 0 0 0 4 14 8 
EITHPGWSTGTH 0 0 1 0 1 0 2 5 4 
EITHPGWSTVTL 0 0 0 0 0 0 1 10 1 
EITHPGWSTVTP 0 0 1 4 0 0 3 14 4 
EITHPGLSTVTH 1 0 1 1 1 1 1 16 6 
DITHPGWSTVTH 0 0 1 1 2 1 3 16 7 
QITHPGWSTVTH 1 0 0 1 0 1 6 14 2 
AITHPGWSTVTH 0 0 0 0 0 0 1 5 2 
SSWWHHLVADRV 32 16 202 66 185 9 159 2474 2263 
SIWWHHLVADRV 0 0 0 0 0 0 0 3 2 
SSWWHHLAADRV 1 0 0 0 0 0 1 3 6 
SSWWHHLVADRA 1 0 0 0 1 0 0 11 4 
SSWWHHLEADRV 0 0 0 0 0 0 0 2 4 
SSWWHHLVADRF 0 0 0 0 0 0 0 6 5 
SSWWHNLVADRV 0 0 0 0 0 0 0 5 1 
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SSWCHHLVADRV 0 0 0 0 2 0 0 4 6 
SSWWNHLVADRV 0 1 0 0 1 0 0 4 5 
SSWWHHLVSDRV 1 0 0 0 0 0 0 1 1 
SSWWHHLVADMV 0 0 0 0 0 0 0 2 4 
SSWWHHLVAYRV 0 0 0 0 0 0 0 4 1 
SSWWHHLGADRV 0 0 0 0 0 0 1 5 6 
SSWWHHLVADRG 2 0 0 2 2 2 1 37 31 
SSWWHLLVADRV 0 0 0 0 0 0 1 2 3 
SSWWHHLVAARV 0 0 0 1 0 0 0 9 7 
SSWWHHLVAVRV 0 0 3 0 0 0 0 6 9 
SSWWHHLVAGRV 0 0 1 0 1 0 1 11 6 
SSWRHHLVADRV 0 0 0 0 0 0 0 5 3 
SSWLHHLVADRV 0 0 0 1 0 0 0 2 6 
SSWGHHLVADRV 0 0 0 0 1 0 0 3 1 
SALKGLFPADHH 124 104 733 219 493 2974 1826 3268 1127 
SALKGLFPADYH 0 0 0 1 0 5 3 6 2 
SALKGLFLADHH 0 0 1 0 0 2 0 4 1 
SALKVLFPADHH 0 0 1 1 0 8 7 4 2 
SALNGLFPADHH 0 0 0 1 1 0 5 4 2 
MADVRHPGGFFF 0 0 0 0 0 0 1 6 1 
MADVRHPGDFFF 0 0 0 0 1 0 0 21 4 
MADVRHPGGFLF 2 0 1 0 2 0 2 73 29 
MADVRHPGDFLF 3 2 13 3 11 0 5 315 99 
HIGTVTSWLRPD 6 10 43 30 35 5 41 1163 412 
HIGKVTSWLRPD 0 0 0 0 0 0 0 3 1 
HIGTVTSWLRHD 0 0 0 0 0 0 0 2 2 
HIVTVTSWLRPD 0 0 0 0 0 0 0 4 2 
HIGTVTSWLLPD 0 0 0 0 0 0 0 5 2 
SMGPNTSYSLAH 38 21 69 53 61 8 125 1808 380 
SMGPNTSYILAH 0 0 0 0 0 0 0 5 2 
SMWPNTSYSLAH 0 0 0 0 0 0 0 3 1 
SMGPNTSYSLAP 0 0 0 0 0 0 0 3 1 
EDLRKEFSRLVD 0 0 0 0 0 0 0 1 2 
EDLRKEASRLVD 0 0 0 0 0 0 1 5 1 
EDLRKESSRLVD 24 12 41 43 42 7 33 477 110 
SQLKPILAWAN 20 9 42 34 44 7 42 1403 456 
SQLKPILAWEN 0 0 0 0 0 0 3 5 1 
SECKATCQAIN 2 1 0 3 1 1 1 57 4 




Table 7.1: Comparison of identified peptides: Specific peptides identified by 
phage display screening against α-synuclein in slow (SR) as well as fast 
washes (FR). Next generation deep sequencing was used to obtain the iteration 
number of each peptide in the parental library and against the protein. 
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Gene sequences with designed primers (peptide phage display)  














Forward primer (XhoI) 
5’ ATGCCCTCCTGGGCCCTC 3’ 
Reverse primer (SacII) 
5’ CCGCGGTATTGGCAGCAG 3’ 
 









Forward primer: Xho1 
CTCGAGATGGCCTTCGTCACCAGG 
Reverse primer: SacII 
5’ CCGCGGCTTGTATTTGTAAAATCC 3’ 
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Forward primer: XhoI 
CTCGAGATGAACTGGGCATTTCTG 
Reverse primer: SacII 
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